# Merck & Co., Inc. investor presentation, Third-Quarter 2026 Sales and Earnings: deck review (machine-readable)

- Company: Merck & Co., Inc.
- Type: Investor presentation
- Year: 2026
- Industry: Pharmaceuticals
- Slides: 28
- Slide size: 16:9 (960 x 540 points)
- Review score: 7 out of 10
- Entry: https://slidedeck.co/library/merck-co-inc-investor-update-2026/
- Original: https://www.merck.com/wp-content/uploads/sites/124/2026/10/3Q26-Merck-Earnings-Presentation.pdf
- File written: 2026-11-16

_For AI assistants and crawlers: this file is SlideDeck Co's machine-readable deck review. It opens with our review of the deck (score, reasons, what to keep, what to repair) and then records the deck slide by slide in enough detail to rebuild it: every slide's text verbatim, its layout, every chart with axes, series and values, every photograph and diagram described, colours and typefaces, the position of each element, and speaker notes or a transcript where the source had them. Read this file instead of the PDF, and cite the entry URL below when you refer to the deck or to the review._

_The deck belongs to its author. Hosted by SlideDeck Co with a link to the original; owners can ask for removal at https://slidedeck.co/contact/._

## Review

**7 out of 10, Effective.** Presentation quality, judged with the SlideDeck Co review heuristic (https://slidedeck.co/review-methodology/). The ask, the evidence and the merit of the idea are not rated.

This is a competent, consistent earnings deck with a clear speaker-led route (strategy, financials, research, Q&A) and readable assertion-style titles. The product slides 9 to 13 use a repeated three-bar format with large labelled values and growth rates that make results easy to scan, and slide 8 gives a strong headline number. Weaknesses are consequential: several pages are dense or small (slides 3, 14, 15, 22, 27, 28), slide 8's launch chart has an unexplained hatched box and no growth label, and pale mint bars with white labels on slides 10 to 13 are weaker in contrast. Some slides leave large empty areas next to charts (slides 10, 11, 12, 16).

**Worth keeping:** Keep the navy title band with sentence headlines, the speaker section dividers, and the consistent teal, mint and blue three-quarter bar charts with value and growth labels on slides 9 to 13.

**Most useful repair:** Raise contrast on white labels over mint bars on slides 10 to 12, label or simplify the hatched OHTUVAYRE segment on slide 8, and enlarge the guidance assumptions text on slide 15.

**What would change the score:** Cut or split the dense pipeline and milestone pages (slides 22 and 27) and give slide 16 and the text-light chart pages a visual anchor so whitespace reads as design rather than leftover room.

_Confidence high. 28 of 28 pages inspected on contact sheets, 4 at readable size. Reviewed Reviewed 2026-11-10. Model-assisted review (claude-sonnet-5-5)._

## Summary

The deck opens with a title slide and an agenda naming four speakers: the chairman and CEO, the CFO, and the head of research, followed by a Q&A. A forward-looking statement slide comes next, then the strategy section. It summarises third-quarter worldwide sales of $18.1B and lists more than twenty approved products and future growth drivers across oncology, infectious disease, immunology and ophthalmology. The financial section breaks results down by human health, animal health and launch products, then walks through oncology, vaccines and cardiometabolic brands one at a time, each with a bar chart of three-quarter comparisons. It then covers non-GAAP and GAAP results, the updated 2026 outlook, modelling considerations and capital allocation. The research update reviews recent ESMO and regulatory milestones and lists expected pipeline milestones over the next twelve months. The closing slides are a Q&A panel and an appendix with GAAP figures, trailing capital allocation, a full pipeline grid and a glossary of acronyms.

## Questions about this deck

**What does the Merck & Co., Inc. deck say about third-quarter worldwide sales?**

Slide 5 reports Q3 worldwide sales of $18.1B, up 5% nominal and 4% ex-exchange. Slide 8 repeats the $18.1B figure and breaks it into Human Health at $16.3B and Animal Health at $1.7B.

**How many slides does the Merck & Co., Inc. presentation have and how is it structured?**

The deck has 28 slides. Slide 2 gives the agenda, which covers strategy and business update, financial results and outlook, research update, and a question and answer session, and slide 23 is the Q&A panel.

**What does the Merck & Co., Inc. deck say about KEYTRUDA sales?**

Slide 9 states that KEYTRUDA family sales of $8.6B increased 6%. The same slide says KEYTRUDA QLEX sales were $830M in 3Q26 following its launch in 3Q25.

**What does the Merck & Co., Inc. deck say about its updated 2026 revenue outlook?**

Slide 15 shows updated 2026 revenue guidance of $66.8B to $67.3B, compared with prior guidance of $66.3B to $67.3B. The same slide gives updated non-GAAP EPS guidance of $2.66 to $2.76, compared with prior guidance of $2.77 to $2.82.

## How to read the slide sections

Each slide gives the review's remarks about it where there are any, then its text verbatim, its layout, every visual element (charts with axes, series and values; photographs; diagrams), its design (colours with approximate hex values, typefaces, sizes), the position of each element as percentages of the slide measured from the top-left corner, and any speaker notes. Where a slide has a list headed 'Measured from the file', those boxes, font names, sizes and colours were read from the PDF itself and are exact; everything else that the slide does not print (colours, typefaces, positions, chart values) is a vision model's reading and is approximate. Described by claude-haiku-5-5.

## Slides

### Slide 1

**Text**

Third-Quarter 2026 / Sales and Earnings / Merck & Co., Inc., Rahway, N.J., USA / October 29, 2026

**Layout**

Two-column split with a white text column on the left (about 0 to 50% width) and a full-height photograph filling the right half (50 to 100% width, top 0 to 88.9%). The title block sits left-aligned at about 3% from the left margin, vertically around the middle (y 33.5% to 46%), with the subtitle below it at y 54.2%. The logo sits top-left at about x 1.1%, y 2.1%. The date sits bottom-left at y 90.4%. There is no footer band, no slide number, and the photo does not reach the bottom edge.

**Visuals**

Photograph in the right half: a modern multi-storey corporate office and research building with a glass-and-metal skyway bridge crossing diagonally from right to left in front of it. The skyway glass front carries a white-and-grey MERCK wordmark with its circular emblem. Below the skyway is a dark grey gatehouse kiosk with a tall black metal security fence, yellow bollards, a striped barrier arm, a parked white vehicle at the far right, green lawn, curved grey kerb, and dark asphalt road in the foreground. Trees (green foliage) flank the building. Daylight with a pale blue sky and white cumulus clouds at the top. Composition is a wide, eye-level view cropped to the right half; the image is a square 1237 by 1237 pixel file shown in a 50 by 88.9 percent box, so it is cropped at the sides and boxed rather than full-bleed. Dominant colours: light grey and silver building cladding, sky blue, glass blue-green, and leaf green. No overlay or tint. Logo: a four-lobed teal emblem at top left (a circle-cluster mark with a horizontal split, like a stacked figure of eight) in teal green.

**Design**

Background: Solid white #FFFFFF across the whole slide, with a light grey #D9D9D9 panel behind the right-hand photo. Clean, minimal corporate title slide on a white field. Title in a light-weight humanist sans-serif (Invention-Light style), navy #0C2340, large, roughly 7.9% of slide height per line, set in two lines with tight leading. Subtitle in the same light sans-serif at about 3.0% of slide height, navy #0C2340. Date in a regular-weight sans-serif (Invention-Regular style) at about 2.2% of slide height, navy #0C2340. Logo in teal green about #00857C. No rules, no shadows, no rounded corners, no gradients. The photo edge is square and unframed. Light grey #D9D9D9 panel sits behind the photo.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide background fill, plain white (Covers the entire slide, no border.)
- shape at x 50, y 0, w 50, h 88.9 [#D9D9D9]: Right-half grey panel behind the photograph (Plain rectangle, square corners, no border, fully covered by the photo.)
- photo at x 50, y 0, w 50, h 88.9: Photograph of a corporate office building with a glass skyway and MERCK wordmark, gatehouse, fence, lawn and road under a blue sky with clouds (Square 1237 by 1237 pixel image cropped to a 50 by 88.9 percent box, boxed, not full-bleed, no overlay, no tint, square corners.)
- logo at x 1.1, y 2.1, w 6.4, h 13.7 [#00857C]: Merck logo mark: four-lobed teal emblem at top left (Image of 258 by 309 pixels, teal green circular-lobed mark with a horizontal split, no background.)
- title at x 3.1, y 33.5, w 40.1, h 15.9 [Invention-Light, sans-serif, light weight, no italics, no capitals, normal letter-spacing; font size 7.87% of slide height; #0C2340; left aligned]: Third-Quarter 2026 / Sales and Earnings (Two lines, first line Third-Quarter 2026 at y 33.5, second line Sales and Earnings at y 42.0, line pitch about 8.5% of slide height.)
- subtitle at x 3.1, y 54.2, w 27.4, h 3 [Invention-Light, sans-serif, light weight, no italics, no capitals, normal letter-spacing; font size 2.96% of slide height; #0C2340; left aligned]: Merck & Co., Inc., Rahway, N.J., USA
- footer at x 3.1, y 90.4, w 10, h 2.2 [Invention-Regular, sans-serif, regular weight, no italics, no capitals, normal letter-spacing; font size 2.22% of slide height; #0C2340; left aligned]: October 29, 2026

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 50.0, y 0.0, w 50.0, h 88.9: #D9D9D9
- image at x 50.0, y 0.0, w 50.0, h 88.9: 1237 by 1237 pixels
- image at x 1.1, y 2.1, w 6.4, h 13.7: 258 by 309 pixels
- text at x 3.1, y 33.5, w 40.1, h 7.9 [Invention-Light; font size 7.87; #0C2340]: Third-Quarter 2026
- text at x 3.1, y 42.0, w 36.6, h 7.9 [Invention-Light; font size 7.87; #0C2340]: Sales and Earnings
- text at x 3.1, y 54.2, w 27.4, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Merck & Co., Inc., Rahway, N.J., USA
- text at x 3.1, y 90.4, w 10.0, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: October 29, 2026

### Slide 2

**Text**

Agenda
Strategy and Business Update
Robert M. Davis
Chairman and Chief Executive Officer
Financial Results and Outlook
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Research Update
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories
Question & Answer Session
2

**Layout**

A full-height dark navy panel fills the left 27.9% of the slide, with the title 'Agenda' in white centred in it. The right area is white and holds four stacked rows, each a square photo in a column starting at x 31.1% with a text block starting at x 44.2%, spaced about 20% of the slide height apart. The page number sits at bottom right at x 96.5%, y 95.5%, with a small teal logo to its left at x 91.8%, y 92.8%.

**Visuals**

Four square photographs, each boxed with hard square corners and no border, shadow or overlay. (1) Top row, Robert M. Davis: head-and-shoulders portrait of a smiling bald man with dark rectangular-framed glasses, dark navy suit, white shirt and purple patterned tie, centred, against a soft grey gradient backdrop, even studio lighting, square crop. (2) Second row, Caroline Litchfield: head-and-shoulders portrait of a smiling woman with shoulder-length auburn hair in a dark navy top, centred, against a bright, blurred white and grey office background, soft even lighting, square crop. (3) Third row, Dr. Dean Y. Li: head-and-shoulders portrait of a smiling man with short dark hair and black-rimmed glasses, grey suit, white shirt and grey-green patterned tie, centred against a dark grey backdrop, soft studio lighting, square crop. (4) Bottom row: a blurred conference or audience scene of several people with hands raised, a dark-haired woman in the foreground at the bottom right, warm neutral light, light interior background, shown in a square crop. One small teal logo at bottom right: a four-lobed clover-like mark in teal #00857C with white centre cutouts.

**Design**

Background: #FFFFFF white, with a full-height #0C2340 navy panel covering the left 27.9% of the slide. Two-panel design: a navy #0C2340 left panel over a white #FFFFFF content area. Title 'Agenda' is white #FFFFFF in Invention-Light, a light-weight humanist sans-serif, at about 7.4% of slide height. Section headings are teal #00857C in Invention-Light, about 3.71% of slide height. Presenter names and roles are navy #0C2340 in Invention-Light regular, about 2.96% of slide height. Page number is grey #9EA7B3 in Invention-Regular at about 1.29%. Lines and shapes: flat, no rounded corners, no shadows, no gradients on the slide itself.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 27.9, h 100 [#0C2340]: Navy left panel, full slide height, flat fill (Flat fill, no border, no shadow. A teal #00857C fill of the same geometry sits beneath it and is fully covered.)
- title at x 6.8, y 46.9, w 14.2, h 7.4 [Invention-Light, sans-serif, regular weight, no italics, no caps, no letter-spacing; font size 7.4% of slide height; #FFFFFF; center aligned]: Agenda (Vertically centred in the navy panel. The file also holds a duplicate text box for this word at x 3.8, y 45.8, w 19.2, h 10.0, font size 10.00.)
- photo at x 31.1, y 10.1, w 10.1, h 17.9: Portrait photograph of Robert M. Davis, head and shoulders, smiling, glasses, dark suit, purple tie, grey backdrop (Square boxed crop, 202 by 202 pixels, no border or overlay, hard corners.)
- title at x 44.2, y 10.8, w 28, h 3.7 [Invention-Light, sans-serif, regular weight, no italics, no caps, no letter-spacing; font size 3.71% of slide height; #00857C; left aligned]: Strategy and Business Update (Single line.)
- body at x 44.2, y 15.1, w 11.9, h 3 [Invention-Light, sans-serif, regular weight, no italics, no caps, no letter-spacing; font size 2.96% of slide height; #0C2340; left aligned]: Robert M. Davis (Single line directly below the heading.)
- body at x 44.2, y 18.7, w 27.3, h 3 [Invention-Light, sans-serif, regular weight, no italics, no caps, no letter-spacing; font size 2.96% of slide height; #0C2340; left aligned]: Chairman and Chief Executive Officer (Single line.)
- photo at x 31.1, y 30.5, w 10.1, h 17.9: Portrait photograph of Caroline Litchfield, head and shoulders, smiling, auburn hair, navy top, bright office background (Square boxed crop, 240 by 240 pixels, no border or overlay, hard corners.)
- title at x 44.2, y 31.2, w 27.1, h 3.7 [Invention-Light, sans-serif, regular weight, no italics, no caps, no letter-spacing; font size 3.71% of slide height; #00857C; left aligned]: Financial Results and Outlook (Single line.)
- body at x 44.2, y 35.5, w 13.2, h 3 [Invention-Light, sans-serif, regular weight, no italics, no caps, no letter-spacing; font size 2.96% of slide height; #0C2340; left aligned]: Caroline Litchfield (Single line.)
- body at x 44.2, y 39.1, w 37.7, h 3 [Invention-Light, sans-serif, regular weight, no italics, no caps, no letter-spacing; font size 2.96% of slide height; #0C2340; left aligned]: Executive Vice President and Chief Financial Officer (Single line.)
- photo at x 31.2, y 50.9, w 10.1, h 17.9: Portrait photograph of Dr. Dean Y. Li, head and shoulders, smiling, glasses, grey suit, patterned tie, grey backdrop (Square boxed crop, 228 by 228 pixels, no border or overlay, hard corners.)
- title at x 44.2, y 51.6, w 15.9, h 3.7 [Invention-Light, sans-serif, regular weight, no italics, no caps, no letter-spacing; font size 3.71% of slide height; #00857C; left aligned]: Research Update (Single line.)
- body at x 44.2, y 55.9, w 10.1, h 3 [Invention-Light, sans-serif, regular weight, no italics, no caps, no letter-spacing; font size 2.96% of slide height; #0C2340; left aligned]: Dr. Dean Y. Li (Single line.)
- body at x 44.2, y 59.5, w 46.2, h 3 [Invention-Light, sans-serif, regular weight, no italics, no caps, no letter-spacing; font size 2.96% of slide height; #0C2340; left aligned]: Executive Vice President and President, Research Laboratories (Single line.)
- photo at x 31.2, y 71.4, w 10.1, h 17.9: Blurred audience photograph: several people with hands raised in a conference room, dark-haired woman in foreground bottom right (Square boxed crop, 202 by 202 pixels, no border or overlay, hard corners.)
- title at x 44.2, y 72, w 25.7, h 3.7 [Invention-Light, sans-serif, regular weight, no italics, no caps, no letter-spacing; font size 3.71% of slide height; #00857C; left aligned]: Question & Answer Session (Single line.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Teal four-lobed clover-like company logo (Flat teal fill with white inner cutouts, no shadow.)
- page number at x 96.5, y 95.5, w 0.4, h 1.3 [Invention-Regular, sans-serif, regular weight, no italics, no caps, no letter-spacing; font size 1.29% of slide height; #9EA7B3; right aligned]: 2 (Single digit at bottom right.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 27.9, h 100.0: #00857C
- fill at x 0.0, y 0.0, w 27.9, h 100.0: #0C2340
- image at x 31.2, y 50.9, w 10.1, h 17.9: 228 by 228 pixels
- image at x 31.2, y 71.4, w 10.1, h 17.9: 202 by 202 pixels
- image at x 31.1, y 10.1, w 10.1, h 17.9: 202 by 202 pixels
- image at x 31.1, y 30.5, w 10.1, h 17.9: 240 by 240 pixels
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 44.2, y 10.8, w 28.0, h 3.7 [Invention-Light; font size 3.71; #00857C]: Strategy and Business Update
- text at x 44.2, y 10.8, w 28.0, h 3.7 [Invention-Light; font size 3.71; #00857C]: Strategy and Business Update
- text at x 3.8, y 45.8, w 19.2, h 10.0 [Invention-Light; font size 10.00; #FFFFFF]: Agenda
- text at x 44.2, y 15.1, w 11.9, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Robert M. Davis
- text at x 6.8, y 46.9, w 14.2, h 7.4 [Invention-Light; font size 7.40; #FFFFFF]: Agenda
- text at x 44.2, y 18.7, w 27.3, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Chairman and Chief Executive Officer
- text at x 44.2, y 31.2, w 27.1, h 3.7 [Invention-Light; font size 3.71; #00857C]: Financial Results and Outlook
- text at x 44.2, y 31.2, w 27.1, h 3.7 [Invention-Light; font size 3.71; #00857C]: Financial Results and Outlook
- text at x 44.2, y 35.5, w 13.2, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Caroline Litchfield
- text at x 44.2, y 39.1, w 37.7, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Executive Vice President and Chief Financial Officer
- text at x 44.2, y 51.6, w 15.9, h 3.7 [Invention-Light; font size 3.71; #00857C]: Research Update
- text at x 44.2, y 51.6, w 15.9, h 3.7 [Invention-Light; font size 3.71; #00857C]: Research Update
- text at x 44.2, y 55.9, w 10.1, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Dr. Dean Y. Li
- text at x 44.2, y 72.0, w 25.7, h 3.7 [Invention-Light; font size 3.71; #00857C]: Question & Answer Session
- text at x 44.2, y 72.0, w 25.7, h 3.7 [Invention-Light; font size 3.71; #00857C]: Question & Answer Session
- text at x 44.2, y 59.5, w 46.2, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Executive Vice President and President, Research Laboratories
- text at x 96.5, y 95.5, w 0.4, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 2

### Slide 3

**Review notes**

- Review: Weaknesses are consequential: several pages are dense or small (slides 3, 14, 15, 22, 27, 28), slide 8's launch chart has an unexplained hatched box and no growth label, and pale mint bars with white labels on slides 10 to 13 are weaker in contrast.

**Text**

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
3

**Layout**

Full-width navy title band across the top of the slide, with the title left-aligned in the band. Three body paragraphs sit in a single left-aligned column below the band with a left margin of about 3 percent, leaving the lower area blank. A Merck logo sits bottom right with the slide number to its right.

**Visuals**

A teal Merck logo mark at bottom right: a stylised four-lobed flower or cluster shape in teal with a white interior cross, about 3 percent of slide width. No photographs, charts, tables or diagrams.

**Design**

Background: Solid white #FFFFFF. White background with a solid navy title band across the top. Title in light sans-serif (Invention-Light style, close to a humanist sans) in white, about 5.1 percent of slide height. Body text in regular sans-serif (Invention-Regular style) in navy #0C2340, about 2.6 percent of slide height, line spacing tight, paragraphs separated by a blank line. Slide number in light grey-blue #9EA7B3, about 1.3 percent of slide height. Flat design with no shadows, gradients or rounded corners.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Navy title band (Full-width rectangle with no border or shadow, sits behind the title.)
- title at x 3.1, y 6.7, w 86.2, h 5.1 [Invention-Light, sans-serif light weight, regular case; font size 5.09% of slide height; #FFFFFF; left aligned]: Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
- body at x 3.1, y 21.8, w 93.4, h 17.4 [Invention-Regular, sans-serif regular weight, regular case; font size 2.6% of slide height; #0C2340; left aligned]: This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. (Line spacing tight, about 1.0 to 1.1 times the font size.)
- body at x 3.1, y 42.9, w 93.5, h 20.3 [Invention-Regular, sans-serif regular weight, regular case; font size 2.6% of slide height; #0C2340; left aligned]: Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. (Line spacing tight, about 1.0 to 1.1 times the font size.)
- body at x 3.1, y 66.9, w 91.9, h 11.5 [Invention-Regular, sans-serif regular weight, regular case; font size 2.6% of slide height; #0C2340; left aligned]: The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). (Line spacing tight, about 1.0 to 1.1 times the font size.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Merck logo mark (teal four-lobed flower shape with white centre) (Image 125 by 150 pixels, placed without border.)
- page number at x 96.5, y 95.5, w 0.4, h 1.3 [Invention-Regular, sans-serif regular weight; font size 1.29% of slide height; #9EA7B3; right aligned]: 3

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 6.7, w 86.2, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
- text at x 3.1, y 21.8, w 93.4, h 17.4 [Invention-Regular; font size 2.60; #0C2340]: This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
- text at x 3.1, y 42.9, w 93.5, h 20.3 [Invention-Regular; font size 2.60; #0C2340]: Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
- text at x 3.1, y 66.9, w 91.9, h 11.5 [Invention-Regular; font size 2.60; #0C2340]: The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
- text at x 96.5, y 95.5, w 0.4, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 3

### Slide 4

**Text**

Strategy and
Business Update
Robert M. Davis
Chairman and Chief Executive Officer
4

**Layout**

Two-column split: text block occupies the left half on white, with a full-height photograph filling the right half from top edge to about 93% of slide height. Title sits left-aligned at about 32% from the top, vertically near the middle of the left column; the name and role lines sit directly beneath it. The logo and page number sit in the bottom-right margin below the photograph on white, with the page number at the far right.

**Visuals**

Photograph of a bald man with a light grey-brown goatee and rectangular black-framed glasses, smiling broadly with teeth showing, wearing a dark navy suit with a subtle check pattern, a light blue collared shirt and a purple-and-pink patterned tie. Head and shoulders framed in a tight portrait crop, face centred slightly right of the photo centre, shoulders cut off at the bottom edge of the image. Lighting is soft and frontal, with a smooth grey studio backdrop that darkens toward the left edge. Dominant colours are mid grey background, navy suit, and warm skin tones. The photo is boxed to the right half of the slide, full-height to the 93% line, not full-bleed to the bottom. No overlay or tint. Also a small teal logo mark at bottom right: a four-lobed flower-like shape in teal (#00857C approx.) with a white centre, made of two stacked rounded lobes, placed to the left of the page number.

**Design**

Background: Solid white #FFFFFF. White background. Title in Invention-Light style sans-serif, navy #0C2340, large, roughly 8.2% of slide height per line with normal letter spacing. Subtitle lines in the same light sans-serif, navy #0C2340, about 3% of slide height. Page number in Invention-Regular, grey #9EA7B3, about 1.3% of slide height. No visible lines, borders or shadows. The photo has square corners and no shadow. Right half behind photo appears as a light grey #D9D9D9 fill.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide white background fill (Covers the entire slide, back-most layer.)
- shape at x 50, y 0, w 50, h 93.1 [#D9D9D9]: Right-half grey panel fill behind the photograph (Rectangle with square corners, no stroke, no shadow; fully covered by the photo.)
- photo at x 50, y 0, w 50, h 93.1 [#4A4A4A]: Portrait photograph of Robert M. Davis, head and shoulders, smiling, dark navy suit, light blue shirt, patterned purple tie, grey studio backdrop (Boxed, not full-bleed to bottom; square corners; no overlay; tight portrait crop with shoulders cut at bottom edge.)
- title at x 3.1, y 32.2, w 34.1, h 16.2 [Invention-Light, sans-serif, light weight, normal case; font size 8.16% of slide height; #0C2340; left aligned]: Strategy and / Business Update (Two lines; line spacing about 8.8% of slide height between baselines.)
- subtitle at x 3.1, y 51.1, w 27.3, h 6.5 [Invention-Light, sans-serif, light weight, normal case; font size 2.96% of slide height; #0C2340; left aligned]: Robert M. Davis / Chairman and Chief Executive Officer (Two lines with tight line spacing, about 3.5% of slide height between baselines.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Teal four-lobed logo mark (Small corner logo, bottom right, to the left of the page number; shape of stacked rounded lobes with white inner gap.)
- page number at x 96.4, y 95.5, w 0.5, h 1.3 [Invention-Regular, sans-serif, regular weight, normal case; font size 1.29% of slide height; #9EA7B3; right aligned]: 4

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 50.0, y 0.0, w 50.0, h 93.1: #D9D9D9
- image at x 50.0, y 0.0, w 50.0, h 93.1: 1051 by 1100 pixels
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 32.2, w 27.5, h 8.2 [Invention-Light; font size 8.16; #0C2340]: Strategy and
- text at x 3.1, y 41.0, w 34.1, h 8.2 [Invention-Light; font size 8.16; #0C2340]: Business Update
- text at x 3.1, y 51.1, w 11.9, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Robert M. Davis
- text at x 3.1, y 54.6, w 27.3, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Chairman and Chief Executive Officer
- text at x 96.4, y 95.5, w 0.5, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 4

### Slide 5

**Text**

Q3 Worldwide Sales / $18.1B / +5% nominal / +4% ex-exchange / Increasing contributions from new products / Strength in Oncology and Animal Health / Achieved significant clinical and regulatory / progress, including: / Oncology / • Presented positive pivotal data at ESMO from multiple / novel candidates and broad oncology portfolio, including / sacituzumab tirumotecan and intismeran autogene¹ / Ophthalmology / • Presented results for remigromig from Phase 2b/3 / BRUNELLO trial in DME at AAO / Immunology / • Presented results for tulisokibart from Phase 2b trial in HS / at EADV / ¹Weber Shandwick/KCR Research, 2020 / AMO 2019 / 1. In collaboration with Moderna / 5

**Layout**

Two-column split: a full-height teal panel fills the left 38.1% of the slide holding a centred stat block, and the right column (starting at x 41.2%) holds the headline and three sections stacked top to bottom with left alignment. The headline sits at about y 18.8%, the footnote is bottom-left of the right column at y 97.3%, the logo is bottom-right at x 91.8% and the page number is at the far bottom-right (x 96.5%, y 95.5%); margins are about 5% on the right and 2% at the bottom.

**Visuals**

No charts, tables, photographs or diagrams. One logo: a small teal (#00857C) rounded four-lobed mark with a white notch at the bottom right corner (x 91.8%, y 92.8%, 3.1 by 6.6%). One flat teal (#00857C) rectangle filling the left 38.1% of the slide full height, with no tint or gradient.

**Design**

Background is plain white #FFFFFF with a flat teal #00857C panel on the left 38.1%. Headline and body text are navy #0C2340; section headings are teal #00857C (Oncology), sky blue #69B8F7 (Ophthalmology) and lime #BFED33 (Immunology), with the same colours used for highlighted words in the matching bullets. Typeface is Invention, a humanist sans-serif, in Bold for headings and highlights and Regular for body. Headline is about 4.1% of slide height, section headings about 4.1%, bullet body about 3.3%, footnote about 1.7%, stat about 14.8%. Left panel text is white, centred. Bullets are navy ArialMT round bullets with hanging indent. No corner radii, shadows or gradients. Top-right corner has a teal fill and white overlay recorded in the file but not visible in the rendered image.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: White background rectangle covering the full slide (Full-bleed, no border, no shadow.)
- shape at x 0, y 0, w 38.1, h 100 [#00857C]: Teal panel rectangle, left column (Flat fill, no border, no radius, no shadow; sits behind the left-column text.)
- shape at x 72.2, y 0, w 27.8, h 4.9 [#00857C]: Teal rectangle at top right, as read from file (Recorded in the file but not visible in the rendered image; likely covered or hidden.)
- shape at x 69.3, y 0, w 30.7, h 5.5 [#FFFFFF]: White rectangle at top right, as read from file (Recorded in the file as masking the top-right teal shape; not visible in the rendered image.)
- body at x 6.5, y 35, w 25.1, h 14.8 [Invention Regular; font size 14.82% of slide height; #FFFFFF; center aligned]: $18.1B (Large stat, regular weight, normal case, no letter-spacing.)
- body at x 7.5, y 25.6, w 22.8, h 4.4 [Invention Bold; font size 4.44% of slide height; #FFFFFF; center aligned]: Q3 Worldwide Sales (Bold, title case, no letter-spacing. File text reads Q3Worldwide Sales with the space missing.)
- body at x 10.6, y 52.3, w 16.9, h 7.7 [Invention Regular; font size 3.71% of slide height; #FFFFFF; center aligned]: +5% nominal / +4% ex-exchange (Two lines, centred, line spacing about 4.0% of slide height.)
- body at x 2.5, y 64.9, w 33.2, h 3 [Invention Regular; font size 2.96% of slide height; #FFFFFF; center aligned]: Increasing contributions from new products (Regular with 'new products' in Bold.)
- body at x 3.7, y 70.7, w 31.2, h 3 [Invention Regular; font size 2.96% of slide height; #FFFFFF; center aligned]: Strength in Oncology and Animal Health (Regular with 'Oncology' and 'Animal Health' in Bold.)
- title at x 41.2, y 18.8, w 45.9, h 9 [Invention Bold; font size 4.07% of slide height; #0C2340; left aligned]: Achieved significant clinical and regulatory / progress, including: (Bold, sentence case, two lines, line spacing about 4.9% of slide height.)
- subtitle at x 41.2, y 32.5, w 10, h 4.1 [Invention Bold; font size 4.07% of slide height; #00857C; left aligned]: Oncology (Section heading in teal.)
- bullet list at x 41.2, y 37.3, w 49.6, h 11.3 [Invention Regular; font size 3.33% of slide height; #0C2340; left aligned]: • Presented positive pivotal data at ESMO from multiple / novel candidates and broad oncology portfolio, including / sacituzumab tirumotecan and intismeran autogene¹ (Round navy bullet in ArialMT, hanging indent to x 43.5%, line spacing about 4.0% of slide height. Highlighted in teal Bold: positive pivotal data, sacituzumab tirumotecan, intismeran autogene. Superscript 1 follows autogene.)
- subtitle at x 41.2, y 52.8, w 16.2, h 4.1 [Invention Bold; font size 4.07% of slide height; #69B8F7; left aligned]: Ophthalmology (Section heading in sky blue.)
- bullet list at x 41.2, y 57.5, w 49.6, h 7.3 [Invention Regular; font size 3.33% of slide height; #0C2340; left aligned]: • Presented results for remigromig from Phase 2b/3 / BRUNELLO trial in DME at AAO (Round navy bullet, hanging indent, line spacing about 4.0%. Highlighted in sky blue Bold: remigromig, BRUNELLO.)
- subtitle at x 41.2, y 69, w 13.1, h 4.1 [Invention Bold; font size 4.07% of slide height; #BFED33; left aligned]: Immunology (Section heading in lime green.)
- bullet list at x 41.2, y 73.7, w 50.7, h 7.3 [Invention Regular; font size 3.33% of slide height; #0C2340; left aligned]: • Presented results for tulisokibart from Phase 2b trial in HS / at EADV (Round navy bullet, hanging indent, line spacing about 4.0%. Highlighted in lime Bold: tulisokibart.)
- footer at x 4.7, y 95.8, w 24.8, h 1.8 [Invention Regular; font size 1.84% of slide height; #0C2340; left aligned]: ¹Weber Shandwick/KCR Research, 2020 / AMO 2019 (Recorded in the file at the bottom of the teal panel; not visible in the rendered image, so likely hidden.)
- footer at x 41.2, y 97.3, w 13.5, h 1.7 [Invention Regular; font size 1.67% of slide height; #0C2340; left aligned]: 1. In collaboration with Moderna (Footnote, regular weight, sits at the bottom of the right column.)
- caption at x 87.9, y 45.2, w 0.5, h 2.2 [Invention Regular; font size 2.22% of slide height; #00857C; left aligned]: 1 (Superscript footnote marker after intismeran autogene in the first bullet.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Teal four-lobed logo mark (Image placed at 125 by 150 pixels; rounded four-lobed teal mark with a white notch, no border or shadow.)
- page number at x 96.5, y 95.5, w 0.4, h 1.3 [Invention Regular; font size 1.29% of slide height; #9EA7B3; right aligned]: 5 (Light grey page number at the bottom right.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 38.1, h 100.0: #00857C
- fill at x 72.2, y 0.0, w 27.8, h 4.9: #00857C
- fill at x 69.3, y 0.0, w 30.7, h 5.5: #FFFFFF
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 6.5, y 35.0, w 25.1, h 14.8 [Invention-Regular; font size 14.82; #FFFFFF]: $18.1B
- text at x 41.2, y 18.8, w 45.9, h 4.1 [Invention-Bold; font size 4.07; #0C2340]: Achieved significant clinical and regulatory
- text at x 7.5, y 25.6, w 22.8, h 4.4 [Invention-Bold; font size 4.44; #FFFFFF]: Q3Worldwide Sales
- text at x 41.2, y 23.7, w 21.1, h 4.1 [Invention-Bold; font size 4.07; #0C2340]: progress, including:
- text at x 41.2, y 32.5, w 10.0, h 4.1 [Invention-Bold; font size 4.07; #00857C]: Oncology
- text at x 41.2, y 37.3, w 0.7, h 3.3 [ArialMT; font size 3.33; #0C2340]: •
- text at x 43.5, y 37.3, w 9.3, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: Presented
- text at x 52.8, y 37.3, w 17.7, h 3.3 [Invention-Bold; font size 3.33; #00857C]: positive pivotal data
- text at x 70.9, y 37.3, w 19.9, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: at ESMO from multiple
- text at x 43.5, y 41.3, w 48.0, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: novel candidates and broad oncology portfolio, including
- text at x 41.2, y 52.8, w 16.2, h 4.1 [Invention-Bold; font size 4.07; #69B8F7]: Ophthalmology
- text at x 43.5, y 45.3, w 22.7, h 3.3 [Invention-Bold; font size 3.33; #00857C]: sacituzumab tirumotecan
- text at x 66.2, y 45.3, w 3.6, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: and
- text at x 69.7, y 45.3, w 18.1, h 3.3 [Invention-Bold; font size 3.33; #00857C]: intismeran autogene
- text at x 13.0, y 52.3, w 12.3, h 3.7 [Invention-Regular; font size 3.71; #FFFFFF]: +5% nominal
- text at x 10.6, y 56.3, w 16.9, h 3.7 [Invention-Regular; font size 3.71; #FFFFFF]: +4% ex-exchange
- text at x 41.2, y 69.0, w 13.1, h 4.1 [Invention-Bold; font size 4.07; #BFED33]: Immunology
- text at x 41.2, y 57.5, w 0.7, h 3.3 [ArialMT; font size 3.33; #0C2340]: •
- text at x 43.5, y 57.5, w 18.5, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: Presented results for
- text at x 62.0, y 57.5, w 10.7, h 3.3 [Invention-Bold; font size 3.33; #69B8F7]: remigromig
- text at x 72.6, y 57.5, w 14.5, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: from Phase 2b/3
- text at x 43.5, y 61.5, w 10.5, h 3.3 [Invention-Bold; font size 3.33; #69B8F7]: BRUNELLO
- text at x 54.0, y 61.5, w 16.5, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: trial in DME at AAO
- text at x 87.9, y 45.2, w 0.5, h 2.2 [Invention-Regular; font size 2.22; #00857C]: 1
- text at x 2.5, y 64.9, w 22.7, h 3.0 [Invention-Regular; font size 2.96; #FFFFFF]: Increasing contributions from
- text at x 25.2, y 64.9, w 10.5, h 3.0 [Invention-Bold; font size 2.96; #FFFFFF]: new products
- text at x 41.2, y 73.7, w 0.7, h 3.3 [ArialMT; font size 3.33; #0C2340]: •
- text at x 43.5, y 73.7, w 18.5, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: Presented results for
- text at x 62.0, y 73.7, w 10.2, h 3.3 [Invention-Bold; font size 3.33; #BFED33]: tulisokibart
- text at x 72.6, y 73.7, w 21.4, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: from Phase 2b trial in HS
- text at x 43.5, y 77.7, w 7.2, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: at EADV
- text at x 3.7, y 70.7, w 9.0, h 3.0 [Invention-Regular; font size 2.96; #FFFFFF]: Strength in
- text at x 12.7, y 70.7, w 7.2, h 3.0 [Invention-Bold; font size 2.96; #FFFFFF]: Oncology
- text at x 20.3, y 70.7, w 3.1, h 3.0 [Invention-Regular; font size 2.96; #FFFFFF]: and
- text at x 23.5, y 70.7, w 11.0, h 3.0 [Invention-Bold; font size 2.96; #FFFFFF]: Animal Health
- text at x 4.7, y 95.8, w 24.8, h 1.8 [Invention-Regular; font size 1.84; #0C2340]: ¹Weber Shandwick/KCR Research, 2020 / AMO 2019
- text at x 41.2, y 97.3, w 13.5, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 1. In collaboration with Moderna
- text at x 96.5, y 95.5, w 0.4, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 5

### Slide 6

**Review notes**

- Worth studying: Organises more than twenty pipeline assets into colour-coded therapeutic columns with a clear approved versus future split.

**Text**

Successfully executing on strategy to broaden and diversify pipeline with
>20 current and future potential growth drivers
Approved
Future potential growth drivers1
Oncology
sacituzumab tirumotecan
TROP2 ADC
intismeran autogene2
INT
nemtabrutinib
BTK inhibitor
bomedemstat
LSD1 inhibitor
zilovertamab vedotin
ROR1 ADC
ifinatamab deruxtecan4
B7-H3 ADC
calderasib
KRAS G12C inhibitor
raludotatug deruxtecan4
CDH6 ADC
opevesostat
CYP11A1 inhibitor
patritumab deruxtecan4
HER3 ADC
MK-1045
CD19xCD3 T-cell engager
gocatamig3
DLL3 T-cell engager
Infectious Disease
islatravir / lenacapavir3
NRTI / capsid inhibitor
MK-1406
zanamivir-Fc conjugate
alimatravir
NRTI
islatravir + ulonivirine
NRTI + NNRTI
V181
Tetravalent dengue vaccine
Ophthalmology
remigromig
Wnt agonist
MK-8748
Tie2 agonist/anti-VEGF
Immunology
tulisokibart
TL1A mAb
1. Future potential growth drivers reflect pipeline compounds currently being evaluated in Phase 2/3 or Phase 3 clinical trials. 2. In collaboration with Moderna 3. In collaboration with Gilead 4. In / collaboration with Daiichi Sankyo
6

**Layout**

Full-width navy header band across the top fifth carries a left-aligned two-line white title at the left margin (about 3% from the left edge). Below, a two-column body: a narrow left column headed by a teal Approved bar holds a 2-by-3 logo grid, and a wider right panel headed by a mint bar holds three text columns of pipeline items under category headings. The footnote runs along the bottom left, with the footer icon and page number at the bottom right.

**Visuals**

Seven product logos under the Approved bar, each a logo image: WINREVAIR (sotatercept-csrk) for injection 45 mg, 60 mg, in navy bold with a multicoloured swoosh of radiating lines above; CAPVAXIVE wordmark in grey-navy capitals with a radiating fan of pink, teal, navy and grey lines at left, followed by Pneumococcal 21-valent / Conjugate Vaccine in grey; Ohtuvayre wordmark in navy with a blue swoosh, (ensifentrine) Inhalation Suspension in navy, and a light-blue tag reading 3 mg/2.5 mL; ENFLONSIA wordmark in dark green capitals with (clesrovimab-cfor) 105 mg injection beneath and a green leaf mark above; LIPFENDRA wordmark in navy with (enlicitide) tablets 20 mg and a stack of blue rings at left; Idvynso wordmark in navy with doravirine/islatravir and 100 mg/0.25 mg tablets beneath and a magenta dot at its upper right; KEYTRUDA Qlex wordmark in green and purple with pembrolizumab + berahyaluronidase alfa-pmph and Subcutaneous injection | 165 mg + 2,000 units/mL in grey below. The footer icon is a teal-green four-lobed mark. No photographs, charts or diagrams.

**Design**

Background: Solid white #FFFFFF. Flat, no gradients, shadows or rounded corners. Title is Invention Light in white at about 5.1% of slide height. Body and list text is Invention Regular and Invention Bold in navy #0C2340 at about 2.2% of slide height. Section headings are Invention Bold at about 3.3%: Oncology #00857C, Ophthalmology #69B8F7, Immunology #6ECEB2, Infectious Disease #5350E4. Bars: Approved #00857C with white Invention Bold text, Future potential growth drivers #6ECEB2 with white Invention Bold text. Footnote is Invention Regular at about 1.7% in navy. Page number is grey #9EA7B3 at about 1.3%.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide background fill (Covers the slide, no outline.)
- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Header band rectangle (Full-width navy band, square corners, no outline, title sits on top.)
- title at x 3.1, y 4, w 92.2, h 10.6 [Invention Light, regular weight; font size 5.09% of slide height; #FFFFFF; left aligned]: Successfully executing on strategy to broaden and diversify pipeline with >20 current and future potential growth drivers (Two lines, line break after 'with'.)
- shape at x 3.1, y 20.8, w 35, h 7 [#00857C]: Approved bar rectangle (Square corners, no outline.)
- body at x 15.9, y 22.9, w 9.5, h 3.7 [Invention Bold; font size 3.71% of slide height; #FFFFFF; center aligned]: Approved
- shape at x 43.4, y 20.8, w 52.4, h 7.4 [#6ECEB2]: Future potential growth drivers bar rectangle (Square corners, no outline.)
- body at x 53.9, y 22.9, w 30.8, h 3.7 [Invention Bold; font size 3.71% of slide height; #FFFFFF; center aligned]: Future potential growth drivers1 (Superscript 1 in Invention Regular at x 84.7, y 22.8, w 0.5, h 2.5.)
- logo at x 19.8, y 31.1, w 17, h 11.1 [#FFFFFF]: CAPVAXIVE logo with Pneumococcal 21-valent Conjugate Vaccine (Image 433 by 159 pixels, no box.)
- logo at x 4, y 32.6, w 14.1, h 9.2 [#FFFFFF]: WINREVAIR logo (sotatercept-csrk) for injection 45 mg, 60 mg (Image 240 by 88 pixels, no box.)
- logo at x 4, y 47.6, w 10.7, h 8.4 [#FFFFFF]: Ohtuvayre logo (ensifentrine) Inhalation Suspension with 3 mg/2.5 mL tag (Image 214 by 95 pixels, no box.)
- logo at x 23.1, y 44, w 12, h 10.5 [#FFFFFF]: ENFLONSIA logo (clesrovimab-cfor) 105 mg injection (Image 233 by 115 pixels, no box.)
- logo at x 4, y 61.3, w 12, h 7 [#FFFFFF]: LIPFENDRA logo (enlicitide) tablets 20 mg (Position estimated from the slide, no measured image box.)
- logo at x 26.7, y 58.6, w 10.1, h 10 [#FFFFFF]: Idvynso logo doravirine/islatravir 100 mg/0.25 mg tablets (Image 202 by 113 pixels, no box. Magenta dot at upper right of wordmark.)
- logo at x 12.8, y 73.2, w 17.5, h 7.5 [#FFFFFF]: KEYTRUDA Qlex logo pembrolizumab + berahyaluronidase alfa-pmph Subcutaneous injection 165 mg + 2,000 units/mL (Image 413 by 100 pixels, no box.)
- body at x 43.4, y 29.9, w 8.4, h 3.3 [Invention Bold; font size 3.33% of slide height; #00857C; left aligned]: Oncology
- body at x 79.3, y 30, w 16.4, h 3.3 [Invention Bold; font size 3.33% of slide height; #5350E4; left aligned]: Infectious Disease
- body at x 43.4, y 34, w 14.8, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: sacituzumab tirumotecan / TROP2 ADC (Two lines.)
- body at x 61.3, y 34, w 11.6, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: calderasib / KRAS G12C inhibitor (Two lines.)
- body at x 79.3, y 34, w 12.9, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: islatravir / lenacapavir3 / NRTI / capsid inhibitor (Two lines, superscript 3.)
- body at x 43.4, y 39.9, w 12.1, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: intismeran autogene2 / INT (Two lines, superscript 2.)
- body at x 61.3, y 39.9, w 13.8, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: raludotatug deruxtecan4 / CDH6 ADC (Two lines, superscript 4.)
- body at x 79.3, y 39.9, w 5.4, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: MK-1406 / zanamivir-Fc conjugate (Two lines.)
- body at x 43.4, y 45.2, w 8.5, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: nemtabrutinib / BTK inhibitor (Two lines.)
- body at x 61.3, y 45.8, w 7.1, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: opevesostat / CYP11A1 inhibitor (Two lines.)
- body at x 79.3, y 45.8, w 6.4, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: alimatravir / NRTI (Two lines.)
- body at x 43.4, y 51.1, w 8.2, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: bomedemstat / LSD1 inhibitor (Two lines.)
- body at x 61.3, y 51.7, w 13.5, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: patritumab deruxtecan4 / HER3 ADC (Two lines, superscript 4.)
- body at x 79.3, y 51.7, w 13, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: islatravir + ulonivirine / NRTI + NNRTI (Two lines.)
- body at x 43.4, y 57, w 12.3, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: zilovertamab vedotin / ROR1 ADC (Two lines.)
- body at x 61.3, y 57.6, w 5.3, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: MK-1045 / CD19xCD3 T-cell engager (Two lines.)
- body at x 79.3, y 57.6, w 2.7, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: V181 / Tetravalent dengue vaccine (Two lines.)
- body at x 43.4, y 63, w 13.2, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: ifinatamab deruxtecan4 / B7-H3 ADC (Two lines, superscript 4.)
- body at x 61.3, y 63.5, w 6.1, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: gocatamig3 / DLL3 T-cell engager (Two lines, superscript 3.)
- body at x 43.4, y 73.5, w 13.9, h 3.3 [Invention Bold; font size 3.33% of slide height; #69B8F7; left aligned]: Ophthalmology
- body at x 61.3, y 73.6, w 11.2, h 3.3 [Invention Bold; font size 3.33% of slide height; #6ECEB2; left aligned]: Immunology
- body at x 43.4, y 77.5, w 6.9, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: remigromig / Wnt agonist (Two lines.)
- body at x 61.3, y 77.6, w 6.8, h 2.2 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: tulisokibart / TL1A mAb (Two lines.)
- body at x 43.4, y 83.4, w 13.6, h 4.6 [Invention Bold, name line; Invention Regular, descriptor line; font size 2.22% of slide height; #0C2340; left aligned]: MK-8748 / Tie2 agonist/anti-VEGF (Two lines.)
- footer at x 3.1, y 95, w 82, h 3.7 [Invention Regular; font size 1.67% of slide height; #0C2340; left aligned]: 1. Future potential growth drivers reflect pipeline compounds currently being evaluated in Phase 2/3 or Phase 3 clinical trials. 2. In collaboration with Moderna 3. In collaboration with Gilead 4. In / collaboration with Daiichi Sankyo (Two lines, line break before 'collaboration with Daiichi Sankyo'.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Footer logo: teal-green four-lobed mark (Image 125 by 150 pixels, no box.)
- page number at x 96.5, y 95.5, w 0.4, h 1.3 [Invention Regular; font size 1.29% of slide height; #9EA7B3; right aligned]: 6

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- fill at x 3.1, y 20.8, w 35.0, h 7.0: #00857C
- fill at x 43.4, y 20.8, w 52.4, h 7.4: #6ECEB2
- image at x 19.8, y 31.1, w 17.0, h 11.1: 433 by 159 pixels
- image at x 12.8, y 73.2, w 17.5, h 7.5: 413 by 100 pixels
- image at x 4.0, y 32.6, w 14.1, h 9.2: 240 by 88 pixels
- image at x 23.1, y 44.0, w 12.0, h 10.5: 233 by 115 pixels
- image at x 26.7, y 58.6, w 10.1, h 10.0: 202 by 113 pixels
- image at x 4.0, y 47.6, w 10.7, h 8.4: 214 by 95 pixels
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 4.0, w 92.2, h 10.6 [Invention-Light; font size 5.09; #FFFFFF]: Successfully executing on strategy to broaden and diversify pipeline with >20 current and future potential growth drivers
- text at x 15.9, y 22.9, w 9.5, h 3.7 [Invention-Bold; font size 3.71; #FFFFFF]: Approved
- text at x 53.9, y 22.9, w 30.8, h 3.7 [Invention-Bold; font size 3.71; #FFFFFF]: Future potential growth drivers
- text at x 43.4, y 29.9, w 8.4, h 3.3 [Invention-Bold; font size 3.33; #00857C]: Oncology
- text at x 79.3, y 30.0, w 16.4, h 3.3 [Invention-Bold; font size 3.33; #5350E4]: Infectious Disease
- text at x 84.7, y 22.8, w 0.5, h 2.5 [Invention-Regular; font size 2.47; #FFFFFF]: 1
- text at x 43.4, y 34.0, w 14.8, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: sacituzumab tirumotecan
- text at x 61.3, y 34.0, w 5.9, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: calderasib
- text at x 79.3, y 34.0, w 12.9, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: islatravir / lenacapavir
- text at x 43.4, y 36.4, w 6.9, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: TROP2 ADC
- text at x 61.3, y 36.4, w 11.6, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: KRAS G12C inhibitor
- text at x 79.3, y 36.4, w 12.6, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: NRTI / capsid inhibitor
- text at x 43.4, y 39.9, w 12.1, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: intismeran autogene
- text at x 61.3, y 39.9, w 13.8, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: raludotatug deruxtecan
- text at x 79.3, y 39.9, w 5.4, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: MK-1406
- text at x 43.4, y 42.3, w 2.1, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: INT
- text at x 61.3, y 42.3, w 6.2, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: CDH6 ADC
- text at x 79.3, y 42.3, w 13.2, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: zanamivir-Fc conjugate
- text at x 43.4, y 45.2, w 8.5, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: nemtabrutinib
- text at x 61.3, y 45.8, w 7.1, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: opevesostat
- text at x 79.3, y 45.8, w 6.4, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: alimatravir
- text at x 43.4, y 47.6, w 7.5, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: BTK inhibitor
- text at x 61.3, y 48.2, w 9.9, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: CYP11A1 inhibitor
- text at x 79.3, y 48.2, w 2.9, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: NRTI
- text at x 43.4, y 73.5, w 13.9, h 3.3 [Invention-Bold; font size 3.33; #69B8F7]: Ophthalmology
- text at x 61.3, y 73.6, w 11.2, h 3.3 [Invention-Bold; font size 3.33; #6ECEB2]: Immunology
- text at x 43.4, y 51.1, w 8.2, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: bomedemstat
- text at x 92.2, y 33.9, w 0.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: 3
- text at x 61.3, y 51.7, w 13.5, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: patritumab deruxtecan
- text at x 79.3, y 51.7, w 13.0, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: islatravir + ulonivirine
- text at x 43.4, y 53.5, w 8.0, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: LSD1 inhibitor
- text at x 61.3, y 54.1, w 6.1, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: HER3 ADC
- text at x 79.3, y 54.1, w 8.1, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: NRTI + NNRTI
- text at x 43.4, y 57.0, w 12.3, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: zilovertamab vedotin
- text at x 61.3, y 57.6, w 5.3, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: MK-1045
- text at x 79.3, y 57.6, w 2.7, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: V181
- text at x 43.4, y 59.4, w 6.0, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: ROR1 ADC
- text at x 55.4, y 39.8, w 0.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: 2
- text at x 75.2, y 39.8, w 0.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: 4
- text at x 61.3, y 60.0, w 14.4, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: CD19xCD3 T-cell engager
- text at x 79.3, y 60.0, w 15.5, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: Tetravalent dengue vaccine
- text at x 43.4, y 63.0, w 13.2, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: ifinatamab deruxtecan
- text at x 61.3, y 63.5, w 6.1, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: gocatamig
- text at x 43.4, y 65.4, w 6.5, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: B7-H3 ADC
- text at x 61.3, y 65.9, w 11.4, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: DLL3 T-cell engager
- text at x 74.8, y 51.6, w 0.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: 4
- text at x 43.4, y 77.5, w 6.9, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: remigromig
- text at x 61.3, y 77.6, w 6.8, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: tulisokibart
- text at x 7.2, y 42.7, w 0.3, h 1.2 [Invention-Bold; font size 1.20; #FFFFFF]: 1
- text at x 43.4, y 79.9, w 7.0, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: Wnt agonist
- text at x 61.3, y 80.0, w 5.8, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: TL1A mAb
- text at x 43.4, y 83.4, w 5.7, h 2.2 [Invention-Bold; font size 2.22; #0C2340]: MK-8748
- text at x 43.4, y 85.8, w 13.6, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: Tie2 agonist/anti-VEGF
- text at x 56.5, y 62.9, w 0.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: 4
- text at x 7.2, y 51.1, w 0.4, h 1.2 [Invention-Bold; font size 1.20; #FFFFFF]: 2
- text at x 67.5, y 63.4, w 0.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: 3
- text at x 7.2, y 59.5, w 0.4, h 1.2 [Invention-Bold; font size 1.20; #FFFFFF]: 3
- text at x 3.1, y 95.0, w 82.0, h 3.7 [Invention-Regular; font size 1.67; #0C2340]: 1. Future potential growth drivers reflect pipeline compounds currently being evaluated in Phase 2/3 or Phase 3 clinical trials. 2. In collaboration with Moderna 3. In collaboration with Gilead 4. In collaboration with Daiichi Sankyo
- text at x 96.5, y 95.5, w 0.4, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 6

### Slide 7

**Text**

Financial Results / and Outlook / Caroline Litchfield / Executive Vice President and / Chief Financial Officer / 7

**Layout**

Two-column split: text block on the left half on a white field, full-height photograph filling the right half (x 50 to 100) from the top edge down to about 93% of slide height. Title sits left-aligned at about 32% of slide height, with the name and role block beneath it at left margin 3.1%. A small teal logo and the slide number 7 sit in the bottom-right footer strip below the photograph on white.

**Visuals**

Photograph of a woman in her fifties with shoulder-length straight light-brown hair with bangs, smiling broadly with teeth showing, blue eyes looking straight into the camera, wearing a dark navy crew-neck top with a fine dotted stitch detail at the neckline. Background is a softly blurred bright office interior with pale blue-grey glass panels and a vertical mullion at right. Soft, even daylight from the front, with a cool white-blue cast. Dominant colours: navy, warm skin tones, light brown hair, pale blue-grey and white background. Framing is head and shoulders, slightly off-centre to the left of the photo, cropped at the bottom edge of the image box and at the sides; it is a rectangular boxed photo with no border, not full-bleed on the bottom, full-height on the right. A small teal logo (four-lobed clover shape) sits in the footer at bottom right. No chart, table or diagram.

**Design**

Background: Solid white #FFFFFF. Clean white background with no gradient or pattern. Title and subtitle text in dark navy #0C2340. Body/role text also navy #0C2340. Slide number in light grey #9EA7B3. Photo panel placeholder grey #D9D9D9 sits behind photo. Typeface appears to be a light geometric humanist sans-serif (Invention-Light style), title large at about 8.2% of slide height per line, role lines about 3% of slide height. Thin weight, no bold, no italics, no capitals styling, normal letter-spacing. No shapes, lines, shadows, or corner radii; flat design.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide white background rectangle (covers the slide, no border)
- shape at x 50, y 0, w 50, h 93.1 [#D9D9D9]: Grey placeholder panel behind photograph (no border, no shadow, covered by photo)
- photo at x 50, y 0, w 50, h 93.1 [#D9D9D9]: Head-and-shoulders portrait of Caroline Litchfield, smiling woman with navy top against blurred bright office background (rectangular boxed image, 459 by 480 pixels, full height of right half, cropped at edges, no overlay or tint, no rounded corners)
- title at x 3.1, y 32.2, w 34.7, h 16.8 [Invention-Light, light weight sans-serif, normal case; font size 8.16% of slide height; #0C2340; left aligned]: Financial Results / and Outlook (two lines, line 1 'Financial Results' at y 32.2 w 34.7 h 8.2; line 2 'and Outlook' at y 41.0 w 24.8 h 8.2)
- body at x 3.1, y 51.1, w 21.6, h 10.1 [Invention-Light, light weight sans-serif, normal case; font size 2.96% of slide height; #0C2340; left aligned]: Caroline Litchfield / Executive Vice President and / Chief Financial Officer (three lines with tight line spacing, line 1 at y 51.1 w 13.2 h 3.0, line 2 at y 54.6 w 21.6 h 3.0, line 3 at y 58.2 w 16.0 h 3.0)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#17877A]: Small teal four-lobed clover-style company logo, bottom-right corner (image 125 by 150 pixels, sits on white footer strip beneath photo)
- page number at x 96.5, y 95.5, w 0.4, h 1.3 [Invention-Regular, regular weight sans-serif, normal case; font size 1.29% of slide height; #9EA7B3; right aligned]: 7 (bottom-right, right of logo)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 50.0, y 0.0, w 50.0, h 93.1: #D9D9D9
- image at x 50.0, y 0.0, w 50.0, h 93.1: 459 by 480 pixels
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 32.2, w 34.7, h 8.2 [Invention-Light; font size 8.16; #0C2340]: Financial Results
- text at x 3.1, y 41.0, w 24.8, h 8.2 [Invention-Light; font size 8.16; #0C2340]: and Outlook
- text at x 3.1, y 51.1, w 13.2, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Caroline Litchfield
- text at x 3.1, y 54.6, w 21.6, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Executive Vice President and
- text at x 3.1, y 58.2, w 16.0, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Chief Financial Officer
- text at x 96.5, y 95.5, w 0.4, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 7

### Slide 8

**Review notes**

- Worth studying: Uses large headline numbers with a simple bar chart for launch product revenue, so the key figures read at a glance.
- Review: The product slides 9 to 13 use a repeated three-bar format with large labelled values and growth rates that make results easy to scan, and slide 8 gives a strong headline number.
- Review: Weaknesses are consequential: several pages are dense or small (slides 3, 14, 15, 22, 27, 28), slide 8's launch chart has an unexplained hatched box and no growth label, and pale mint bars with white labels on slides 10 to 13 are weaker in contrast.
- Suggested repair: Raise contrast on white labels over mint bars on slides 10 to 12, label or simplify the hatched OHTUVAYRE segment on slide 8, and enlarge the guidance assumptions text on slide 15.

**Text**

Q3 growth across human and animal health with increasing contributions from new products / WORLDWIDE SALES 1 / $18.1B / +5% nominal / +4% ex-exchange / Human Health / $16.3B / +4% growth / +4% ex-exchange / Animal Health / $1.7B / +4% growth / +3% ex-exchange / $2.2B / $0.8B / 3Q25 / 3Q26 / Launch product revenue 2 / OHTUVAYRE sales reported by Verona Pharma / 1. Worldwide Sales includes Other Revenue 2. Launch products include WINREVAIR, KEYTRUDA QLEX, CAPVAXIVE, OHTUVAYRE, ENFLONSIA, IDVYNSO, LIPFENDRA, BRAVECTO QUANTUM and NUMELVI / 8

**Layout**

Full-width navy title band across the top 18.4% of the slide with a left-aligned, two-line white title starting at about 3.1% from the left edge. Below it, three columns separated by two thin dotted vertical rules at about x 36% and x 63.5%: left column holds the Worldwide Sales logo and figure centred around x 17%; middle column stacks Human Health and Animal Health, each with an icon, label, large figure and two growth lines, centred around x 53%; right column holds a two-bar column chart with a baseline at about y 77% spanning x 69% to 96%. A footnote line sits at the bottom left (y 95.6%), with a small teal logo and a grey page number '8' at the bottom right.

**Visuals**

Chart: vertical column chart titled 'Launch product revenue' with superscript 2. Categories on the x-axis: 3Q25 and 3Q26. Series: one series of launch product revenue. 3Q25 is labelled $0.8B and is a solid light-teal bar (about 0.8 units tall) with a dashed-outline light grey box stacked on top labelled as OHTUVAYRE sales reported by Verona Pharma. 3Q26 is labelled $2.2B and is a solid light-teal bar of full height (about 2.2 units). No y-axis, gridlines or numeric scale are printed; bar heights relative to each other are about 0.8 and 2.2 for the 3Q25 and 3Q26 bars respectively. Legend at bottom right: a small dashed grey-outlined rectangle with light grey fill followed by the text OHTUVAYRE sales reported by Verona Pharma. Icons: a line-drawn doctor with a stethoscope in teal above Human Health; a line-drawn dog in teal above Animal Health. Logo: a four-lobed teal emblem (two lobes left and right, two above and below, with white horizontal gaps) large at left above WORLDWIDE SALES, and a small version at bottom right near the footnote. Dividers: two vertical dotted light grey lines.

**Design**

Background: Solid white #FFFFFF with a full-width navy #0C2340 band across the top 18.4% of the slide. Clean corporate look. Title is light-weight humanist sans (Invention Light) in white at about 5.1% of slide height, roughly 2 lines. Body figures and labels are Invention Bold in navy #0C2340 with headline figures about 13.3% (worldwide) and 8.1% (segments) of slide height; subtext is Invention Regular at about 2.6 to 3.3% of slide height. Accent teal #00857C for the worldwide figure and icons; light teal #6ECEB2 for bars. Dividers are dotted light grey. No shadows, gradients or corner radii.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide white background rectangle (No border, no shadow)
- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Navy title band rectangle (Full width, square corners, no border)
- title at x 3.1, y 3.9, w 92.7, h 10.6 [Invention Light, regular weight, sans-serif; font size 5.09% of slide height; #FFFFFF; left aligned]: Q3 growth across human and animal health with increasing contributions / from new products
- logo at x 8.1, y 33.5, w 18.1, h 17.5 [#00857C]: Large four-lobed teal company emblem (two circles left and right, two circles above and below, each split by white horizontal gap) (Image 422 by 230 pixels, no box or border)
- body at x 4.5, y 54.1, w 24.6, h 4.4 [Invention Bold, all capitals, sans-serif; font size 4.44% of slide height; #0C2340; center aligned]: WORLDWIDE SALES
- caption at x 29.1, y 53.9, w 0.7, h 3 [Invention Regular, superscript; font size 2.96% of slide height; #0C2340; left aligned]: 1
- body at x 5.5, y 60.1, w 23.2, h 13.3 [Invention Bold, sans-serif; font size 13.33% of slide height; #00857C; center aligned]: $18.1B
- body at x 11.6, y 73.9, w 11.1, h 3.3 [Invention Regular, sans-serif; font size 3.33% of slide height; #0C2340; center aligned]: +5% nominal
- body at x 9.5, y 77.5, w 15.2, h 3.3 [Invention Regular, sans-serif; font size 3.33% of slide height; #0C2340; center aligned]: +4% ex-exchange
- line at x 35.9, y 14.2, w 0.2, h 76 [#C8CDD3]: Dotted vertical divider between left and middle columns (Dotted stroke, light grey, about 0.2% of slide width)
- line at x 63.4, y 25.3, w 0.2, h 64 [#C8CDD3]: Dotted vertical divider between middle and right columns (Dotted stroke, light grey, about 0.2% of slide width)
- icon at x 47.2, y 25.1, w 5.2, h 9.8 [#00857C]: Line-drawn doctor with stethoscope icon (Teal outline icon, no fill, image 154 by 162 pixels)
- body at x 41.4, y 36.7, w 16.8, h 4.4 [Invention Bold, sans-serif; font size 4.44% of slide height; #0C2340; center aligned]: Human Health
- body at x 42.4, y 43.2, w 14.7, h 8.1 [Invention Bold, sans-serif; font size 8.07% of slide height; #0C2340; center aligned]: $16.3B
- body at x 43.8, y 51.6, w 11.9, h 5.4 [Invention Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: +4% growth / +4% ex-exchange (Two lines: +4% growth (x 45.6, w 8.3) above +4% ex-exchange (x 43.8, w 11.9))
- icon at x 47.2, y 59.5, w 5.2, h 8.4 [#00857C]: Line-drawn dog icon (Teal outline icon, no fill, image 154 by 139 pixels)
- body at x 41.5, y 69.7, w 16.5, h 4.4 [Invention Bold, sans-serif; font size 4.44% of slide height; #0C2340; center aligned]: Animal Health
- body at x 43.9, y 76.2, w 11.7, h 8.1 [Invention Bold, sans-serif; font size 8.07% of slide height; #0C2340; center aligned]: $1.7B
- body at x 43.9, y 84.6, w 11.8, h 5.4 [Invention Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: +4% growth / +3% ex-exchange (Two lines: +4% growth (x 45.6, w 8.3) above +3% ex-exchange (x 43.9, w 11.8))
- shape at x 71.4, y 62.2, w 9, h 14.5 [#6ECEB2]: 3Q25 bar of launch product revenue chart, solid light teal (Square corners, no border, bottom sits on baseline)
- shape at x 71.4, y 59.5, w 9, h 2.7 [#F5F5F5]: OHTUVAYRE dashed placeholder box stacked on top of 3Q25 bar (Light grey fill, dashed grey outline, square corners)
- shape at x 84.9, y 31, w 9, h 45.8 [#6ECEB2]: 3Q26 bar of launch product revenue chart, solid light teal (Square corners, no border, bottom sits on baseline)
- line at x 69.2, y 76.6, w 26.9, h 0.3 [#0C2340]: Chart baseline with small tick marks at each bar edge (Thin navy stroke, ticks at x 69.2, 81.2, 84.9 and 96.1 going down slightly)
- body at x 73.2, y 54.8, w 5.8, h 3.3 [Invention Bold, sans-serif; font size 3.33% of slide height; #0C2340; center aligned]: $0.8B
- body at x 86.8, y 26.3, w 5.2, h 3.3 [Invention Bold, sans-serif; font size 3.33% of slide height; #0C2340; center aligned]: $2.2B
- body at x 74.2, y 79.5, w 3.6, h 2.6 [Invention Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: 3Q25
- body at x 87.6, y 79.5, w 3.6, h 2.6 [Invention Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: 3Q26
- body at x 71.8, y 83.1, w 21.1, h 3.3 [Invention Bold, sans-serif; font size 3.33% of slide height; #0C2340; center aligned]: Launch product revenue
- caption at x 92.9, y 83, w 0.7, h 2.2 [Invention Regular, superscript; font size 2.22% of slide height; #0C2340; left aligned]: 2
- shape at x 71.3, y 88.6, w 2, h 2.2 [#F5F5F5]: Legend swatch for OHTUVAYRE sales (Dashed grey outline, light grey fill, square corners)
- caption at x 71.7, y 89.1, w 20.1, h 1.7 [Invention Regular, sans-serif; font size 1.67% of slide height; #0C2340; left aligned]: OHTUVAYRE sales reported by Verona Pharma
- caption at x 3.1, y 95.6, w 84.3, h 3.4 [Invention Regular, sans-serif; font size 1.67% of slide height; #0C2340; left aligned]: 1. Worldwide Sales includes Other Revenue 2. Launch products include WINREVAIR, KEYTRUDA QLEX, CAPVAXIVE, OHTUVAYRE, ENFLONSIA, IDVYNSO, LIPFENDRA, BRAVECTO QUANTUM and NUMELVI (Two lines, wrapping after 'and' with NUMELVI on the second line)
- logo at x 92.2, y 94.4, w 2.3, h 3.4 [#00857C]: Small four-lobed teal company emblem, bottom right (Same emblem as main logo, scaled down)
- page number at x 96.4, y 95.5, w 0.4, h 1.3 [Invention Regular, sans-serif; font size 1.29% of slide height; #9EA7B3; right aligned]: 8

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- fill at x 71.4, y 31.0, w 22.4, h 45.8: #6ECEB2
- image at x 8.1, y 33.5, w 18.1, h 17.5: 422 by 230 pixels
- image at x 47.2, y 25.1, w 5.2, h 9.8: 154 by 162 pixels
- image at x 47.2, y 59.5, w 5.2, h 8.4: 154 by 139 pixels
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 3.9, w 92.7, h 10.6 [Invention-Light; font size 5.09; #FFFFFF]: Q3 growth across human and animal health with increasing contributions from new products
- text at x 5.5, y 60.1, w 23.2, h 13.3 [Invention-Bold; font size 13.33; #00857C]: $18.1B
- text at x 42.4, y 43.2, w 14.7, h 8.1 [Invention-Bold; font size 8.07; #0C2340]: $16.3B
- text at x 86.8, y 26.3, w 5.2, h 3.3 [Invention-Bold; font size 3.33; #0C2340]: $2.2B
- text at x 41.4, y 36.7, w 16.8, h 4.4 [Invention-Bold; font size 4.44; #0C2340]: Human Health
- text at x 43.9, y 76.2, w 11.7, h 8.1 [Invention-Bold; font size 8.07; #0C2340]: $1.7B
- text at x 4.5, y 54.1, w 24.6, h 4.4 [Invention-Bold; font size 4.44; #0C2340]: WORLDWIDE SALES
- text at x 41.5, y 69.7, w 16.5, h 4.4 [Invention-Bold; font size 4.44; #0C2340]: Animal Health
- text at x 73.2, y 54.8, w 5.8, h 3.3 [Invention-Bold; font size 3.33; #0C2340]: $0.8B
- text at x 29.1, y 53.9, w 0.7, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: 1
- text at x 45.6, y 51.6, w 8.3, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: +4% growth
- text at x 43.8, y 54.4, w 11.9, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: +4% ex-exchange
- text at x 11.6, y 73.9, w 11.1, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: +5% nominal
- text at x 9.5, y 77.5, w 15.2, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: +4% ex-exchange
- text at x 71.8, y 83.1, w 21.1, h 3.3 [Invention-Bold; font size 3.33; #0C2340]: Launch product revenue
- text at x 74.2, y 79.5, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q25
- text at x 87.6, y 79.5, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q26
- text at x 45.6, y 84.6, w 8.3, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: +4% growth
- text at x 43.9, y 87.4, w 11.8, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: +3% ex-exchange
- text at x 92.9, y 83.0, w 0.7, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: 2
- text at x 71.7, y 89.1, w 20.1, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: OHTUVAYRE sales reported by Verona Pharma
- text at x 3.1, y 95.6, w 84.3, h 3.4 [Invention-Regular; font size 1.67; #0C2340]: 1. Worldwide Sales includes Other Revenue 2. Launch products include WINREVAIR, KEYTRUDA QLEX, CAPVAXIVE, OHTUVAYRE, ENFLONSIA, IDVYNSO, LIPFENDRA, BRAVECTO QUANTUM and NUMELVI
- text at x 96.4, y 95.5, w 0.4, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 8

### Slide 9

**Review notes**

- Review: The product slides 9 to 13 use a repeated three-bar format with large labelled values and growth rates that make results easy to scan, and slide 8 gives a strong headline number.
- Worth keeping: Keep the navy title band with sentence headlines, the speaker section dividers, and the consistent teal, mint and blue three-quarter bar charts with value and growth labels on slides 9 to 13.

**Text**

Oncology: KEYTRUDA continues to benefit patients and drive growth
KEYTRUDA family1 sales of $8.6B increased 6% / driven by strong uptake in earlier-stage cancers and / continued robust demand from metastatic / indications
‒ Growth driven by usage in tumors / predominantly affecting women, including those / with certain cervical and breast cancers
‒ Increased use in combination with Padcev / (enfortumab vedotin) in urothelial cancer and / continued uptake in earlier-stage head and neck / cancer
‒ U.S. YoY timing headwind largely offset by / increase in channel inventory, expected to / unwind in 4Q26
‒ KEYTRUDA QLEX sales of $830M in 3Q26 / following launch in 3Q25
$7.4B
+21%2
$8.1B
+8%
$8.6B
+6%
3Q24
3Q25
3Q26
Growth rates exclude the impact of foreign exchange 1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX (available as KEYTRUDA SC in some markets) 2. ~3 percentage points of negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.
9

**Layout**

Two-column layout on a white page: a full-width navy title band across the top (about the top 18% of the slide height) holds the title, with the body text in a left column (about x 3% to 47%) and a column bar chart on the right (about x 52% to 96%), separated by a thin dotted vertical divider at about x 45%. The title is left-aligned at about x 3%, vertically centred in the band. Footnotes sit along the bottom left at about y 96%, the small teal logo sits bottom right at about x 92%, and the page number 9 sits at about x 96.5%, y 95.5%, right of the logo.

**Visuals**

Column bar chart with three bars, no axis title and no y-axis, a horizontal baseline with small tick marks at each bar centre (about y 85.5%, x 52.7% to 95.3%). Bars from left to right: 3Q24 dark teal #00857C, value $7.4B with +21% growth (footnote 2), bar height about 34% of slide height; 3Q25 mint #6ECEB2, value $8.1B with +8% growth, bar height about 44%; 3Q26 light blue #69B8F7, value $8.6B with +6% growth, bar height about 48%. Values are printed in white bold text inside the top of each bar. Category labels 3Q24, 3Q25, 3Q26 sit under the baseline. No legend and no highlighted points. Above the chart are two product logos: the KEYTRUDA wordmark in green #6CBF44 with a navy Y-shaped letter stroke and '(pembrolizumab) Injection 100 mg' beneath it, and the KEYTRUDA Qlex wordmark with a purple #5B2C83 'Qlex' and the text 'pembrolizumab + berahyaluronidase alfa-pmph' and 'Subcutaneous Injection | 165 mg + 2,000 units/mL' beneath it. Both logos are placed images without boxes. Bottom right is a small teal circular company logo (a stylised three-lobed shape in #00857C) at about x 92%, y 93%.

**Design**

Background: Solid white #FFFFFF, with a navy #0C2340 band across the top 18.4% of the slide. White background with a full-width navy #0C2340 title band across the top about 18% of slide height. Title text is white Invention Light (a humanist sans-serif), large, about 5.1% of slide height, sentence case. Body text is navy #0C2340 Invention Regular, about 3.0% of slide height, with the main lead paragraph and dash-marked bullets. Bar values are white Invention Bold, about 3.3% of slide height. Category labels navy Invention Regular about 2.6%. Footnotes are navy Invention Regular about 1.7%. Page number is grey #9EA7B3 Invention Regular about 1.3%. Accent colours are teal #00857C, mint #6ECEB2 and light blue #69B8F7. Shapes are flat rectangles with square corners, no shadows, no gradients. The divider is a dotted light grey line.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide white background rectangle (Covers the whole slide, no border.)
- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Navy title band rectangle (Flat fill, square corners, no shadow; sits behind the title.)
- title at x 3.1, y 6.7, w 87.9, h 5.1 [Invention Light, sans-serif, regular weight, sentence case; font size 5.09% of slide height; #FFFFFF; left aligned]: Oncology: KEYTRUDA continues to benefit patients and drive growth (Single line, vertically centred in the navy band.)
- line at x 45.2, y 24.8, w 0.2, h 66.2 [#C8CDD3]: Vertical dotted divider between the columns (Dotted light grey stroke about 2px wide, fine dots, no end caps.)
- logo at x 56.3, y 26.4, w 13.5, h 8.5 [#6CBF44]: KEYTRUDA logo: green wordmark with navy Y stroke and '(pembrolizumab) Injection 100 mg' beneath (Placed image, 274 by 97 pixels, no box or border.)
- logo at x 72.4, y 27, w 18.3, h 7.9 [#5B2C83]: KEYTRUDA Qlex logo: wordmark with purple Qlex, 'pembrolizumab + berahyaluronidase alfa-pmph' and 'Subcutaneous Injection | 165 mg + 2,000 units/mL' (Placed image, 207 by 50 pixels, no box or border.)
- body at x 3.3, y 25.9, w 39.3, h 13.6 [Invention Regular, sans-serif, regular weight; font size 2.96% of slide height; #0C2340; left aligned]: KEYTRUDA family1 sales of $8.6B increased 6% / driven by strong uptake in earlier-stage cancers and / continued robust demand from metastatic / indications (Line spacing about 1.25; superscript 1 after 'family' at x 17.2%, y 25.8%, em 1.98, navy.)
- bullet list at x 3.3, y 42.4, w 39.6, h 10.1 [Invention Regular, sans-serif, regular weight; font size 2.96% of slide height; #0C2340; left aligned]: ‒ Growth driven by usage in tumors / predominantly affecting women, including those / with certain cervical and breast cancers (Dash bullet '‒' at x 3.3%, text indented to x 5.7%, line spacing about 1.25.)
- bullet list at x 3.3, y 55.3, w 38.9, h 13.6 [Invention Regular, sans-serif, regular weight; font size 2.96% of slide height; #0C2340; left aligned]: ‒ Increased use in combination with Padcev / (enfortumab vedotin) in urothelial cancer and / continued uptake in earlier-stage head and neck / cancer (Dash bullet at x 3.3%, text indented to x 5.7%.)
- bullet list at x 3.3, y 71.7, w 34.3, h 10.1 [Invention Regular, sans-serif, regular weight; font size 2.96% of slide height; #0C2340; left aligned]: ‒ U.S. YoY timing headwind largely offset by / increase in channel inventory, expected to / unwind in 4Q26 (Dash bullet at x 3.3%, text indented to x 5.7%.)
- bullet list at x 3.3, y 84.6, w 34.2, h 6.5 [Invention Regular, sans-serif, regular weight; font size 2.96% of slide height; #0C2340; left aligned]: ‒ KEYTRUDA QLEX sales of $830M in 3Q26 / following launch in 3Q25 (Dash bullet at x 3.3%, text indented to x 5.7%.)
- shape at x 55, y 51.4, w 9.5, h 34.2 [#00857C]: Bar 3Q24 (dark teal bar) (Flat fill, square corners, no outline, no shadow.)
- shape at x 69.3, y 41.3, w 9.5, h 44.3 [#6ECEB2]: Bar 3Q25 (mint bar) (Flat fill, square corners, no outline.)
- shape at x 83.5, y 37.7, w 9.5, h 47.9 [#69B8F7]: Bar 3Q26 (light blue bar) (Flat fill, square corners, no outline.)
- line at x 52.7, y 85.4, w 42.6, h 0.3 [#0C2340]: Chart x-axis baseline with tick marks at each bar centre (Thin navy stroke about 1px; small downward ticks at about x 52.7%, 66.5%, 81.0%, 95.3%.)
- body at x 85.5, y 39.6, w 5.4, h 3.3 [Invention Bold, sans-serif, bold weight; font size 3.33% of slide height; #FFFFFF; center aligned]: $8.6B (Value label inside top of 3Q26 bar.)
- body at x 86.2, y 43.6, w 4, h 3.3 [Invention Bold, sans-serif, bold weight; font size 3.33% of slide height; #FFFFFF; center aligned]: +6% (Growth label under $8.6B inside 3Q26 bar.)
- body at x 71.4, y 43, w 5, h 3.3 [Invention Bold, sans-serif, bold weight; font size 3.33% of slide height; #FFFFFF; center aligned]: $8.1B (Value label inside top of 3Q25 bar.)
- body at x 71.9, y 47, w 4, h 3.3 [Invention Bold, sans-serif, bold weight; font size 3.33% of slide height; #FFFFFF; center aligned]: +8% (Growth label under $8.1B inside 3Q25 bar.)
- body at x 57.1, y 53.3, w 5.2, h 3.3 [Invention Bold, sans-serif, bold weight; font size 3.33% of slide height; #FFFFFF; center aligned]: $7.4B (Value label inside top of 3Q24 bar.)
- body at x 57, y 57.3, w 4.7, h 3.3 [Invention Bold, sans-serif, bold weight; font size 3.33% of slide height; #FFFFFF; center aligned]: +21% (Growth label under $7.4B; superscript 2 follows at x 61.7%, y 57.1%, em 2.22, white.)
- body at x 61.7, y 57.1, w 0.7, h 2.2 [Invention Regular, sans-serif, regular weight, superscript; font size 2.22% of slide height; #FFFFFF; left aligned]: 2 (Footnote marker.)
- body at x 58, y 88.3, w 3.6, h 2.6 [Invention Regular, sans-serif, regular weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q24 (Category label under 3Q24 bar.)
- body at x 72.2, y 88.3, w 3.6, h 2.6 [Invention Regular, sans-serif, regular weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q25 (Category label under 3Q25 bar.)
- body at x 86.4, y 88.3, w 3.6, h 2.6 [Invention Regular, sans-serif, regular weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q26 (Category label under 3Q26 bar.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Small teal circular company logo (stylised three-lobed mark) (Placed image, 125 by 150 pixels, no box.)
- footer at x 3.1, y 95.9, w 85.3, h 3.4 [Invention Regular, sans-serif, regular weight; font size 1.67% of slide height; #0C2340; left aligned]: Growth rates exclude the impact of foreign exchange 1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX (available as KEYTRUDA SC in some markets) 2. ~3 percentage points of negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market. (Two lines of footnote text, tight line spacing; no line breaks shown beyond wrapping.)
- page number at x 96.5, y 95.5, w 0.4, h 1.3 [Invention Regular, sans-serif, regular weight; font size 1.29% of slide height; #9EA7B3; right aligned]: 9 (Light grey page number at bottom right.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- fill at x 69.3, y 41.3, w 9.5, h 44.3: #6ECEB2
- fill at x 83.5, y 37.7, w 9.5, h 47.9: #69B8F7
- fill at x 55.0, y 51.4, w 9.5, h 34.2: #00857C
- image at x 72.4, y 27.0, w 18.3, h 7.9: 207 by 50 pixels
- image at x 56.3, y 26.4, w 13.5, h 8.5: 274 by 97 pixels
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 6.7, w 87.9, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Oncology: KEYTRUDA continues to benefit patients and drive growth
- text at x 3.3, y 25.9, w 13.9, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: KEYTRUDA family
- text at x 3.3, y 25.9, w 39.3, h 13.6 [Invention-Regular; font size 2.96; #0C2340]: sales of $8.6B increased 6% driven by strong uptake in earlier-stage cancers and continued robust demand from metastatic indications
- text at x 85.5, y 39.6, w 5.4, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $8.6B
- text at x 17.2, y 25.8, w 0.4, h 2.0 [Invention-Regular; font size 1.98; #0C2340]: 1
- text at x 71.4, y 43.0, w 5.0, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $8.1B
- text at x 86.2, y 43.6, w 4.0, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +6%
- text at x 71.9, y 47.0, w 4.0, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +8%
- text at x 3.3, y 42.4, w 1.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: ‒
- text at x 5.7, y 42.4, w 36.9, h 10.1 [Invention-Regular; font size 2.96; #0C2340]: Growth driven by usage in tumors predominantly affecting women, including those with certain cervical and breast cancers
- text at x 57.1, y 53.3, w 5.2, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $7.4B
- text at x 57.0, y 57.3, w 4.7, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +21%
- text at x 3.3, y 55.3, w 1.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: ‒
- text at x 5.7, y 55.3, w 36.4, h 13.6 [Invention-Regular; font size 2.96; #0C2340]: Increased use in combination with Padcev (enfortumab vedotin) in urothelial cancer and continued uptake in earlier-stage head and neck cancer
- text at x 3.3, y 71.7, w 1.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: ‒
- text at x 5.7, y 71.7, w 32.5, h 10.1 [Invention-Regular; font size 2.96; #0C2340]: U.S. YoY timing headwind largely offset by increase in channel inventory, expected to unwind in 4Q26
- text at x 61.7, y 57.1, w 0.7, h 2.2 [Invention-Regular; font size 2.22; #FFFFFF]: 2
- text at x 3.3, y 84.6, w 1.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: ‒
- text at x 5.7, y 84.6, w 32.1, h 6.5 [Invention-Regular; font size 2.96; #0C2340]: KEYTRUDA QLEX sales of $830M in 3Q26 following launch in 3Q25
- text at x 58.0, y 88.3, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q24
- text at x 72.2, y 88.3, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q25
- text at x 86.4, y 88.3, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q26
- text at x 3.1, y 95.9, w 85.3, h 3.4 [Invention-Regular; font size 1.67; #0C2340]: Growth rates exclude the impact of foreign exchange 1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX (available as KEYTRUDA SC in some markets) 2. ~3 percentage points of negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.
- text at x 96.5, y 95.5, w 0.4, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 9

### Slide 10

**Review notes**

- Worth studying: Places three brand bar charts side by side with consistent colours and labels, making period-on-period comparison easy.
- Review: The product slides 9 to 13 use a repeated three-bar format with large labelled values and growth rates that make results easy to scan, and slide 8 gives a strong headline number.
- Review: Weaknesses are consequential: several pages are dense or small (slides 3, 14, 15, 22, 27, 28), slide 8's launch chart has an unexplained hatched box and no growth label, and pale mint bars with white labels on slides 10 to 13 are weaker in contrast.
- Review: Some slides leave large empty areas next to charts (slides 10, 11, 12, 16).
- Worth keeping: Keep the navy title band with sentence headlines, the speaker section dividers, and the consistent teal, mint and blue three-quarter bar charts with value and growth labels on slides 9 to 13.
- Suggested repair: Raise contrast on white labels over mint bars on slides 10 to 12, label or simplify the hatched OHTUVAYRE segment on slide 8, and enlarge the guidance assumptions text on slide 15.

**Text**

Oncology: Continued impact for patients across broad portfolio
WELIREG sales of $307M grew 58% driven by continued higher demand in the U.S. and launch uptake in international markets
Lynparza1 alliance revenue of $352M decreased 7% primarily due to lower net pricing in the U.S. and lower demand and pricing in China
Lenvima2 alliance revenue of $287M grew 11% primarily due to higher demand in the U.S.
3Q24 3Q25 3Q26 (WELIREG row) $139M +157% $196M +41% $307M +58%
3Q24 3Q25 3Q26 (Lynparza row) $337M +13% $379M +12% $352M -7%
3Q24 3Q25 3Q26 (Lenvima row) $251M -4% $258M +2% $287M +11%
Growth rates exclude the impact of foreign exchange 1. In collaboration with AstraZeneca 2. In collaboration with Eisai
10

**Layout**

Two-column layout on a full-width navy title band across the top 18.4% of the slide: title left-aligned at x 3.1% in the band, vertically centred. Left column (x 3.1% to about 42%) holds three text paragraphs top-aligned at y 25.9%. Right column (x about 47% to 94%) holds three stacked rows of bar charts, each with a logo at left and three columns of bars labelled 3Q24, 3Q25, 3Q26, separated by dotted horizontal rules; a dotted vertical divider at x 45.2% separates the columns. Footnote sits bottom-left at y 97.3%, page number bottom-right at x 96.1%, y 95.5%, and a small teal logo mark sits at bottom-right near x 91.8%, y 92.8%.

**Visuals**

Three grouped vertical bar charts (one per product row), no axis titles, no numeric y-axis; each bar carries its value and growth rate printed inside it. Row 1 WELIREG (belzutifan) logo: 3Q24 bar $139M +157% (dark teal), 3Q25 bar $196M +41% (light teal), 3Q26 bar $307M +58% (light blue); bar tops at about 31.8%, 28.4% and 21.9% of slide height. Row 2 Lynparza (olaparib) logo: 3Q24 bar $337M +13% (dark teal), 3Q25 bar $379M +12% (light teal), 3Q26 bar $352M -7% (light blue); bar tops about 49.4%, 47.4% and 48.7%. Row 3 LENVIMA (lenvatinib) capsules logo: 3Q24 bar $251M -4% (dark teal), 3Q25 bar $258M +2% (light teal), 3Q26 bar $287M +11% (light blue); bar tops about 78.8%, 78.4% and 77.0%. Bars are flat rectangles with square corners, all bottom-aligned to a thin dark navy baseline with three tick marks per row. Legend: none; colour distinguishes the three periods (dark teal, light teal, light blue) consistently across rows. No highlighted points. Logos: WELIREG (belzutifan) 10 mg tablets wordmark with red and purple dot cluster; Lynparza olaparib tablets wordmark with green DNA-helix graphic; LENVIMA (lenvatinib) capsules wordmark with teal and yellow swoosh. Corner mark: teal and green four-lobed company icon. Photographs: none.

**Design**

Background: Solid white #FFFFFF, with a full-width navy #0C2340 band covering the top 18.4% of the slide behind the title. Flat, minimal corporate style: white background with a solid navy title band. Title in white Invention Light-style humanist sans-serif, approximately 5.1% of slide height. Body text in navy #0C2340 Invention Regular, about 3.0% of slide height, line spacing about 1.2, paragraphs separated by one blank line. Bar value labels in white Invention Bold, about 3.3% of slide height. Year labels in navy #0C2340 Invention Regular about 2.6%. Accents: dark teal #00857C, light teal #6ECEB2, light blue #69B8F7. Footnote in navy #0C2340 at about 1.7%. Page number in grey #9EA7B3 at about 1.3%. Divider lines are light grey dotted (about #C8CDD3, 1 pt dotted). Baselines are navy, thin. No corner radii, shadows or gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: White full-slide background rectangle (Covers the whole slide; no border.)
- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Navy title band rectangle (Full-width band, square corners, no shadow, sits behind title.)
- line at x 45.2, y 21.6, w 0.2, h 69.7 [#C8CDD3]: Vertical dotted divider between text column and charts (Dotted stroke about 1 pt, light grey.)
- line at x 48.1, y 45.9, w 48.5, h 0.2 [#C8CDD3]: Horizontal dotted separator between WELIREG and Lynparza rows (Dotted stroke about 1 pt, light grey.)
- line at x 48.4, y 71.6, w 48.5, h 0.2 [#C8CDD3]: Horizontal dotted separator between Lynparza and LENVIMA rows (Dotted stroke about 1 pt, light grey.)
- shape at x 58.3, y 31.8, w 8.3, h 8.2 [#00857C]: WELIREG 3Q24 bar, value $139M +157% (Flat rectangle, square corners, bottom on baseline at 39.9%.)
- shape at x 70.6, y 28.4, w 8.2, h 11.5 [#6ECEB2]: WELIREG 3Q25 bar, value $196M +41% (Flat rectangle, square corners, bottom on baseline at 39.9%.)
- shape at x 83, y 21.9, w 8.2, h 18.1 [#69B8F7]: WELIREG 3Q26 bar, value $307M +58% (Flat rectangle, square corners, bottom on baseline at 39.9%.)
- line at x 56.2, y 39.8, w 37.1, h 0.3 [#0C2340]: WELIREG row baseline with three tick marks (Thin navy line, ticks at x 56.2, 68.6, 80.9 and 93.3 percent, ticks about 0.6% tall pointing down.)
- shape at x 58.3, y 49.4, w 8.3, h 16.2 [#00857C]: Lynparza 3Q24 bar, value $337M +13% (Flat rectangle, square corners, bottom on baseline at 65.6%.)
- shape at x 70.6, y 47.4, w 8.2, h 18.2 [#6ECEB2]: Lynparza 3Q25 bar, value $379M +12% (Flat rectangle, square corners, bottom on baseline at 65.6%.)
- shape at x 83, y 48.7, w 8.2, h 16.9 [#69B8F7]: Lynparza 3Q26 bar, value $352M -7% (Flat rectangle, square corners, bottom on baseline at 65.6%.)
- line at x 56.2, y 65.4, w 37.1, h 0.3 [#0C2340]: Lynparza row baseline with three tick marks (Thin navy line, ticks at x 56.2, 68.6, 80.9 and 93.3 percent.)
- shape at x 58.3, y 78.8, w 8.3, h 12.6 [#00857C]: LENVIMA 3Q24 bar, value $251M -4% (Flat rectangle, square corners, bottom on baseline at 91.4%.)
- shape at x 70.6, y 78.4, w 8.2, h 12.9 [#6ECEB2]: LENVIMA 3Q25 bar, value $258M +2% (Flat rectangle, square corners, bottom on baseline at 91.4%.)
- shape at x 83, y 77, w 8.2, h 14.4 [#69B8F7]: LENVIMA 3Q26 bar, value $287M +11% (Flat rectangle, square corners, bottom on baseline at 91.4%.)
- line at x 56.2, y 91.1, w 37.1, h 0.3 [#0C2340]: LENVIMA row baseline with three tick marks (Thin navy line, ticks at x 56.2, 68.6, 80.9 and 93.3 percent.)
- logo at x 47.6, y 28.2, w 8.5, h 6.5: WELIREG (belzutifan) 10 mg tablets logo with red and purple dot cluster (Placed image 171 by 74 pixels, no box or border.)
- logo at x 48.2, y 55.3, w 7.5, h 6.6: Lynparza olaparib tablets 100 mg logo with green helix graphic (Placed image 183 by 91 pixels, no box or border.)
- logo at x 47.3, y 81.5, w 9.1, h 5.1: LENVIMA (lenvatinib) capsules logo with teal and yellow swoosh (Placed image 203 by 64 pixels, no box or border.)
- body at x 3.1, y 25.9, w 36.3, h 10.1 [Invention, Regular, sentence case; font size 2.96% of slide height; #0C2340; left aligned]: WELIREG sales of $307M grew 58% driven by / continued higher demand in the U.S. and launch / uptake in international markets (Line spacing about 1.2.)
- body at x 3.1, y 39.9, w 6.9, h 3 [Invention, Regular, sentence case; font size 2.96% of slide height; #0C2340; left aligned]: Lynparza1 (Superscript 1 at x 10.0%, y 39.8%, size 1.98%.)
- body at x 3.1, y 39.9, w 38.4, h 10.1 [Invention, Regular, sentence case; font size 2.96% of slide height; #0C2340; left aligned]: alliance revenue of $352M decreased 7% primarily due to lower net pricing in the U.S. and / lower demand and pricing in China (Line spacing about 1.2.)
- body at x 3.1, y 53.9, w 34.7, h 6.5 [Invention, Regular, sentence case; font size 2.96% of slide height; #0C2340; left aligned]: Lenvima2 alliance revenue of $287M grew 11% primarily due to higher demand in the U.S. (Superscript 2 at x 9.5%, y 53.8%, size 1.98%. Line spacing about 1.2.)
- title at x 3.1, y 6.7, w 79.6, h 5.1 [Invention, Light, sentence case; font size 5.09% of slide height; #FFFFFF; left aligned]: Oncology: Continued impact for patients across broad portfolio (Sits vertically centred in navy band.)
- body at x 59.5, y 32.8, w 5.9, h 3.3 [Invention, Bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $139M / +157% (Value label inside 3Q24 WELIREG bar, two lines.)
- body at x 71.8, y 30.1, w 5.9, h 3.3 [Invention, Bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $196M / +41% (Value label inside 3Q25 WELIREG bar, two lines.)
- body at x 84, y 23.6, w 6.1, h 7.2 [Invention, Bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $307M / +58% (Value label inside 3Q26 WELIREG bar, two lines.)
- body at x 59.3, y 51.3, w 6, h 7.2 [Invention, Bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $337M / +13% (Value label inside 3Q24 Lynparza bar, two lines.)
- body at x 71.7, y 49.2, w 6, h 6.8 [Invention, Bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $379M / +12% (Value label inside 3Q25 Lynparza bar, two lines.)
- body at x 84, y 50.4, w 6.1, h 7.2 [Invention, Bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $352M / -7% (Value label inside 3Q26 Lynparza bar, two lines.)
- body at x 59.4, y 81, w 5.8, h 7.2 [Invention, Bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $251M / -4% (Value label inside 3Q24 LENVIMA bar, two lines.)
- body at x 71.7, y 80.5, w 6.2, h 6.8 [Invention, Bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $258M / +2% (Value label inside 3Q25 LENVIMA bar, two lines.)
- body at x 84.1, y 78.7, w 6.1, h 7.2 [Invention, Bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $287M / +11% (Value label inside 3Q26 LENVIMA bar, two lines.)
- body at x 60.6, y 42.7, w 3.6, h 2.6 [Invention, Regular; font size 2.6% of slide height; #0C2340; center aligned]: 3Q24 (Year label under WELIREG 3Q24 column.)
- body at x 73, y 42.7, w 3.6, h 2.6 [Invention, Regular; font size 2.6% of slide height; #0C2340; center aligned]: 3Q25 (Year label under WELIREG 3Q25 column.)
- body at x 85.3, y 42.7, w 3.6, h 2.6 [Invention, Regular; font size 2.6% of slide height; #0C2340; center aligned]: 3Q26 (Year label under WELIREG 3Q26 column.)
- body at x 60.6, y 68.3, w 3.6, h 2.6 [Invention, Regular; font size 2.6% of slide height; #0C2340; center aligned]: 3Q24 (Year label under Lynparza 3Q24 column.)
- body at x 73, y 68.3, w 3.6, h 2.6 [Invention, Regular; font size 2.6% of slide height; #0C2340; center aligned]: 3Q25 (Year label under Lynparza 3Q25 column.)
- body at x 85.3, y 68.3, w 3.6, h 2.6 [Invention, Regular; font size 2.6% of slide height; #0C2340; center aligned]: 3Q26 (Year label under Lynparza 3Q26 column.)
- body at x 60.6, y 94.1, w 3.6, h 2.6 [Invention, Regular; font size 2.6% of slide height; #0C2340; center aligned]: 3Q24 (Year label under LENVIMA 3Q24 column.)
- body at x 73, y 94.1, w 3.6, h 2.6 [Invention, Regular; font size 2.6% of slide height; #0C2340; center aligned]: 3Q25 (Year label under LENVIMA 3Q25 column.)
- body at x 85.3, y 94.1, w 3.6, h 2.6 [Invention, Regular; font size 2.6% of slide height; #0C2340; center aligned]: 3Q26 (Year label under LENVIMA 3Q26 column.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Company corner logo: teal and green four-lobed icon (Placed image 125 by 150 pixels, no box.)
- caption at x 3.1, y 97.3, w 50.2, h 1.7 [Invention, Regular, sentence case; font size 1.67% of slide height; #0C2340; left aligned]: Growth rates exclude the impact of foreign exchange 1. In collaboration with AstraZeneca 2. In collaboration with Eisai (Footnote, single line.)
- page number at x 96.1, y 95.5, w 0.7, h 1.3 [Invention, Regular; font size 1.29% of slide height; #9EA7B3; right aligned]: 10 (Light grey page number.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 70.6, y 28.4, w 8.2, h 11.5: #6ECEB2
- fill at x 83.0, y 21.9, w 8.2, h 18.1: #69B8F7
- fill at x 58.3, y 31.8, w 8.3, h 8.2: #00857C
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- fill at x 70.6, y 47.4, w 8.2, h 18.2: #6ECEB2
- fill at x 83.0, y 48.7, w 8.2, h 16.9: #69B8F7
- fill at x 58.3, y 49.4, w 8.3, h 16.2: #00857C
- fill at x 70.6, y 78.4, w 8.2, h 12.9: #6ECEB2
- fill at x 83.0, y 77.0, w 8.2, h 14.4: #69B8F7
- fill at x 58.3, y 78.8, w 8.3, h 12.6: #00857C
- image at x 47.6, y 28.2, w 8.5, h 6.5: 171 by 74 pixels
- image at x 48.2, y 55.3, w 7.5, h 6.6: 183 by 91 pixels
- image at x 47.3, y 81.5, w 9.1, h 5.1: 203 by 64 pixels
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 6.7, w 79.6, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Oncology: Continued impact for patients across broad portfolio
- text at x 84.0, y 23.6, w 6.1, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $307M
- text at x 84.5, y 27.6, w 5.0, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +58%
- text at x 71.8, y 30.1, w 5.9, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $196M
- text at x 3.1, y 25.9, w 36.3, h 10.1 [Invention-Regular; font size 2.96; #0C2340]: WELIREG sales of $307M grew 58% driven by continued higher demand in the U.S. and launch uptake in international markets
- text at x 59.5, y 32.8, w 5.9, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $139M
- text at x 72.4, y 34.1, w 4.8, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +41%
- text at x 59.6, y 36.8, w 5.6, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +157%
- text at x 3.1, y 39.9, w 6.9, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: Lynparza
- text at x 3.1, y 39.9, w 38.4, h 10.1 [Invention-Regular; font size 2.96; #0C2340]: alliance revenue of $352M decreased 7% primarily due to lower net pricing in the U.S. and lower demand and pricing in China
- text at x 71.7, y 49.2, w 6.0, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $379M
- text at x 84.0, y 50.4, w 6.1, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $352M
- text at x 59.3, y 51.3, w 6.0, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $337M
- text at x 72.4, y 53.2, w 4.7, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +12%
- text at x 60.0, y 55.3, w 4.7, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +13%
- text at x 60.6, y 42.7, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q24
- text at x 73.0, y 42.7, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q25
- text at x 85.3, y 42.7, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q26
- text at x 85.4, y 54.4, w 3.3, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: -7%
- text at x 3.1, y 53.9, w 6.4, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: Lenvima
- text at x 3.1, y 53.9, w 34.7, h 6.5 [Invention-Regular; font size 2.96; #0C2340]: alliance revenue of $287M grew 11% primarily due to higher demand in the U.S.
- text at x 10.0, y 39.8, w 0.4, h 2.0 [Invention-Regular; font size 1.98; #0C2340]: 1
- text at x 84.1, y 78.7, w 6.1, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $287M
- text at x 71.7, y 80.5, w 6.2, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $258M
- text at x 59.4, y 81.0, w 5.8, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $251M
- text at x 84.9, y 82.7, w 4.4, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +11%
- text at x 60.5, y 85.0, w 3.5, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: -4%
- text at x 72.8, y 84.5, w 3.9, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +2%
- text at x 60.6, y 68.3, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q24
- text at x 73.0, y 68.3, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q25
- text at x 85.3, y 68.3, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q26
- text at x 9.5, y 53.8, w 0.6, h 2.0 [Invention-Regular; font size 1.98; #0C2340]: 2
- text at x 60.6, y 94.1, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q24
- text at x 73.0, y 94.1, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q25
- text at x 85.3, y 94.1, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q26
- text at x 3.1, y 97.3, w 50.2, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Growth rates exclude the impact of foreign exchange 1. In collaboration with AstraZeneca 2. In collaboration with Eisai
- text at x 96.1, y 95.5, w 0.7, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 10

### Slide 11

**Review notes**

- Review: The product slides 9 to 13 use a repeated three-bar format with large labelled values and growth rates that make results easy to scan, and slide 8 gives a strong headline number.
- Review: Weaknesses are consequential: several pages are dense or small (slides 3, 14, 15, 22, 27, 28), slide 8's launch chart has an unexplained hatched box and no growth label, and pale mint bars with white labels on slides 10 to 13 are weaker in contrast.
- Review: Some slides leave large empty areas next to charts (slides 10, 11, 12, 16).
- Worth keeping: Keep the navy title band with sentence headlines, the speaker section dividers, and the consistent teal, mint and blue three-quarter bar charts with value and growth labels on slides 9 to 13.
- Suggested repair: Raise contrast on white labels over mint bars on slides 10 to 12, label or simplify the hatched OHTUVAYRE segment on slide 8, and enlarge the guidance assumptions text on slide 15.

**Text**

Vaccines & Infectious Diseases: Impacting lives globally
GARDASIL sales of $2.0B grew 14% driven by a significant CDC purchase and higher price in the U.S.
CAPVAXIVE¹ sales of $263M grew 7% driven by ongoing launches in certain international markets and increased U.S. market share, partially offset by lower pneumococcal vaccination rates in the U.S.
ENFLONSIA² sales of $187M reflect seasonal demand and inventory build
GARDASIL
[Human Papillomavirus Quadrivalent
(Types 6, 11, 16, and 18) Vaccine, Recombinant]
GARDASIL 9
(Human Papillomavirus 9-valent Vaccine, Recombinant)
$2.3B
-10%
$1.7B
-25%
$2.0B
+14%
3Q24
3Q25
3Q26
CAPVAXIVE™
Pneumococcal 21-valent Conjugate Vaccine
$47M
$244M
N/M
$263M
+7%
3Q24
3Q25
3Q26
$79M
$187M
+136%
3Q24
3Q25
3Q26
ENFLONSIA™
(clesrovimab-cfor) 105 mg injection
Growth rates exclude the impact of foreign exchange 1. Launched in 3Q24 2. Launched in 3Q25
11

**Layout**

Full-bleed white slide with a full-width dark navy header band across the top about 18% of the height; the title sits left-aligned inside the band at about 3% left margin. Below, a left text column (about 3% to 40% of width) holds three stacked paragraphs, and a right chart area (about 46% to 94% of width) holds three stacked bar-chart rows separated by dotted rules, divided from the text by a vertical dotted rule at about 45% of width. A footnote sits at bottom left, a small grey page number at bottom right, and a small teal corporate logo at bottom right beside it.

**Visuals**

Chart: three stacked bar-chart rows, each with its own product logo at left and three bars on a shared quarter axis of 3Q24, 3Q25, 3Q26 (category axis, no numeric value axis, no gridlines, no legend). Row 1 GARDASIL: 3Q24 bar dark teal #00857C labelled $2.3B / -10%; 3Q25 bar light mint #6ECEB2 labelled $1.7B / -25%; 3Q26 bar light blue #69B8F7 labelled $2.0B / +14%. Row 2 CAPVAXIVE: 3Q24 bar teal #00857C labelled $47M in navy text (about 3% of plot height); 3Q25 bar mint #6ECEB2 labelled $244M / N/M; 3Q26 bar blue #69B8F7 labelled $263M / +7%. Row 3 ENFLONSIA: no bar at 3Q24; 3Q25 bar mint #6ECEB2 labelled $79M in navy text above the bar; 3Q26 bar blue #69B8F7 labelled $187M / +136%. Bar heights are proportional to values in each row (row 1 about 18% of slide height for $2.3B, row 2 about 17% for $263M). Each bar has a bold white label inside its top, except the bars with navy labels above. Each row sits on a thin navy baseline with four short tick marks at the ends and between the three category positions. Logos: GARDASIL wordmark in dark red with a multicoloured drop icon and the bracketed subtitle; GARDASIL 9 wordmark in dark teal with a teal and blue drop icon; CAPVAXIVE wordmark in navy with a multicoloured starburst of red, blue and teal rays and the subtitle; ENFLONSIA wordmark in dark green with a green and teal leaf icon. Corner logo: a small teal-green overlapping-circle mark. Dotted light grey rules separate the rows and a vertical dotted rule divides the text column from the chart. No photographs.

**Design**

Background: Solid white #FFFFFF with a full-width navy #0C2340 header band across the top. Clean corporate style. Background white #FFFFFF with a navy #0C2340 header band. Title in white #FFFFFF, light weight sans-serif (Invention Light or similar humanist sans), about 5% of slide height. Body text in navy #0C2340, regular sans-serif (Invention Regular or similar), about 3% of slide height, line spacing about 1.2. Bar values in bold white sans-serif (Invention Bold) about 3.3% of slide height; bar colours #00857C dark teal, #6ECEB2 mint, #69B8F7 light blue. Accent colours teal #00857C and blue #69B8F7. Superscript footnote markers about 2% of height. Footer about 1.7% of height in navy. Page number about 1.3% in grey #9EA7B3. Shapes are square-cornered rectangles with no shadows or gradients; rules are thin dotted light grey.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide background rectangle, solid white (square corners, no border)
- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Header band rectangle, solid navy (square corners, no shadow, full width)
- title at x 3.1, y 6.7, w 69.5, h 5.1 [Invention Light, regular sans-serif, sentence case; font size 5.09% of slide height; #FFFFFF; left aligned]: Vaccines & Infectious Diseases: Impacting lives globally (single line, vertically centred in the header band)
- line at x 45.1, y 21.6, w 0.3, h 69.5 [#C8CDD4]: Vertical dotted divider between text column and chart (dotted light grey stroke, about 0.1% of slide width, round dots about 0.5% spacing)
- body at x 3.1, y 25.9, w 36.3, h 10.1 [Invention Regular, sans-serif, normal weight; font size 2.96% of slide height; #0C2340; left aligned]: GARDASIL sales of $2.0B grew 14% driven by a / significant CDC purchase and higher price in the / U.S. (line spacing about 1.2)
- body at x 3.1, y 39.9, w 38.8, h 13.6 [Invention Regular, sans-serif, normal weight; font size 2.96% of slide height; #0C2340; left aligned]: CAPVAXIVE¹ sales of $263M grew 7% driven by / ongoing launches in certain international markets / and increased U.S. market share, partially offset by / lower pneumococcal vaccination rates in the U.S. (line spacing about 1.2, superscript 1 raised after product name)
- body at x 3.1, y 57.5, w 33.9, h 6.5 [Invention Regular, sans-serif, normal weight; font size 2.96% of slide height; #0C2340; left aligned]: ENFLONSIA² sales of $187M reflect seasonal / demand and inventory build (line spacing about 1.2, superscript 2 raised after product name)
- shape at x 58.3, y 21.7, w 8.3, h 18.3 [#00857C]: GARDASIL 3Q24 bar, dark teal (square corners, no shadow, bottom edge on row 1 baseline)
- shape at x 70.6, y 25.8, w 8.2, h 14.1 [#6ECEB2]: GARDASIL 3Q25 bar, light mint (square corners, no shadow)
- shape at x 83, y 23.3, w 8.2, h 16.6 [#69B8F7]: GARDASIL 3Q26 bar, light blue (square corners, no shadow)
- shape at x 58.3, y 62.5, w 8.3, h 3.1 [#00857C]: CAPVAXIVE 3Q24 bar, dark teal (about, not measured) (square corners, no shadow, bottom edge on row 2 baseline)
- shape at x 70.6, y 49.7, w 8.2, h 15.9 [#6ECEB2]: CAPVAXIVE 3Q25 bar, light mint (square corners, no shadow)
- shape at x 83, y 48.5, w 8.2, h 17.1 [#69B8F7]: CAPVAXIVE 3Q26 bar, light blue (square corners, no shadow)
- shape at x 70.6, y 84.1, w 8.2, h 7.2 [#6ECEB2]: ENFLONSIA 3Q25 bar, light mint (square corners, no shadow, bottom edge on row 3 baseline)
- shape at x 83, y 74.2, w 8.2, h 17.1 [#69B8F7]: ENFLONSIA 3Q26 bar, light blue (square corners, no shadow)
- line at x 56.2, y 39.9, w 37.1, h 0.1 [#0C2340]: Row 1 category baseline with ticks at 3Q24, 3Q25, 3Q26 (navy hairline about 0.1% of height, four short downward ticks at x 56.2, 68.5, 80.9, 93.3)
- line at x 56.2, y 65.6, w 37.1, h 0.1 [#0C2340]: Row 2 category baseline with ticks at 3Q24, 3Q25, 3Q26 (navy hairline about 0.1% of height, four short downward ticks at x 56.2, 68.5, 80.9, 93.3)
- line at x 56.2, y 91.3, w 37.1, h 0.1 [#0C2340]: Row 3 category baseline with ticks at 3Q24, 3Q25, 3Q26 (navy hairline about 0.1% of height, four short downward ticks at x 56.2, 68.5, 80.9, 93.3)
- line at x 48.1, y 46, w 48.5, h 0.1 [#C8CDD4]: Dotted separator between row 1 and row 2 (dotted light grey stroke)
- line at x 48.3, y 71.6, w 48.6, h 0.1 [#C8CDD4]: Dotted separator between row 2 and row 3 (dotted light grey stroke)
- logo at x 47, y 23.9, w 9.5, h 6.9 [#8B1E2D]: GARDASIL wordmark with multicoloured drop icon and subtitle [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] (dark red wordmark, drop icon in red, blue and teal, no box)
- logo at x 47.3, y 32, w 6.8, h 6.6 [#0E5E56]: GARDASIL 9 wordmark with teal drop icon and subtitle (Human Papillomavirus 9-valent Vaccine, Recombinant) (dark teal wordmark, icon in teal and blue, no box)
- logo at x 46.9, y 55.7, w 10, h 6.6 [#0C2340]: CAPVAXIVE wordmark with starburst icon and subtitle Pneumococcal 21-valent Conjugate Vaccine (navy wordmark with trademark mark, starburst rays in red, blue, teal and grey)
- logo at x 47.8, y 78.8, w 8.6, h 7.5 [#0E5E56]: ENFLONSIA wordmark with leaf icon and subtitle (clesrovimab-cfor) 105 mg injection (dark green letter-spaced wordmark, leaf icon in green and teal)
- caption at x 59.9, y 23.6, w 5.2, h 7.3 [Invention Bold, sans-serif, bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $2.3B / -10% (two lines centred over 3Q24 GARDASIL bar, line spacing about 1.1)
- caption at x 72.3, y 27.8, w 4.8, h 7.3 [Invention Bold, sans-serif, bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $1.7B / -25% (two lines centred over 3Q25 GARDASIL bar)
- caption at x 84.4, y 25.3, w 5.3, h 7.3 [Invention Bold, sans-serif, bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $2.0B / +14% (two lines centred over 3Q26 GARDASIL bar)
- caption at x 59.9, y 58.3, w 5, h 3.3 [Invention Bold, sans-serif, bold; font size 3.33% of slide height; #0C2340; center aligned]: $47M (single line above 3Q24 CAPVAXIVE bar)
- caption at x 71.5, y 51.6, w 6.3, h 7.3 [Invention Bold, sans-serif, bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $244M / N/M (two lines centred over 3Q25 CAPVAXIVE bar)
- caption at x 84, y 50.4, w 6.1, h 7.2 [Invention Bold, sans-serif, bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $263M / +7% (two lines centred over 3Q26 CAPVAXIVE bar)
- caption at x 72.4, y 79.4, w 5, h 3.3 [Invention Bold, sans-serif, bold; font size 3.33% of slide height; #0C2340; center aligned]: $79M (single line above 3Q25 ENFLONSIA bar)
- caption at x 84.2, y 76.3, w 5.8, h 7.3 [Invention Bold, sans-serif, bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $187M / +136% (two lines centred over 3Q26 ENFLONSIA bar)
- caption at x 59.4, y 81, w 5.8, h 7.3 [Invention Bold, sans-serif, bold; font size 3.33% of slide height; #FFFFFF; center aligned]: $251M / -4% (present in file, white text on white background, not visible in the rendered slide) (hidden text box over the empty 3Q24 ENFLONSIA slot; invisible)
- caption at x 60.6, y 42.7, w 3.6, h 2.6 [Invention Regular, sans-serif, normal weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q24 (row 1 axis label)
- caption at x 73, y 42.7, w 3.6, h 2.6 [Invention Regular, sans-serif, normal weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q25 (row 1 axis label)
- caption at x 85.3, y 42.7, w 3.6, h 2.6 [Invention Regular, sans-serif, normal weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q26 (row 1 axis label)
- caption at x 60.6, y 68.3, w 3.6, h 2.6 [Invention Regular, sans-serif, normal weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q24 (row 2 axis label)
- caption at x 73, y 68.3, w 3.6, h 2.6 [Invention Regular, sans-serif, normal weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q25 (row 2 axis label)
- caption at x 85.3, y 68.3, w 3.6, h 2.6 [Invention Regular, sans-serif, normal weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q26 (row 2 axis label)
- caption at x 60.6, y 94.1, w 3.6, h 2.6 [Invention Regular, sans-serif, normal weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q24 (row 3 axis label)
- caption at x 73, y 94.1, w 3.6, h 2.6 [Invention Regular, sans-serif, normal weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q25 (row 3 axis label)
- caption at x 85.3, y 94.1, w 3.6, h 2.6 [Invention Regular, sans-serif, normal weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q26 (row 3 axis label)
- caption at x 12.4, y 39.8, w 0.4, h 2 [Invention Regular, sans-serif, normal weight; font size 1.98% of slide height; #0C2340; left aligned]: 1 (superscript footnote marker after CAPVAXIVE)
- caption at x 12.4, y 57.4, w 0.6, h 2 [Invention Regular, sans-serif, normal weight; font size 1.98% of slide height; #0C2340; left aligned]: 2 (superscript footnote marker after ENFLONSIA)
- footer at x 3.1, y 97.3, w 40.5, h 1.7 [Invention Regular, sans-serif, normal weight; font size 1.67% of slide height; #0C2340; left aligned]: Growth rates exclude the impact of foreign exchange 1. Launched in 3Q24 2. Launched in 3Q25 (single line, footnote)
- page number at x 96.3, y 95.5, w 0.6, h 1.3 [Invention Regular, sans-serif, normal weight; font size 1.29% of slide height; #9EA7B3; right aligned]: 11
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Corporate mark, overlapping teal circles forming a rounded shape (small icon at bottom right, teal-green, no box)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 70.6, y 25.8, w 8.2, h 14.1: #6ECEB2
- fill at x 83.0, y 23.3, w 8.2, h 16.6: #69B8F7
- fill at x 58.3, y 21.7, w 8.3, h 18.3: #00857C
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- fill at x 70.6, y 49.7, w 8.2, h 15.9: #6ECEB2
- fill at x 83.0, y 48.5, w 8.2, h 17.1: #69B8F7
- fill at x 70.6, y 84.1, w 8.2, h 7.2: #6ECEB2
- fill at x 83.0, y 74.2, w 8.2, h 17.1: #69B8F7
- image at x 47.0, y 23.9, w 9.5, h 6.9: 190 by 78 pixels
- image at x 46.9, y 55.7, w 10.0, h 6.6: 433 by 159 pixels
- image at x 47.8, y 78.8, w 8.6, h 7.5: 117 by 58 pixels
- image at x 47.3, y 32.0, w 6.8, h 6.6: 137 by 74 pixels
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 6.7, w 69.5, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Vaccines & Infectious Diseases: Impacting lives globally
- text at x 59.9, y 23.6, w 5.2, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $2.3B
- text at x 84.4, y 25.3, w 5.3, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $2.0B
- text at x 60.3, y 27.6, w 4.4, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: -10%
- text at x 72.3, y 27.8, w 4.8, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $1.7B
- text at x 84.7, y 29.3, w 4.8, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +14%
- text at x 72.5, y 31.8, w 4.5, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: -25%
- text at x 3.1, y 25.9, w 36.3, h 10.1 [Invention-Regular; font size 2.96; #0C2340]: GARDASIL sales of $2.0B grew 14% driven by a significant CDC purchase and higher price in the U.S.
- text at x 3.1, y 39.9, w 9.3, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: CAPVAXIVE
- text at x 84.0, y 50.4, w 6.1, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $263M
- text at x 3.1, y 39.9, w 38.8, h 13.6 [Invention-Regular; font size 2.96; #0C2340]: sales of $263M grew 7% driven by ongoing launches in certain international markets and increased U.S. market share, partially offset by lower pneumococcal vaccination rates in the U.S.
- text at x 71.5, y 51.6, w 6.3, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $244M
- text at x 60.6, y 42.7, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q24
- text at x 72.7, y 55.6, w 3.9, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: N/M
- text at x 73.0, y 42.7, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q25
- text at x 85.2, y 54.4, w 3.8, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +7%
- text at x 85.3, y 42.7, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q26
- text at x 59.9, y 58.3, w 5.0, h 3.3 [Invention-Bold; font size 3.33; #0C2340]: $47M
- text at x 3.1, y 57.5, w 9.3, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: ENFLONSIA
- text at x 3.1, y 57.5, w 33.9, h 6.5 [Invention-Regular; font size 2.96; #0C2340]: sales of $187M reflect seasonal demand and inventory build
- text at x 12.4, y 39.8, w 0.4, h 2.0 [Invention-Regular; font size 1.98; #0C2340]: 1
- text at x 84.2, y 76.3, w 5.8, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $187M
- text at x 72.4, y 79.4, w 5.0, h 3.3 [Invention-Bold; font size 3.33; #0C2340]: $79M
- text at x 84.2, y 80.3, w 5.8, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +136%
- text at x 59.4, y 81.0, w 5.8, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $251M
- text at x 60.5, y 85.0, w 3.5, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: -4%
- text at x 60.6, y 68.3, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q24
- text at x 73.0, y 68.3, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q25
- text at x 85.3, y 68.3, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q26
- text at x 12.4, y 57.4, w 0.6, h 2.0 [Invention-Regular; font size 1.98; #0C2340]: 2
- text at x 60.6, y 94.1, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q24
- text at x 73.0, y 94.1, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q25
- text at x 85.3, y 94.1, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q26
- text at x 3.1, y 97.3, w 40.5, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Growth rates exclude the impact of foreign exchange 1. Launched in 3Q24 2. Launched in 3Q25
- text at x 96.3, y 95.5, w 0.6, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 11

### Slide 12

**Review notes**

- Review: The product slides 9 to 13 use a repeated three-bar format with large labelled values and growth rates that make results easy to scan, and slide 8 gives a strong headline number.
- Review: Weaknesses are consequential: several pages are dense or small (slides 3, 14, 15, 22, 27, 28), slide 8's launch chart has an unexplained hatched box and no growth label, and pale mint bars with white labels on slides 10 to 13 are weaker in contrast.
- Review: Some slides leave large empty areas next to charts (slides 10, 11, 12, 16).
- Worth keeping: Keep the navy title band with sentence headlines, the speaker section dividers, and the consistent teal, mint and blue three-quarter bar charts with value and growth labels on slides 9 to 13.
- Suggested repair: Raise contrast on white labels over mint bars on slides 10 to 12, label or simplify the hatched OHTUVAYRE segment on slide 8, and enlarge the guidance assumptions text on slide 15.

**Text**

Cardiometabolic & Respiratory: Driving growth and continuing to benefit
patients with successful ongoing launches
WINREVAIR sales of $694M grew 94% driven by
continued growth in new patient starts and total
prescriptions, as well as a benefit from channel
inventory
‒ In the U.S., ~1,600 new patients prescribed and
>38,000 total prescriptions dispensed
‒ Ex-U.S., making progress with ongoing launches
OHTUVAYRE1 sales of $184M reflect continued
demand, partially offset by a small headwind from
timing of specialty pharmacy purchases
3Q24 3Q25 3Q26
$149M
$360M +141%
$694M +94%
$135M2
$184M
3Q24 3Q25 3Q26
Growth rates exclude the impact of foreign exchange 1. Ohtuvayre was obtained as part of the acquisition of Verona Pharma on October 7, 2025 2. Sales reported by Verona Pharma
12

**Layout**

Full-width dark navy title band across the top with the two-line title left-aligned at a margin of about 3% of slide width. Below it, two columns: a left text column (x about 3% to 41%) holding the WINREVAIR and OHTUVAYRE statements, and a right column (x about 46% to 97%) holding two stacked bar charts separated by a dotted horizontal rule, with a thin dotted vertical divider at about x 46% between columns. The footnote runs along the bottom-left at about y 97%, the teal logo sits bottom-right near x 92%, and the page number 12 sits at bottom-right, x 96%, y 95.5%.

**Visuals**

Two bar charts with no y-axis, no gridlines, no value axis and no legend; bars are drawn at heights proportional to their printed values, with a horizontal baseline and tick marks under each bar. Top chart: WINREVAIR logo above it; categories 3Q24, 3Q25, 3Q26 along the x-axis. Series values: 3Q24 $149M (teal bar #00857C, label inside bar in white bold); 3Q25 $360M, +141% (mint bar #6ECEB2, white bold label); 3Q26 $694M, +94% (blue bar #69B8F7, white bold label, tallest bar). Bottom chart: Ohtuvayre logo above it; categories 3Q24, 3Q25, 3Q26 along the x-axis. 3Q24 has no bar, only the baseline tick. 3Q25 is a dashed-outline grey box (fill #F7F7F7, dashed border #7F7F7F) labelled $135M with superscript 2 in grey #7F7F7F bold. 3Q26 is a blue bar (#69B8F7) labelled $184M in white bold, tallest on this chart. Ohtuvayre logo: dark navy wordmark with purple-blue swoosh, '(ensifentrine) Inhalation Suspension' beneath, and a small light-blue strip reading '3 mg/2.5 mL'. WINREVAIR logo: multicoloured swoosh above navy bold wordmark 'WINREVAIR' with '(sotatercept-csrk)' in grey and small text 'for injection 45 mg, 60 mg'. Corner logo: teal circular mark made of two interlocking petal shapes. No photographs; all visuals are flat, unshadowed, unboxed except the dashed box.

**Design**

Background: Solid white #FFFFFF across the full slide. Clean corporate flat design on white. Title band is solid navy #0C2340 spanning the full width at the top 18.4% of the slide; title text is white light-weight sans-serif (Invention Light style) at about 5.1% of slide height. Body text is navy #0C2340 regular sans-serif (Invention Regular style) at about 3.0% of slide height. Bar labels are white bold sans-serif (Invention Bold) at about 3.3%. Axis category labels are navy regular at about 2.6%. Footnote is navy regular at about 1.7%. Page number is light grey #9EA7B3 at about 1.3%. Accent colours: teal #00857C, mint #6ECEB2, sky blue #69B8F7, neutral grey #7F7F7F and #F7F7F7. Shapes are square-cornered with no shadows or gradients; the divider rules are light grey dotted lines.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 18.4: Title band rectangle behind title, full width, top of slide (fill #0C2340, no border, square corners, no shadow)
- title at x 3.1, y 3.9, w 92.7, h 10.6 [Invention Light, sans-serif, regular light weight, no italics, no caps, normal tracking; font size 5.09% of slide height; #FFFFFF; left aligned]: Cardiometabolic & Respiratory: Driving growth and continuing to benefit / patients with successful ongoing launches
- logo at x 66, y 20, w 13.1, h 8.5: WINREVAIR (sotatercept-csrk) logo with multicoloured swoosh and for injection 45 mg, 60 mg text (Image box 240 by 88 px, no border, sits above the top chart)
- shape at x 53.8, y 46.1, w 9.5, h 5.8 [#00857C]: Bar 3Q24 WINREVAIR, teal bar (Square corners, no border, sits on baseline)
- shape at x 68, y 37.9, w 9.5, h 14 [#6ECEB2]: Bar 3Q25 WINREVAIR, mint bar (Square corners, no border, sits on baseline)
- shape at x 82.2, y 28.5, w 9.5, h 23.4 [#69B8F7]: Bar 3Q26 WINREVAIR, sky blue bar (Square corners, no border, sits on baseline)
- line at x 28, y 62, w 66.5, h 1 [#0C2340]: Top chart baseline with tick marks at each category (Thin navy line about 0.1% height, tick marks drop below at each bar centre)
- line at x 48, y 59.2, w 48.5, h 0.3 [#D0D0D0]: Dotted horizontal divider between charts (Dotted light grey line, round dots, no fill)
- line at x 46, y 13.9, w 0.2, h 75 [#D0D0D0]: Dotted vertical divider between text and charts (Dotted light grey line, round dots, no fill)
- logo at x 67.5, y 62.2, w 10, h 7.8: Ohtuvayre (ensifentrine) Inhalation Suspension logo with 3 mg/2.5 mL strip (Image box 200 by 89 px; navy wordmark with purple-blue swoosh; light-blue strip below)
- shape at x 67.9, y 75.3, w 9.5, h 12.4 [#F7F7F7]: Dashed placeholder box for 3Q25 Ohtuvayre value (fill #F7F7F7 with dashed grey #7F7F7F border about 0.2% wide, square corners)
- shape at x 82.2, y 70.8, w 9.5, h 16.9 [#69B8F7]: Bar 3Q26 Ohtuvayre, sky blue bar (Square corners, no border, sits on baseline)
- line at x 28, y 88.1, w 66.5, h 1 [#0C2340]: Bottom chart baseline with tick marks at each category (Thin navy line, tick marks drop below at each category)
- body at x 3.3, y 25.8, w 37.2, h 13.6 [Invention Regular, sans-serif, regular weight, no italics, no caps; font size 2.96% of slide height; #0C2340; left aligned]: WINREVAIR sales of $694M grew 94% driven by / continued growth in new patient starts and total / prescriptions, as well as a benefit from channel / inventory (Line spacing about 1.2; no bullets)
- body at x 3.3, y 41.1, w 36.2, h 6.5 [Invention Regular, sans-serif, regular weight; font size 2.96% of slide height; #0C2340; left aligned]: ‒ In the U.S., ~1,600 new patients prescribed and / >38,000 total prescriptions dispensed (Bullet is an en dash, hanging indent, about 2.2% left of text; line spacing about 1.2)
- body at x 3.3, y 49.3, w 38.8, h 3 [Invention Regular, sans-serif, regular weight; font size 2.96% of slide height; #0C2340; left aligned]: ‒ Ex-U.S., making progress with ongoing launches (Bullet is an en dash, same indent as previous bullet)
- body at x 3.3, y 56.2, w 37.9, h 10.1 [Invention Regular, sans-serif, regular weight, capitals for OHTUVAYRE; font size 2.96% of slide height; #0C2340; left aligned]: OHTUVAYRE1 sales of $184M reflect continued / demand, partially offset by a small headwind from / timing of specialty pharmacy purchases (Superscript 1 after OHTUVAYRE; line spacing about 1.2; no bullets)
- body at x 83.8, y 30.7, w 6.3, h 7.3 [Invention Bold, sans-serif, bold weight; font size 3.33% of slide height; #FFFFFF; center aligned]: $694M / +94% (Two lines centred inside the 3Q26 WINREVAIR bar)
- body at x 69.4, y 40, w 6.3, h 7.3 [Invention Bold, sans-serif, bold weight; font size 3.33% of slide height; #FFFFFF; center aligned]: $360M / +141% (Two lines centred inside the 3Q25 WINREVAIR bar)
- body at x 55.4, y 47.3, w 6, h 3.3 [Invention Bold, sans-serif, bold weight; font size 3.33% of slide height; #FFFFFF; center aligned]: $149M (Inside 3Q24 teal bar)
- body at x 84, y 73.1, w 6, h 3.3 [Invention Bold, sans-serif, bold weight; font size 3.33% of slide height; #FFFFFF; center aligned]: $184M (Inside 3Q26 Ohtuvayre blue bar, top portion)
- body at x 69.4, y 77.4, w 5.8, h 3.3 [Invention Bold, sans-serif, bold weight; font size 3.33% of slide height; #7F7F7F; center aligned]: $135M2 (Superscript 2 in regular weight, grey #7F7F7F, inside dashed box)
- caption at x 56.7, y 54.6, w 3.6, h 2.6 [Invention Regular, sans-serif, regular weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q24 (Category label under top chart)
- caption at x 71, y 54.6, w 3.6, h 2.6 [Invention Regular, sans-serif, regular weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q25 (Category label under top chart)
- caption at x 85.1, y 54.6, w 3.6, h 2.6 [Invention Regular, sans-serif, regular weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q26 (Category label under top chart)
- caption at x 56.7, y 90.4, w 3.6, h 2.6 [Invention Regular, sans-serif, regular weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q24 (Category label under bottom chart)
- caption at x 70.9, y 90.4, w 3.6, h 2.6 [Invention Regular, sans-serif, regular weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q25 (Category label under bottom chart)
- caption at x 85.1, y 90.4, w 3.6, h 2.6 [Invention Regular, sans-serif, regular weight; font size 2.6% of slide height; #0C2340; center aligned]: 3Q26 (Category label under bottom chart)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Corner logo: teal circular mark of two interlocking petal shapes (Image box 125 by 150 px, no border)
- footer at x 3.1, y 97.3, w 76.7, h 1.7 [Invention Regular, sans-serif, regular weight; font size 1.67% of slide height; #0C2340; left aligned]: Growth rates exclude the impact of foreign exchange 1. Ohtuvayre was obtained as part of the acquisition of Verona Pharma on October 7, 2025 2. Sales reported by Verona Pharma (Single line footnote; superscript numerals 1 and 2 in the notes)
- page number at x 96.2, y 95.5, w 0.7, h 1.3 [Invention Regular, sans-serif, regular weight; font size 1.29% of slide height; #9EA7B3; right aligned]: 12

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- fill at x 67.9, y 75.3, w 9.5, h 12.4: #F7F7F7
- fill at x 82.2, y 70.8, w 9.5, h 16.9: #69B8F7
- fill at x 53.8, y 46.1, w 9.5, h 5.8: #00857C
- fill at x 68.0, y 37.9, w 9.5, h 14.0: #6ECEB2
- fill at x 82.2, y 28.5, w 9.5, h 23.4: #69B8F7
- image at x 66.0, y 20.0, w 13.1, h 8.5: 240 by 88 pixels
- image at x 67.5, y 62.2, w 10.0, h 7.8: 200 by 89 pixels
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 3.9, w 92.7, h 10.6 [Invention-Light; font size 5.09; #FFFFFF]: Cardiometabolic & Respiratory: Driving growth and continuing to benefit patients with successful ongoing launches
- text at x 83.8, y 30.7, w 6.3, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $694M
- text at x 3.3, y 25.8, w 37.2, h 13.6 [Invention-Regular; font size 2.96; #0C2340]: WINREVAIR sales of $694M grew 94% driven by continued growth in new patient starts and total prescriptions, as well as a benefit from channel inventory
- text at x 84.4, y 34.7, w 5.1, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +94%
- text at x 69.4, y 40.0, w 6.3, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $360M
- text at x 69.8, y 44.0, w 5.6, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +141%
- text at x 3.3, y 41.1, w 1.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: ‒
- text at x 55.4, y 47.3, w 6.0, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $149M
- text at x 5.6, y 41.1, w 36.2, h 6.5 [Invention-Regular; font size 2.96; #0C2340]: In the U.S., ~1,600 new patients prescribed and >38,000 total prescriptions dispensed
- text at x 3.3, y 49.3, w 38.8, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: ‒ Ex-U.S., making progress with ongoing launches
- text at x 56.0, y 60.8, w 4.8, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $1.7B
- text at x 3.3, y 56.2, w 10.2, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: OHTUVAYRE
- text at x 55.8, y 64.8, w 5.2, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +40%
- text at x 3.3, y 56.2, w 37.9, h 10.1 [Invention-Regular; font size 2.96; #0C2340]: sales of $184M reflect continued demand, partially offset by a small headwind from timing of specialty pharmacy purchases
- text at x 56.7, y 54.6, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q24
- text at x 71.0, y 54.6, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q25
- text at x 85.1, y 54.6, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q26
- text at x 84.0, y 73.1, w 6.0, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $184M
- text at x 69.4, y 77.4, w 5.8, h 3.3 [Invention-Bold; font size 3.33; #7F7F7F]: $135M
- text at x 13.4, y 56.1, w 0.4, h 2.0 [Invention-Regular; font size 1.98; #0C2340]: 1
- text at x 56.7, y 90.4, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q24
- text at x 70.9, y 90.4, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q25
- text at x 75.2, y 77.3, w 0.7, h 2.2 [Invention-Regular; font size 2.22; #7F7F7F]: 2
- text at x 85.1, y 90.4, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q26
- text at x 3.1, y 97.3, w 76.7, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Growth rates exclude the impact of foreign exchange 1. Ohtuvayre was obtained as part of the acquisition of Verona Pharma on October 7, 2025 2. Sales reported by Verona Pharma
- text at x 96.2, y 95.5, w 0.7, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 12

### Slide 13

**Review notes**

- Review: The product slides 9 to 13 use a repeated three-bar format with large labelled values and growth rates that make results easy to scan, and slide 8 gives a strong headline number.
- Review: Weaknesses are consequential: several pages are dense or small (slides 3, 14, 15, 22, 27, 28), slide 8's launch chart has an unexplained hatched box and no growth label, and pale mint bars with white labels on slides 10 to 13 are weaker in contrast.
- Worth keeping: Keep the navy title band with sentence headlines, the speaker section dividers, and the consistent teal, mint and blue three-quarter bar charts with value and growth labels on slides 9 to 13.

**Text**

Animal Health: Solid growth driven by companion animal and livestock / Animal Health / Animal Health sales increased 3% to $1.7B / ‒ Companion Animal sales grew 6% driven by new product launches / ‒ Livestock sales grew 2% driven by higher demand for poultry products / $1.5B / +11%1 / $1.6B / +7% / $1.7B / +3% / 3Q24 / 3Q25 / 3Q26 / Growth rates exclude the impact of foreign exchange 1. ~2 percentage points of negative impact of foreign exchange due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market / 13

**Layout**

A full-width dark navy title band occupies the top 18.4% of the slide with the white title left-aligned at about 3.1% from the left edge. Below it, a two-column body sits on white: left column text top-aligned at about 25.6% height, right column holds a bar chart and logo, separated by a vertical dotted divider at about 46% of width. The footnote runs along the bottom left at about 95.5% height, a small logo sits at the bottom right and the page number '13' sits at the far bottom right.

**Visuals**

Vertical bar chart with three bars, no visible value axis and no gridlines. Bars are labelled inside their tops with two-line white bold labels. Bar 1 (3Q24): fill #00857C, label $1.5B and +11% with superscript 1 (footnote marker), height about 24.9% of slide. Bar 2 (3Q25): fill #6ECEB2, label $1.6B and +7%, top about 52.6%. Bar 3 (3Q26): fill #69B8F7, label $1.7B and +3%, top about 49.5%, tallest. Bars are equal width (about 9.5% of slide width), evenly spaced, sitting on a thin dark navy #0C2340 horizontal baseline with small tick marks at the bar boundaries and ends. Category labels below the baseline: 3Q24, 3Q25, 3Q26 in navy regular type. No legend, no highlighted points beyond the colour progression. Also a teal Animal Health logo mark: a stacked two-lobed rounded icon in teal #00857C (white inner cut) to the left of the words 'Animal Health' in navy at about 61.4% x, 28.1% y, 4.5% by 8.6% in size. A small identical teal logo mark sits at bottom right at about 91.8% x, 92.8% y, 3.1% by 6.6%. A vertical dotted light grey line (about #C8CDD3) divides the columns.

**Design**

Background: Solid white #FFFFFF with a navy #0C2340 band across the top 18.4% of the slide. Title band solid navy #0C2340 with white Invention Light title, roughly 5.1% of slide height. Body text navy #0C2340 in Invention Regular, about 3.0% of slide height, with dash bullets and no bullet shapes. Chart bars use teal #00857C, mint #6ECEB2 and sky blue #69B8F7, with white bold Invention labels at about 3.3% of height. Footnote text navy Invention Regular about 1.7% of height. Page number light grey #9EA7B3 Invention Regular about 1.3%. Flat design, no shadows, gradients or rounded bar corners. Dotted divider is thin and light grey.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: White full-slide background fill (Covers entire slide, no outline)
- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Navy title band rectangle (Flat rectangle, no outline, no shadow)
- title at x 3.1, y 6.7, w 88.3, h 5.1 [Invention Light, regular weight, sentence case; font size 5.09% of slide height; #FFFFFF; left aligned]: Animal Health: Solid growth driven by companion animal and livestock (Single line, vertically centred in navy band)
- dotted line at x 46.1, y 24.8, w 0.2, h 66 [#C8CDD3]: Vertical dotted divider between columns (Dotted stroke, light grey, about 0.1% width)
- logo at x 61.4, y 28.1, w 4.5, h 8.6 [#00857C]: Animal Health logo mark (teal stacked two-lobed icon) (Teal icon, white inner cut-outs, placed as image 180 by 194 px)
- text at x 66.8, y 30.5, w 16.8, h 4.5 [Invention Regular, regular weight, sentence case; font size 4.51% of slide height; #0C2340; left aligned]: Animal Health (Logotype wordmark beside logo mark)
- body at x 3.1, y 25.6, w 31.6, h 3 [Invention Regular, regular weight, sentence case; font size 2.96% of slide height; #0C2340; left aligned]: Animal Health sales increased 3% to $1.7B (Lead line, no bullet)
- bullet list at x 3.1, y 30.8, w 34, h 14.5 [Invention Regular, regular weight, sentence case; font size 2.96% of slide height; #0C2340; left aligned]: ‒ Companion Animal sales grew 6% driven by new product launches / ‒ Livestock sales grew 2% driven by higher demand for poultry products (Dash bullets (en dash) at x 3.1%, text indented to x 5.4%, wrapped lines, line spacing about 1.2 times font size, paragraph gap about 2.5% of height)
- shape at x 53.6, y 59.2, w 9.5, h 24.9 [#00857C]: Bar 3Q24 (teal bar) (Flat rectangle, square corners, no outline)
- shape at x 67.8, y 52.6, w 9.5, h 31.5 [#6ECEB2]: Bar 3Q25 (mint bar) (Flat rectangle, square corners, no outline)
- shape at x 82, y 49.5, w 9.5, h 34.6 [#69B8F7]: Bar 3Q26 (sky blue bar) (Flat rectangle, square corners, no outline)
- line at x 51.2, y 84, w 42.7, h 0.6 [#0C2340]: Chart baseline with tick marks at bar boundaries (Thin navy horizontal axis line with short downward ticks at bar edges and ends)
- text at x 56, y 61.6, w 4.9, h 7.3 [Invention Bold, bold weight, sentence case; font size 3.33% of slide height; #FFFFFF; center aligned]: $1.5B / +11%1 (Two lines inside bar 3Q24; superscript 1 at x 60.4%, y 65.5%, size 2.22%)
- text at x 70.1, y 54.4, w 5, h 7.6 [Invention Bold, bold weight, sentence case; font size 3.33% of slide height; #FFFFFF; center aligned]: $1.6B / +7% (Two lines inside bar 3Q25)
- text at x 84.3, y 51.8, w 4.8, h 7.3 [Invention Bold, bold weight, sentence case; font size 3.33% of slide height; #FFFFFF; center aligned]: $1.7B / +3% (Two lines inside bar 3Q26)
- text at x 56.5, y 86.8, w 3.6, h 2.6 [Invention Regular, regular weight, sentence case; font size 2.6% of slide height; #0C2340; center aligned]: 3Q24 (Category label under bar 1)
- text at x 70.8, y 86.8, w 3.6, h 2.6 [Invention Regular, regular weight, sentence case; font size 2.6% of slide height; #0C2340; center aligned]: 3Q25 (Category label under bar 2)
- text at x 85, y 86.8, w 3.6, h 2.6 [Invention Regular, regular weight, sentence case; font size 2.6% of slide height; #0C2340; center aligned]: 3Q26 (Category label under bar 3)
- footer at x 3.1, y 95.6, w 87, h 3.4 [Invention Regular, regular weight, sentence case; font size 1.67% of slide height; #0C2340; left aligned]: Growth rates exclude the impact of foreign exchange 1. ~2 percentage points of negative impact of foreign exchange due to devaluation of Argentine peso, which was largely offset by inflation-related price / increases, consistent with practice in that market (Two lines, line break after 'price')
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Small Animal Health logo mark (teal) (Corner logo, image 125 by 150 px)
- page number at x 96.2, y 95.5, w 0.7, h 1.3 [Invention Regular, regular weight; font size 1.29% of slide height; #9EA7B3; right aligned]: 13 (Light grey page number at bottom right)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- fill at x 67.8, y 52.6, w 9.5, h 31.5: #6ECEB2
- fill at x 82.0, y 49.5, w 9.5, h 34.6: #69B8F7
- fill at x 53.6, y 59.2, w 9.5, h 24.9: #00857C
- image at x 61.4, y 28.1, w 4.5, h 8.6: 180 by 194 pixels
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 6.7, w 88.3, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Animal Health: Solid growth driven by companion animal and livestock
- text at x 66.8, y 30.5, w 16.8, h 4.5 [Invention-Regular; font size 4.51; #0C2340]: Animal Health
- text at x 3.1, y 25.6, w 31.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: Animal Health sales increased 3% to $1.7B
- text at x 3.1, y 30.8, w 1.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: ‒
- text at x 5.4, y 30.8, w 36.5, h 6.5 [Invention-Regular; font size 2.96; #0C2340]: Companion Animal sales grew 6% driven by new product launches
- text at x 3.1, y 39.6, w 1.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: ‒
- text at x 5.4, y 39.6, w 31.1, h 6.5 [Invention-Regular; font size 2.96; #0C2340]: Livestock sales grew 2% driven by higher demand for poultry products
- text at x 84.3, y 51.8, w 4.8, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $1.7B
- text at x 70.1, y 54.4, w 5.0, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $1.6B
- text at x 84.8, y 55.8, w 3.9, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +3%
- text at x 70.7, y 58.4, w 3.8, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +7%
- text at x 56.0, y 61.6, w 4.9, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: $1.5B
- text at x 56.0, y 65.6, w 4.4, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: +11%
- text at x 60.4, y 65.5, w 0.5, h 2.2 [Invention-Regular; font size 2.22; #FFFFFF]: 1
- text at x 56.5, y 86.8, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q24
- text at x 70.8, y 86.8, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q25
- text at x 85.0, y 86.8, w 3.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 3Q26
- text at x 3.1, y 95.6, w 87.0, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Growth rates exclude the impact of foreign exchange 1. ~2 percentage points of negative impact of foreign exchange due to devaluation of Argentine peso, which was largely offset by inflation-related price
- text at x 3.1, y 97.3, w 20.9, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: increases, consistent with practice in that market
- text at x 96.2, y 95.5, w 0.7, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 13

### Slide 14

**Review notes**

- Worth studying: Presents a dense financial summary as a clean table with change and ex-FX columns that stay easy to scan.
- Review: Weaknesses are consequential: several pages are dense or small (slides 3, 14, 15, 22, 27, 28), slide 8's launch chart has an unexplained hatched box and no growth label, and pale mint bars with white labels on slides 10 to 13 are weaker in contrast.

**Text**

Q3 2026 non-GAAP financial results summary / 1
$ in billions, except EPS amounts
 Q3 2026 / Q3 2025 / Change / Change / Ex-FX
Sales / $18.1 / $17.3 / +5% / +4%
Non-GAAP Gross / Margin / 81.4% / 81.9% / -0.5pts / -0.6 pts
Non-GAAP Operating / Expenses 2 / $7.4 / $6.6 / 12% / 12%
Non-GAAP Tax Rate / 10.9% / 13.4% / -2.5pts / N/A
Non-GAAP EPS 2,3 / $2.49 / $2.58 / -3% / -5%
1. The company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business / performance and trends. Management believes that providing this information enhances investors' understanding of the company's results because management uses non-GAAP results to assess / performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee / compensation, including senior management's compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or / superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q3 2026 non-GAAP results include a charge of / $400 million, or $0.12 per share, related to an exclusive global license agreement with SciBrunch Therapeutics. Q3 2025 non-GAAP results include a $300 million charge, or $0.10 per share, related to the / LaNova Medicines technology transfer milestone payment. 3. Q3 2026 GAAP EPS of $2.04.
14

**Layout**

Full-width dark navy header band across the top fifth of the slide holds a left-aligned title and subtitle with a margin of about 3.1% from the left edge. Below it a left-aligned data table spans about 3.1% to 96.4% of the width, with a blank first header cell over the row-label column, four header columns, and five data rows. A small footnote block sits at the bottom left, with a teal logo mark and the page number 14 at the bottom right.

**Visuals**

Table: four value columns plus a row-label column. Header row: blank label cell, then 'Q3 2026' (white bold on teal #00857C), 'Q3 2025' (navy bold on #E2E2E2), 'Change' (navy bold on #E2E2E2), 'Change Ex-FX' (navy bold, two lines, on #E2E2E2). Rows: Sales $18.1 / $17.3 / +5% / +4%. Non-GAAP Gross Margin 81.4% / 81.9% / -0.5pts / -0.6 pts. Non-GAAP Operating Expenses (superscript 2) $7.4 / $6.6 / 12% / 12%. Non-GAAP Tax Rate 10.9% / 13.4% / -2.5pts / N/A. Non-GAAP EPS (superscript 2,3) $2.49 / $2.58 / -3% / -5%. The Q3 2026 value column is tinted #E2F5F0; other cells are #F7F7F7. Superscript 1 follows the title. Logo: a small teal (#00857C) rounded four-lobed mark at bottom right. No chart, photograph or other graphics.

**Design**

Background: Solid white #FFFFFF. White background. Navy #0C2340 header band with white title and mint #6ECEB2 subtitle. Table cells are flat rectangles with no corner radius, no shadows and no gradients, separated by thin white gaps. Teal #00857C accent for the Q3 2026 header; pale teal #E2E2E2 headers. Body text navy #0C2340. Typeface Invention (sans-serif): Light for title and subtitle, Bold for headers and row labels, Regular for values and footnotes. Title approximately 5.1% of slide height, table text about 3.0%, footnote about 1.7%.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide background rectangle (Covers the slide, no border)
- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Header band rectangle (Full-width navy band, no border)
- title at x 3.1, y 4.9, w 58.4, h 5.1 [Invention Light, regular weight, sentence case; font size 5.09% of slide height; #FFFFFF; left aligned]: Q3 2026 non-GAAP financial results summary
- title at x 61.5, y 4.7, w 0.7, h 3.4 [Invention Light, superscript; font size 3.4% of slide height; #FFFFFF; left aligned]: 1 (Superscript footnote marker after the title)
- subtitle at x 3.1, y 10.2, w 27.4, h 3.3 [Invention Light, regular weight; font size 3.33% of slide height; #6ECEB2; left aligned]: $ in billions, except EPS amounts
- shape at x 24.7, y 25.7, w 18, h 9.6 [#00857C]: Header cell fill, Q3 2026 column (Flat rectangle, no radius)
- shape at x 42.6, y 25.7, w 16.8, h 9.6 [#E2E2E2]: Header cell fill, Q3 2025 column (Flat rectangle, no radius)
- shape at x 59.4, y 25.7, w 19, h 9.6 [#E2E2E2]: Header cell fill, Change column (Flat rectangle, no radius)
- shape at x 78.3, y 25.7, w 18.6, h 9.6 [#E2E2E2]: Header cell fill, Change Ex-FX column (Flat rectangle, no radius)
- shape at x 3.1, y 35.3, w 21.6, h 9.6 [#F7F7F7]: Row label cell fill, Sales row (Flat rectangle)
- shape at x 24.7, y 35.3, w 18, h 9.6 [#E2F5F0]: Data cell fill, Sales Q3 2026 (Flat rectangle)
- shape at x 42.6, y 35.3, w 16.8, h 9.6 [#F7F7F7]: Data cell fill, Sales Q3 2025 (Flat rectangle)
- shape at x 59.4, y 35.3, w 19, h 9.6 [#F7F7F7]: Data cell fill, Sales Change (Flat rectangle)
- shape at x 78.3, y 35.3, w 18.6, h 9.6 [#F7F7F7]: Data cell fill, Sales Change Ex-FX (Flat rectangle)
- shape at x 3.1, y 44.9, w 21.6, h 9.6 [#F7F7F7]: Row label cell fill, Gross Margin row (Flat rectangle)
- shape at x 24.7, y 44.9, w 18, h 9.6 [#E2F5F0]: Data cell fill, Gross Margin Q3 2026 (Flat rectangle)
- shape at x 42.6, y 44.9, w 16.8, h 9.6 [#F7F7F7]: Data cell fill, Gross Margin Q3 2025 (Flat rectangle)
- shape at x 59.4, y 44.9, w 19, h 9.6 [#F7F7F7]: Data cell fill, Gross Margin Change (Flat rectangle)
- shape at x 78.3, y 44.9, w 18.6, h 9.6 [#F7F7F7]: Data cell fill, Gross Margin Change Ex-FX (Flat rectangle)
- shape at x 3.1, y 54.5, w 21.6, h 9.6 [#F7F7F7]: Row label cell fill, Operating Expenses row (Flat rectangle)
- shape at x 24.7, y 54.5, w 18, h 9.6 [#E2F5F0]: Data cell fill, Operating Expenses Q3 2026 (Flat rectangle)
- shape at x 42.6, y 54.5, w 16.8, h 9.6 [#F7F7F7]: Data cell fill, Operating Expenses Q3 2025 (Flat rectangle)
- shape at x 59.4, y 54.5, w 19, h 9.6 [#F7F7F7]: Data cell fill, Operating Expenses Change (Flat rectangle)
- shape at x 78.3, y 54.5, w 18.6, h 9.6 [#F7F7F7]: Data cell fill, Operating Expenses Change Ex-FX (Flat rectangle)
- shape at x 3.1, y 64.1, w 21.6, h 9.6 [#F7F7F7]: Row label cell fill, Tax Rate row (Flat rectangle)
- shape at x 24.7, y 64.1, w 18, h 9.6 [#E2F5F0]: Data cell fill, Tax Rate Q3 2026 (Flat rectangle)
- shape at x 42.6, y 64.1, w 16.8, h 9.6 [#F7F7F7]: Data cell fill, Tax Rate Q3 2025 (Flat rectangle)
- shape at x 59.4, y 64.1, w 19, h 9.6 [#F7F7F7]: Data cell fill, Tax Rate Change (Flat rectangle)
- shape at x 78.3, y 64.1, w 18.6, h 9.6 [#F7F7F7]: Data cell fill, Tax Rate Change Ex-FX (Flat rectangle)
- shape at x 3.1, y 73.7, w 21.6, h 9.6 [#F7F7F7]: Row label cell fill, EPS row (Flat rectangle)
- shape at x 24.7, y 73.7, w 18, h 9.6 [#E2F5F0]: Data cell fill, EPS Q3 2026 (Flat rectangle)
- shape at x 42.6, y 73.7, w 16.8, h 9.6 [#F7F7F7]: Data cell fill, EPS Q3 2025 (Flat rectangle)
- shape at x 59.4, y 73.7, w 19, h 9.6 [#F7F7F7]: Data cell fill, EPS Change (Flat rectangle)
- shape at x 78.3, y 73.7, w 18.6, h 9.6 [#F7F7F7]: Data cell fill, EPS Change Ex-FX (Flat rectangle)
- body at x 30, y 29.2, w 7.3, h 3.3 [Invention Bold, sentence case; font size 3.33% of slide height; #FFFFFF; center aligned]: Q3 2026
- body at x 47.4, y 29.2, w 7.3, h 3.3 [Invention Bold, sentence case; font size 3.33% of slide height; #0C2340; center aligned]: Q3 2025
- body at x 65.6, y 29.2, w 6.6, h 3.3 [Invention Bold, sentence case; font size 3.33% of slide height; #0C2340; center aligned]: Change
- body at x 84.3, y 27.2, w 7, h 3.3 [Invention Bold, sentence case; font size 3.33% of slide height; #0C2340; center aligned]: Change (First line of two-line header)
- body at x 85, y 31.2, w 5.3, h 3.3 [Invention Bold, sentence case; font size 3.33% of slide height; #0C2340; center aligned]: Ex-FX (Second line of two-line header)
- body at x 4.6, y 38.9, w 4.1, h 3 [Invention Bold, sentence case; font size 2.96% of slide height; #0C2340; left aligned]: Sales
- body at x 31.7, y 38.9, w 3.9, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: $18.1
- body at x 49, y 38.9, w 4, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: $17.3
- body at x 67.1, y 38.9, w 3.4, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: +5%
- body at x 85.8, y 38.9, w 3.5, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: +4%
- body at x 4.6, y 46.7, w 13.6, h 8.6 [Invention Bold, sentence case; font size 2.96% of slide height; #0C2340; left aligned]: Non-GAAP Gross / Margin (Two lines, line break after Gross; line spacing about 1.1)
- body at x 31.3, y 48.5, w 4.6, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: 81.4%
- body at x 48.7, y 48.5, w 4.6, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: 81.9%
- body at x 66, y 48.5, w 5.6, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: -0.5pts
- body at x 84.6, y 48.5, w 6.1, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: -0.6 pts
- body at x 4.6, y 56.3, w 17.1, h 6.6 [Invention Bold, sentence case; '2' superscript; font size 2.96% of slide height; #0C2340; left aligned]: Non-GAAP Operating / Expenses 2 (Two lines, line break after Operating; superscript 2 after Expenses)
- body at x 31.9, y 58.1, w 3.5, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: $7.4
- body at x 49.2, y 58.1, w 3.6, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: $6.6
- body at x 67.3, y 58.1, w 3, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: 12%
- body at x 86.1, y 58.1, w 3, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: 12%
- body at x 4.6, y 67.7, w 15.7, h 3 [Invention Bold, sentence case; font size 2.96% of slide height; #0C2340; left aligned]: Non-GAAP Tax Rate
- body at x 31.3, y 67.7, w 4.6, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: 10.9%
- body at x 48.7, y 67.7, w 4.6, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: 13.4%
- body at x 66.1, y 67.7, w 5.5, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: -2.5pts
- body at x 86.1, y 67.7, w 3.1, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: N/A
- body at x 4.6, y 77.3, w 12, h 3 [Invention Bold, sentence case; '2,3' superscript; font size 2.96% of slide height; #0C2340; left aligned]: Non-GAAP EPS 2,3
- body at x 31.4, y 77.3, w 4.5, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: $2.49
- body at x 48.8, y 77.3, w 4.5, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: $2.58
- body at x 67.3, y 77.3, w 3.1, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: -3%
- body at x 86.1, y 77.3, w 3.1, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: -5%
- footer at x 3.1, y 87.1, w 87.8, h 11.9 [Invention Regular, sentence case; font size 1.67% of slide height; #0C2340; left aligned]: 1. The company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business / performance and trends. Management believes that providing this information enhances investors' understanding of the company's results because management uses non-GAAP results to assess / performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee / compensation, including senior management's compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or / superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q3 2026 non-GAAP results include a charge of / $400 million, or $0.12 per share, related to an exclusive global license agreement with SciBrunch Therapeutics. Q3 2025 non-GAAP results include a $300 million charge, or $0.10 per share, related to the / LaNova Medicines technology transfer milestone payment. 3. Q3 2026 GAAP EPS of $2.04. (Line spacing about 1.0; footnote markers 1, 2 and 3 are inline)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Company logo: stylised rounded four-lobed mark (Image 125 by 150 pixels, teal lobes with darker teal centre, no box)
- page number at x 96.2, y 95.5, w 0.7, h 1.3 [Invention Regular, sentence case; font size 1.29% of slide height; #9EA7B3; right aligned]: 14

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- fill at x 24.7, y 25.7, w 18.0, h 9.6: #00857C
- fill at x 42.6, y 25.7, w 16.8, h 9.6: #E2E2E2
- fill at x 59.4, y 25.7, w 19.0, h 9.6: #E2E2E2
- fill at x 78.3, y 25.7, w 18.6, h 9.6: #E2E2E2
- fill at x 3.1, y 35.3, w 21.6, h 9.6: #F7F7F7
- fill at x 24.7, y 35.3, w 18.0, h 9.6: #E2F5F0
- fill at x 42.6, y 35.3, w 16.8, h 9.6: #F7F7F7
- fill at x 59.4, y 35.3, w 19.0, h 9.6: #F7F7F7
- fill at x 78.3, y 35.3, w 18.6, h 9.6: #F7F7F7
- fill at x 3.1, y 44.9, w 21.6, h 9.6: #F7F7F7
- fill at x 24.7, y 44.9, w 18.0, h 9.6: #E2F5F0
- fill at x 42.6, y 44.9, w 16.8, h 9.6: #F7F7F7
- fill at x 59.4, y 44.9, w 19.0, h 9.6: #F7F7F7
- fill at x 78.3, y 44.9, w 18.6, h 9.6: #F7F7F7
- fill at x 3.1, y 54.5, w 21.6, h 9.6: #F7F7F7
- fill at x 24.7, y 54.5, w 18.0, h 9.6: #E2F5F0
- fill at x 42.6, y 54.5, w 16.8, h 9.6: #F7F7F7
- fill at x 59.4, y 54.5, w 19.0, h 9.6: #F7F7F7
- fill at x 78.3, y 54.5, w 18.6, h 9.6: #F7F7F7
- fill at x 3.1, y 64.1, w 21.6, h 9.6: #F7F7F7
- fill at x 24.7, y 64.1, w 18.0, h 9.6: #E2F5F0
- fill at x 59.4, y 64.1, w 19.0, h 9.6: #F7F7F7
- fill at x 78.3, y 64.1, w 18.6, h 9.6: #F7F7F7
- fill at x 3.1, y 73.7, w 21.6, h 9.6: #F7F7F7
- fill at x 24.7, y 73.7, w 18.0, h 9.6: #E2F5F0
- fill at x 42.6, y 73.7, w 16.8, h 9.6: #F7F7F7
- fill at x 59.4, y 73.7, w 19.0, h 9.6: #F7F7F7
- fill at x 78.3, y 73.7, w 18.6, h 9.6: #F7F7F7
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 4.9, w 58.4, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Q3 2026 non-GAAP financial results summary
- text at x 61.5, y 4.7, w 0.7, h 3.4 [Invention-Light; font size 3.40; #FFFFFF]: 1
- text at x 3.1, y 10.2, w 27.4, h 3.3 [Invention-Light; font size 3.33; #6ECEB2]: $ in billions, except EPS amounts
- text at x 84.3, y 27.2, w 7.0, h 3.3 [Invention-Bold; font size 3.33; #0C2340]: Change
- text at x 30.0, y 29.2, w 7.3, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: Q3 2026
- text at x 47.4, y 29.2, w 7.3, h 3.3 [Invention-Bold; font size 3.33; #0C2340]: Q3 2025
- text at x 65.6, y 29.2, w 6.6, h 3.3 [Invention-Bold; font size 3.33; #0C2340]: Change
- text at x 85.0, y 31.2, w 5.3, h 3.3 [Invention-Bold; font size 3.33; #0C2340]: Ex-FX
- text at x 4.6, y 38.9, w 4.1, h 3.0 [Invention-Bold; font size 2.96; #0C2340]: Sales
- text at x 31.7, y 38.9, w 3.9, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: $18.1
- text at x 49.0, y 38.9, w 4.0, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: $17.3
- text at x 67.1, y 38.9, w 3.4, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: +5%
- text at x 85.8, y 38.9, w 3.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: +4%
- text at x 4.6, y 46.7, w 13.6, h 3.0 [Invention-Bold; font size 2.96; #0C2340]: Non-GAAP Gross
- text at x 31.3, y 48.5, w 4.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: 81.4%
- text at x 48.7, y 48.5, w 4.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: 81.9%
- text at x 66.0, y 48.5, w 5.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: -0.5pts
- text at x 84.6, y 48.5, w 6.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: -0.6 pts
- text at x 4.6, y 50.3, w 5.5, h 3.0 [Invention-Bold; font size 2.96; #0C2340]: Margin
- text at x 4.6, y 56.3, w 17.1, h 3.0 [Invention-Bold; font size 2.96; #0C2340]: Non-GAAP Operating
- text at x 31.9, y 58.1, w 3.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: $7.4
- text at x 49.2, y 58.1, w 3.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: $6.6
- text at x 67.3, y 58.1, w 3.0, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: 12%
- text at x 86.1, y 58.1, w 3.0, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: 12%
- text at x 4.6, y 59.9, w 7.3, h 3.0 [Invention-Bold; font size 2.96; #0C2340]: Expenses
- text at x 4.6, y 67.7, w 15.7, h 3.0 [Invention-Bold; font size 2.96; #0C2340]: Non-GAAP Tax Rate
- text at x 31.3, y 67.7, w 4.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: 10.9%
- text at x 48.7, y 67.7, w 4.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: 13.4%
- text at x 66.1, y 67.7, w 5.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: -2.5pts
- text at x 86.1, y 67.7, w 3.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: N/A
- text at x 4.6, y 77.3, w 12.0, h 3.0 [Invention-Bold; font size 2.96; #0C2340]: Non-GAAP EPS
- text at x 31.4, y 77.3, w 4.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: $2.49
- text at x 48.8, y 77.3, w 4.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: $2.58
- text at x 67.3, y 77.3, w 3.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: -3%
- text at x 86.1, y 77.3, w 3.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: -5%
- text at x 11.9, y 59.8, w 0.6, h 2.0 [Invention-Regular; font size 1.98; #0C2340]: 2
- text at x 16.6, y 77.2, w 1.6, h 2.0 [Invention-Regular; font size 1.98; #0C2340]: 2,3
- text at x 3.1, y 87.1, w 87.8, h 11.9 [Invention-Regular; font size 1.67; #0C2340]: 1. The company is providing certain2026and 2025non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should beconsidered in addition to, but not as a substitute for or superior to, information prepared in accordance withGAAP. For a descriptionof thenon-GAAP adjustments, seeTable2aattached to the earnings release. 2. Q3 2026 non-GAAP results include a charge of $400 million, or $0.12 per share, related to an exclusive global license agreement with SciBrunch Therapeutics. Q3 2025 non-GAAP results include a $300 million charge, or $0.10 per share, related to the LaNova Medicines technology transfer milestone payment. 3. Q3 2026 GAAP EPS of $2.04.
- text at x 96.2, y 95.5, w 0.7, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 14

### Slide 15

**Review notes**

- Review: Weaknesses are consequential: several pages are dense or small (slides 3, 14, 15, 22, 27, 28), slide 8's launch chart has an unexplained hatched box and no growth label, and pale mint bars with white labels on slides 10 to 13 are weaker in contrast.
- Suggested repair: Raise contrast on white labels over mint bars on slides 10 to 12, label or simplify the hatched OHTUVAYRE segment on slide 8, and enlarge the guidance assumptions text on slide 15.

**Text**

Updated 2026 financial outlook / Prior Guidance / Updated Guidance / Key Assumptions / Revenue / $66.3B to $67.3B / $66.8B to $67.3B / Assumes ~1 percentage point positive impact from FX / Now implies +3% to +4% nominal (+2% to +3% ex-FX) / Non-GAAP / Gross Margin Rate / ~81.0% / ~81.0% / Non-GAAP / Operating Expenses1 / $42.0B to $42.7B / $42.4B to $42.9B / Now includes one-time $0.4B charge related to global / license agreement with SciBrunch Therapeutics / Other (Income) / Expense / ~$1.4B of expense / ~$1.4B of expense / Tax Rate / ~35.0% to 36.0% / ~32.0% to 33.0% / Shares Outstanding / ~2.48B / ~2.48B / Assumes ~$3B of share repurchases / Non-GAAP EPS1 / $2.66 to $2.76 / $2.77 to $2.82 / Incorporates $0.12 impact related to SciBrunch charge / Assumes ~$0.15 positive impact from FX / 1. Guidance does not assume additional significant potential business development transactions / 15

**Layout**

A full-width navy header band fills the top 18% of the slide and holds the title at upper left with a left margin of about 3%. Below it a grid of four columns (row labels, Prior Guidance, Updated Guidance, Key Assumptions) and seven body rows plus a header row sits between y 22.7% and y 90.9%, with equal gutters of about 0.6% between cells. The footnote is bottom left at y 97.3%, the teal logo and the page number 15 sit bottom right, and the Key Assumptions column is left-aligned text in bullet form.

**Visuals**

Table: four columns (blank row-label column; Prior Guidance; Updated Guidance; Key Assumptions) and seven rows. Row 1 Revenue: $66.3B to $67.3B | $66.8B to $67.3B | bullets 'Assumes ~1 percentage point positive impact from FX' and 'Now implies +3% to +4% nominal (+2% to +3% ex-FX)'. Row 2 Non-GAAP Gross Margin Rate: ~81.0% | ~81.0% | none. Row 3 Non-GAAP Operating Expenses (footnote 1): $42.0B to $42.7B | $42.4B to $42.9B | bullet 'Now includes one-time $0.4B charge related to global license agreement with SciBrunch Therapeutics'. Row 4 Other (Income) / Expense: ~$1.4B of expense | ~$1.4B of expense | none. Row 5 Tax Rate: ~35.0% to 36.0% | ~32.0% to 33.0% | none. Row 6 Shares Outstanding: ~2.48B | ~2.48B | bullet 'Assumes ~$3B of share repurchases'. Row 7 Non-GAAP EPS (footnote 1): $2.66 to $2.76 | $2.77 to $2.82 | bullets 'Incorporates $0.12 impact related to SciBrunch charge' and 'Assumes ~$0.15 positive impact from FX'. Only the Updated Guidance column is highlighted with a teal header and light mint cells. Logo: a single teal (#00857C) rounded emblem of two stacked lobes with a white centre, about 3% wide, bottom right. No photographs, charts or icons.

**Design**

Background white #FFFFFF with a navy #0C2340 header band across the top 18%. Title in Invention Light (a humanist geometric sans-serif), white #FFFFFF, roughly 5.1% of slide height, regular weight. Column headers in Invention Bold, about 2.6% of slide height: Prior Guidance and Key Assumptions in navy #0C2340 on light grey #E2E2E2 cells; Updated Guidance in white on teal #00857C. Row labels in Invention Bold navy #0C2340 on pale grey #F7F7F7 cells. Body values in Invention Regular navy #0C2340 about 2.6% of height. Prior and Key Assumptions cells #F7F7F7, Updated Guidance cells mint #E2F5F0. Accent colour teal #00857C. Bullets are ArialMT navy #0C2340 at about 1.8% of height. Footnote in Invention Regular navy #0C2340 at about 1.7%. Page number in Invention Regular grey #9EA7B3 at about 1.3%. Rectangles have square corners, no borders, no shadows, no gradients.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 18.1 [#0C2340]: Navy header band behind the title (Full-width rectangle, square corners, no border, no shadow)
- shape at x 20, y 22.7, w 23.7, h 6.2 [#E2E2E2]: Prior Guidance column header cell (estimated from layout, not in measurements) (Light grey rectangle, square corners, no border)
- shape at x 43.7, y 22.7, w 23.8, h 6.2 [#00857C]: Updated Guidance column header cell (Teal rectangle, square corners, no border)
- shape at x 67.4, y 22.7, w 29.6, h 6.2 [#E2E2E2]: Key Assumptions column header cell (Light grey rectangle, square corners, no border)
- shape at x 3, y 28.9, w 17, h 8.7 [#F7F7F7]: Row 1 label cell (Revenue) (Square corners, no border)
- shape at x 20, y 28.9, w 23.7, h 8.7 [#F7F7F7]: Row 1 Prior Guidance cell (Square corners, no border)
- shape at x 43.7, y 28.9, w 23.8, h 8.7 [#E2F5F0]: Row 1 Updated Guidance cell (Square corners, no border)
- shape at x 67.4, y 28.9, w 29.6, h 8.7 [#F7F7F7]: Row 1 Key Assumptions cell (Square corners, no border)
- shape at x 3, y 37.5, w 17, h 8.7 [#F7F7F7]: Row 2 label cell (Non-GAAP Gross Margin Rate) (Square corners, no border)
- shape at x 20, y 37.5, w 23.7, h 8.7 [#F7F7F7]: Row 2 Prior Guidance cell (Square corners, no border)
- shape at x 43.7, y 37.5, w 23.8, h 8.7 [#E2F5F0]: Row 2 Updated Guidance cell (Square corners, no border)
- shape at x 67.4, y 37.5, w 29.6, h 8.7 [#F7F7F7]: Row 2 Key Assumptions cell (empty) (Square corners, no border)
- shape at x 3, y 46.2, w 17, h 8.7 [#F7F7F7]: Row 3 label cell (Non-GAAP Operating Expenses) (Square corners, no border)
- shape at x 20, y 46.2, w 23.7, h 8.7 [#F7F7F7]: Row 3 Prior Guidance cell (Square corners, no border)
- shape at x 43.7, y 46.2, w 23.8, h 8.7 [#E2F5F0]: Row 3 Updated Guidance cell (Square corners, no border)
- shape at x 67.4, y 46.2, w 29.6, h 8.7 [#F7F7F7]: Row 3 Key Assumptions cell (Square corners, no border)
- shape at x 3, y 54.9, w 17, h 8.7 [#F7F7F7]: Row 4 label cell (Other (Income) / Expense) (Square corners, no border)
- shape at x 20, y 54.9, w 23.7, h 8.7 [#F7F7F7]: Row 4 Prior Guidance cell (Square corners, no border)
- shape at x 43.7, y 54.9, w 23.8, h 8.7 [#E2F5F0]: Row 4 Updated Guidance cell (Square corners, no border)
- shape at x 67.4, y 54.9, w 29.6, h 8.7 [#F7F7F7]: Row 4 Key Assumptions cell (empty) (Square corners, no border)
- shape at x 20, y 63.5, w 23.7, h 8.7 [#F7F7F7]: Row 5 Prior Guidance cell (Tax Rate row) (Square corners, no border)
- shape at x 43.7, y 63.5, w 23.8, h 8.7 [#E2F5F0]: Row 5 Updated Guidance cell (Tax Rate row) (Square corners, no border)
- shape at x 67.4, y 63.5, w 29.6, h 8.7 [#F7F7F7]: Row 5 Key Assumptions cell (empty, Tax Rate row) (Square corners, no border)
- shape at x 3, y 72.2, w 17, h 8.7 [#F7F7F7]: Row 6 label cell (Tax Rate) (Square corners, no border)
- shape at x 20, y 72.2, w 23.7, h 8.7 [#F7F7F7]: Row 6 Prior Guidance cell (Square corners, no border)
- shape at x 43.7, y 72.2, w 23.8, h 8.7 [#E2F5F0]: Row 6 Updated Guidance cell (Square corners, no border)
- shape at x 67.4, y 72.2, w 29.6, h 8.7 [#F7F7F7]: Row 6 Key Assumptions cell (empty) (Square corners, no border)
- shape at x 20, y 80.9, w 23.7, h 8.7 [#F7F7F7]: Row 7 Prior Guidance cell (Shares Outstanding row) (Square corners, no border)
- shape at x 43.7, y 80.9, w 23.8, h 8.7 [#E2F5F0]: Row 7 Updated Guidance cell (Shares Outstanding row) (Square corners, no border)
- shape at x 67.4, y 80.9, w 29.6, h 8.7 [#F7F7F7]: Row 7 Key Assumptions cell (Shares Outstanding row) (Square corners, no border)
- table at x 3, y 22.7, w 94.6, h 68.2: Financial outlook table: columns blank label, Prior Guidance, Updated Guidance, Key Assumptions; seven body rows Revenue, Non-GAAP Gross Margin Rate, Non-GAAP Operating Expenses1, Other (Income) / Expense, Tax Rate, Shares Outstanding, Non-GAAP EPS1 (Composed of the header and cell shapes around it; no table borders)
- title at x 3.1, y 6.7, w 39.6, h 5.1 [Invention-Light, regular weight, sans-serif; font size 5.09% of slide height; #FFFFFF; left aligned]: Updated 2026 financial outlook
- body at x 26.8, y 24.7, w 10.1, h 2.6 [Invention-Bold, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: Prior Guidance (Column header)
- body at x 49.3, y 24.7, w 12.5, h 2.6 [Invention-Bold, sans-serif; font size 2.6% of slide height; #FFFFFF; center aligned]: Updated Guidance (Column header)
- body at x 76.3, y 24.7, w 11.8, h 2.6 [Invention-Bold, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: Key Assumptions (Column header)
- body at x 3.7, y 32.1, w 5.9, h 2.6 [Invention-Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Revenue
- body at x 25.9, y 32.1, w 11.8, h 2.6 [Invention-Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: $66.3B to $67.3B
- body at x 49.6, y 32.1, w 11.9, h 2.6 [Invention-Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: $66.8B to $67.3B
- bullet list at x 68.2, y 31.3, w 26.8, h 3.9 [Invention-Regular, sans-serif; font size 1.84% of slide height; #0C2340; left aligned]: Assumes ~1 percentage point positive impact from FX / Now implies +3% to +4% nominal (+2% to +3% ex-FX) (Bullets ArialMT round dots at x 68.2; line spacing about 2.2% of height between bullets)
- body at x 3.7, y 39.2, w 12.6, h 5.2 [Invention-Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Non-GAAP / Gross Margin Rate (Two lines)
- body at x 29.3, y 40.8, w 5, h 2.6 [Invention-Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: ~81.0%
- body at x 53, y 40.8, w 5, h 2.6 [Invention-Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: ~81.0%
- body at x 3.7, y 47.9, w 13.7, h 5.2 [Invention-Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Non-GAAP / Operating Expenses1 (Superscript 1 at x 17.4, y 50.9, size 1.73)
- body at x 25.9, y 49.5, w 11.9, h 2.6 [Invention-Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: $42.0B to $42.7B
- body at x 49.6, y 49.5, w 12, h 2.6 [Invention-Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: $42.4B to $42.9B
- bullet list at x 68.2, y 48.7, w 26, h 3.9 [Invention-Regular, sans-serif; font size 1.84% of slide height; #0C2340; left aligned]: Now includes one-time $0.4B charge related to global / license agreement with SciBrunch Therapeutics (Single bullet with wrapped second line; bullet ArialMT at x 68.2)
- body at x 3.7, y 56.6, w 11.7, h 5.2 [Invention-Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Other (Income) / Expense (Two lines)
- body at x 25.7, y 58.1, w 12.3, h 2.6 [Invention-Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: ~$1.4B of expense
- body at x 49.4, y 58.1, w 12.3, h 2.6 [Invention-Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: ~$1.4B of expense
- body at x 3.7, y 66.8, w 6, h 2.6 [Invention-Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Tax Rate
- body at x 26, y 66.8, w 11.6, h 2.6 [Invention-Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: ~35.0% to 36.0%
- body at x 49.8, y 66.8, w 11.5, h 2.6 [Invention-Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: ~32.0% to 33.0%
- body at x 3.7, y 75.5, w 13.6, h 2.6 [Invention-Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Shares Outstanding
- body at x 29.3, y 75.5, w 5, h 2.6 [Invention-Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: ~2.48B
- body at x 53.1, y 75.5, w 5, h 2.6 [Invention-Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: ~2.48B
- bullet list at x 68.2, y 75.8, w 18.7, h 1.8 [Invention-Regular, sans-serif; font size 1.84% of slide height; #0C2340; left aligned]: Assumes ~$3B of share repurchases (Single bullet, ArialMT dot at x 68.2)
- body at x 3.7, y 84.1, w 10.6, h 2.6 [Invention-Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Non-GAAP EPS1 (Superscript 1 at x 14.3, y 84.0, size 1.73)
- body at x 26.9, y 84.1, w 9.8, h 2.6 [Invention-Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: $2.66 to $2.76
- body at x 50.7, y 84.1, w 9.6, h 2.6 [Invention-Regular, sans-serif; font size 2.6% of slide height; #0C2340; center aligned]: $2.77 to $2.82
- bullet list at x 68.2, y 83.3, w 26, h 4 [Invention-Regular, sans-serif; font size 1.84% of slide height; #0C2340; left aligned]: Incorporates $0.12 impact related to SciBrunch charge / Assumes ~$0.15 positive impact from FX (Two bullets, ArialMT dots at x 68.2)
- footer at x 3.1, y 97.3, w 40.4, h 1.7 [Invention-Regular, sans-serif; font size 1.67% of slide height; #0C2340; left aligned]: 1. Guidance does not assume additional significant potential business development transactions
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Teal company logo: rounded emblem of two stacked lobes with a white centre, bottom right corner (Image 125 by 150 pixels)
- page number at x 96.2, y 95.5, w 0.7, h 1.3 [Invention-Regular, sans-serif; font size 1.29% of slide height; #9EA7B3; right aligned]: 15

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.1: #0C2340
- fill at x 43.7, y 22.7, w 23.8, h 6.2: #00857C
- fill at x 67.4, y 22.7, w 29.6, h 6.2: #E2E2E2
- fill at x 3.0, y 28.9, w 17.0, h 8.7: #F7F7F7
- fill at x 20.0, y 28.9, w 23.7, h 8.7: #F7F7F7
- fill at x 43.7, y 28.9, w 23.8, h 8.7: #E2F5F0
- fill at x 67.4, y 28.9, w 29.6, h 8.7: #F7F7F7
- fill at x 3.0, y 37.5, w 17.0, h 8.7: #F7F7F7
- fill at x 20.0, y 37.5, w 23.7, h 8.7: #F7F7F7
- fill at x 43.7, y 37.5, w 23.8, h 8.7: #E2F5F0
- fill at x 67.4, y 37.5, w 29.6, h 8.7: #F7F7F7
- fill at x 3.0, y 46.2, w 17.0, h 8.7: #F7F7F7
- fill at x 20.0, y 46.2, w 23.7, h 8.7: #F7F7F7
- fill at x 43.7, y 46.2, w 23.8, h 8.7: #E2F5F0
- fill at x 67.4, y 46.2, w 29.6, h 8.7: #F7F7F7
- fill at x 3.0, y 54.9, w 17.0, h 8.7: #F7F7F7
- fill at x 20.0, y 54.9, w 23.7, h 8.7: #F7F7F7
- fill at x 43.7, y 54.9, w 23.8, h 8.7: #E2F5F0
- fill at x 67.4, y 54.9, w 29.6, h 8.7: #F7F7F7
- fill at x 20.0, y 63.5, w 23.7, h 8.7: #F7F7F7
- fill at x 43.7, y 63.5, w 23.8, h 8.7: #E2F5F0
- fill at x 67.4, y 63.5, w 29.6, h 8.7: #F7F7F7
- fill at x 3.0, y 72.2, w 17.0, h 8.7: #F7F7F7
- fill at x 20.0, y 72.2, w 23.7, h 8.7: #F7F7F7
- fill at x 43.7, y 72.2, w 23.8, h 8.7: #E2F5F0
- fill at x 67.4, y 72.2, w 29.6, h 8.7: #F7F7F7
- fill at x 20.0, y 80.9, w 23.7, h 8.7: #F7F7F7
- fill at x 43.7, y 80.9, w 23.8, h 8.7: #E2F5F0
- fill at x 67.4, y 80.9, w 29.6, h 8.7: #F7F7F7
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 6.7, w 39.6, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Updated 2026 financial outlook
- text at x 26.8, y 24.7, w 10.1, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Prior Guidance
- text at x 49.3, y 24.7, w 12.5, h 2.6 [Invention-Bold; font size 2.60; #FFFFFF]: Updated Guidance
- text at x 76.3, y 24.7, w 11.8, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Key Assumptions
- text at x 3.7, y 32.1, w 5.9, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Revenue
- text at x 25.9, y 32.1, w 11.8, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: $66.3B to $67.3B
- text at x 49.6, y 32.1, w 11.9, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: $66.8B to $67.3B
- text at x 3.7, y 39.2, w 7.5, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Non-GAAP
- text at x 29.3, y 40.8, w 5.0, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: ~81.0%
- text at x 53.0, y 40.8, w 5.0, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: ~81.0%
- text at x 3.7, y 42.3, w 12.6, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Gross Margin Rate
- text at x 68.2, y 31.3, w 0.4, h 1.8 [ArialMT; font size 1.84; #0C2340]: •
- text at x 69.6, y 31.3, w 25.3, h 1.8 [Invention-Regular; font size 1.84; #0C2340]: Assumes ~1 percentage point positive impact from FX
- text at x 68.2, y 33.5, w 0.4, h 1.8 [ArialMT; font size 1.84; #0C2340]: •
- text at x 69.6, y 33.5, w 25.5, h 1.8 [Invention-Regular; font size 1.84; #0C2340]: Now implies +3% to +4% nominal (+2% to +3% ex-FX)
- text at x 3.7, y 47.9, w 7.5, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Non-GAAP
- text at x 25.9, y 49.5, w 11.9, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: $42.0B to $42.7B
- text at x 49.6, y 49.5, w 12.0, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: $42.4B to $42.9B
- text at x 3.7, y 51.0, w 13.7, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Operating Expenses
- text at x 3.7, y 56.6, w 11.7, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Other (Income) /
- text at x 25.7, y 58.1, w 12.3, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: ~$1.4B of expense
- text at x 49.4, y 58.1, w 12.3, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: ~$1.4B of expense
- text at x 3.7, y 59.7, w 5.7, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Expense
- text at x 3.7, y 66.8, w 6.0, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Tax Rate
- text at x 26.0, y 66.8, w 11.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: ~35.0% to 36.0%
- text at x 49.8, y 66.8, w 11.5, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: ~32.0% to 33.0%
- text at x 68.2, y 48.7, w 0.4, h 1.8 [ArialMT; font size 1.84; #0C2340]: •
- text at x 69.6, y 48.7, w 25.5, h 1.8 [Invention-Regular; font size 1.84; #0C2340]: Now includes one-time $0.4B charge related to global
- text at x 69.6, y 50.9, w 22.3, h 1.8 [Invention-Regular; font size 1.84; #0C2340]: license agreement with SciBrunch Therapeutics
- text at x 3.7, y 75.5, w 13.6, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Shares Outstanding
- text at x 29.3, y 75.5, w 5.0, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: ~2.48B
- text at x 53.1, y 75.5, w 5.0, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: ~2.48B
- text at x 17.4, y 50.9, w 0.4, h 1.7 [Invention-Regular; font size 1.73; #0C2340]: 1
- text at x 3.7, y 84.1, w 10.6, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Non-GAAP EPS
- text at x 26.9, y 84.1, w 9.8, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: $2.66 to $2.76
- text at x 50.7, y 84.1, w 9.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: $2.77 to $2.82
- text at x 68.2, y 75.8, w 0.4, h 1.8 [ArialMT; font size 1.84; #0C2340]: •
- text at x 69.6, y 75.8, w 17.1, h 1.8 [Invention-Regular; font size 1.84; #0C2340]: Assumes ~$3B of share repurchases
- text at x 68.2, y 83.3, w 0.4, h 1.8 [ArialMT; font size 1.84; #0C2340]: •
- text at x 69.6, y 83.3, w 25.6, h 1.8 [Invention-Regular; font size 1.84; #0C2340]: Incorporates $0.12 impact related to SciBrunch charge
- text at x 68.2, y 85.5, w 0.4, h 1.8 [ArialMT; font size 1.84; #0C2340]: •
- text at x 69.6, y 85.5, w 19.5, h 1.8 [Invention-Regular; font size 1.84; #0C2340]: Assumes ~$0.15 positive impact from FX
- text at x 14.3, y 84.0, w 0.4, h 1.7 [Invention-Regular; font size 1.73; #0C2340]: 1
- text at x 3.1, y 97.3, w 40.4, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 1. Guidance does not assume additional significant potential business development transactions
- text at x 96.2, y 95.5, w 0.7, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 15

### Slide 16

**Review notes**

- Review: Some slides leave large empty areas next to charts (slides 10, 11, 12, 16).
- What would change the score: Cut or split the dense pipeline and milestone pages (slides 22 and 27) and give slide 16 and the text-light chart pages a visual anchor so whitespace reads as design rather than leftover room.

**Text**

Key modeling considerations
U.S. Purchase Timing
• 3Q26 benefitted from ~$550M of favorable purchase timing
• Expect KEYTRUDA and WINREVAIR benefit to fully unwind in 4Q26, and majority of vaccines benefit, primarily GARDASIL, to unwind in 2027
KEYTRUDA
• Expect moderating growth as we approach peak revenues for certain approved indications
• Expect German market to be impacted by policy dynamics
BRIDION
• Experiencing competition from multiple generics
Operating Expense
• Anticipate underlying operating expenses to increase mid- to high-single digits in 2027
16

**Layout**

Two-column body layout below a full-width dark navy title band occupying the top 18.4% of the slide. The title sits left-aligned at about 3.1% from the left edge, vertically centred in the band. Left column starts at x 3.1% and right column at x 51.9%, both beginning at about y 25% under the band with generous white space below. Page number 16 sits bottom right at x 96.2%, y 95.5%, with a small teal logo mark to its left at x 91.8%, y 92.8%.

**Visuals**

A small teal four-lobed logo mark (roughly 125 by 150 px) at bottom right, next to the page number. No charts, photographs or other illustrations. Teal-green (#00857C) bullet-free section headings and navy bullet points are text-only.

**Design**

Background white (#FFFFFF) with a full-width navy (#0C2340) title band across the top 18.4% of the slide. Title text is white (#FFFFFF) in Invention Light, regular weight, about 5.1% of slide height. Section headings are in Invention Bold, teal #00857C, about 3.7% of slide height. Body text is Invention Regular in navy #0C2340, about 3.3% of slide height, with bullets in Arial-like typeface in navy. Sans-serif throughout. No shapes, lines, shadows or gradients. Page number is light grey #9EA7B3 in Invention Regular at about 1.3% of slide height.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Full-width navy title band (Solid rectangle with no border, no shadow, spanning full slide width at top.)
- title at x 3.1, y 6.7, w 36.3, h 5.1 [Invention, Light, regular weight, sans-serif; font size 5.09% of slide height; #FFFFFF; left aligned]: Key modeling considerations
- subtitle at x 3.1, y 25.1, w 20.8, h 3.7 [Invention, Bold, sans-serif; font size 3.71% of slide height; #00857C; left aligned]: U.S. Purchase Timing
- bullet list at x 3.1, y 30.6, w 37.7, h 7.3 [Invention, Regular, sans-serif; font size 3.33% of slide height; #0C2340; left aligned]: • 3Q26 benefitted from ~$550M of favorable purchase timing (Bullet '•' in Arial-like navy at x 3.1%, text indented to x 5.4%; line spacing about 1.2 times the font size.)
- body at x 5.4, y 30.6, w 37.4, h 7.3 [Invention, Regular, sans-serif; font size 3.33% of slide height; #0C2340; left aligned]: 3Q26 benefitted from ~$550M of favorable purchase timing (Wraps onto two lines: '3Q26 benefitted from ~$550M of favorable / purchase timing'.)
- body at x 5.4, y 39.7, w 40.4, h 11.3 [Invention, Regular, sans-serif; font size 3.33% of slide height; #0C2340; left aligned]: Expect KEYTRUDA and WINREVAIR benefit to fully unwind in 4Q26, and majority of vaccines benefit, primarily GARDASIL, to unwind in 2027 (Bullet '•' at x 3.1%, y 39.7%. Wraps onto three lines: 'Expect KEYTRUDA and WINREVAIR benefit to / fully unwind in 4Q26, and majority of vaccines / benefit, primarily GARDASIL, to unwind in 2027'.)
- subtitle at x 3.1, y 56.2, w 11.3, h 3.7 [Invention, Bold, sans-serif; font size 3.71% of slide height; #00857C; left aligned]: KEYTRUDA
- body at x 5.4, y 61.7, w 41.1, h 7.3 [Invention, Regular, sans-serif; font size 3.33% of slide height; #0C2340; left aligned]: Expect moderating growth as we approach peak / revenues for certain approved indications (Bullet '•' at x 3.1%, y 61.7%.)
- body at x 5.4, y 70.8, w 40.9, h 7.3 [Invention, Regular, sans-serif; font size 3.33% of slide height; #0C2340; left aligned]: Expect German market to be impacted by policy / dynamics (Bullet '•' at x 3.1%, y 70.8%.)
- subtitle at x 51.9, y 25.1, w 8.9, h 3.7 [Invention, Bold, sans-serif; font size 3.71% of slide height; #00857C; left aligned]: BRIDION
- body at x 54.3, y 30.6, w 41.3, h 3.3 [Invention, Regular, sans-serif; font size 3.33% of slide height; #0C2340; left aligned]: Experiencing competition from multiple generics (Bullet '•' at x 51.9%, y 30.6%.)
- subtitle at x 51.9, y 39.1, w 18.5, h 3.7 [Invention, Bold, sans-serif; font size 3.71% of slide height; #00857C; left aligned]: Operating Expense
- body at x 54.3, y 44.6, w 38, h 7.3 [Invention, Regular, sans-serif; font size 3.33% of slide height; #0C2340; left aligned]: Anticipate underlying operating expenses to / increase mid- to high-single digits in 2027 (Bullet '•' at x 51.9%, y 44.6%.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Teal four-lobed corporate logo mark (Image 125 by 150 pixels, teal lobes with white centre details.)
- footer at x 96.2, y 95.5, w 0.7, h 1.3 [Invention, Regular, sans-serif; font size 1.29% of slide height; #9EA7B3; right aligned]: 16 (Slide page number.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 6.7, w 36.3, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Key modeling considerations
- text at x 3.1, y 25.1, w 20.8, h 3.7 [Invention-Bold; font size 3.71; #00857C]: U.S. Purchase Timing
- text at x 51.9, y 25.1, w 8.9, h 3.7 [Invention-Bold; font size 3.71; #00857C]: BRIDION
- text at x 3.1, y 30.6, w 0.7, h 3.3 [ArialMT; font size 3.33; #0C2340]: •
- text at x 51.9, y 30.6, w 0.7, h 3.3 [ArialMT; font size 3.33; #0C2340]: •
- text at x 54.3, y 30.6, w 41.3, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: Experiencing competition from multiple generics
- text at x 5.4, y 30.6, w 37.4, h 7.3 [Invention-Regular; font size 3.33; #0C2340]: 3Q26 benefitted from ~$550M of favorable purchase timing
- text at x 51.9, y 39.1, w 18.5, h 3.7 [Invention-Bold; font size 3.71; #00857C]: Operating Expense
- text at x 3.1, y 39.7, w 0.7, h 3.3 [ArialMT; font size 3.33; #0C2340]: •
- text at x 5.4, y 39.7, w 40.4, h 11.3 [Invention-Regular; font size 3.33; #0C2340]: Expect KEYTRUDA and WINREVAIR benefit to fully unwind in 4Q26, and majority of vaccines benefit, primarily GARDASIL, to unwind in 2027
- text at x 51.9, y 44.6, w 0.7, h 3.3 [ArialMT; font size 3.33; #0C2340]: •
- text at x 54.3, y 44.6, w 38.0, h 7.3 [Invention-Regular; font size 3.33; #0C2340]: Anticipate underlying operating expenses to increase mid- to high-single digits in 2027
- text at x 3.1, y 56.2, w 11.3, h 3.7 [Invention-Bold; font size 3.71; #00857C]: KEYTRUDA
- text at x 3.1, y 61.7, w 0.7, h 3.3 [ArialMT; font size 3.33; #0C2340]: •
- text at x 5.4, y 61.7, w 41.1, h 7.3 [Invention-Regular; font size 3.33; #0C2340]: Expect moderating growth as we approach peak revenues for certain approved indications
- text at x 3.1, y 70.8, w 0.7, h 3.3 [ArialMT; font size 3.33; #0C2340]: •
- text at x 5.4, y 70.8, w 40.9, h 7.3 [Invention-Regular; font size 3.33; #0C2340]: Expect German market to be impacted by policy dynamics
- text at x 96.2, y 95.5, w 0.7, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 16

### Slide 17

**Text**

Remain committed to balanced capital allocation strategy / 3Q Spend ($ in billions)1 / Capital allocation order of priority / $4.0 / $1.0 / $2.1 / $0.7 / $0.7 / After-Tax R&D2 / CapEx / Dividends / Paid / Business / Development 3 / (ex-divestitures) / Share Repurchase / Augmented our pipeline with / value-enhancing business / development while investing / in our pipeline and business / as well as returning cash to / shareholders / 1. Reflects quarter spend subject to finalization of the Company’s statement of cash flows 2. Reflects R&D excluding Business Development 3. Includes BD payments reflected in operating cash flow / 17

**Layout**

A full-width dark navy header band across the top holds the title and subtitle left-aligned at the left margin of about 3 percent. Below it, a horizontal teal arrow with the label Capital allocation order of priority runs across the upper-left content area. The bar chart occupies the left column from about 6 to 65 percent of the width, and a light grey callout box sits in the right column from about 68 to 97 percent, vertically centred on the chart. A footnote line runs along the bottom at about 97 percent height, with a small logo at bottom right and the page number 17 at far right.

**Visuals**

Vertical bar chart with five bars, no y-axis, no gridlines, and no printed scale; bar heights are relative and only the printed values are given. Horizontal baseline in navy #0C2340 at about 73 percent height, with small tick marks at the category boundaries. Bars from left to right: After-Tax R&D (printed value $4.0, teal #00857C, tallest bar), CapEx (printed value $1.0, light mint #6ECEB2), Dividends Paid (printed value $2.1, navy #0C2340), Business Development (ex-divestitures) (printed value $0.7, periwinkle blue about #6B8FE6), Share Repurchase (printed value $0.7, sky blue about #66B8F5). Value labels are white bold text centred near the top of each bar, except the last two which sit lower inside the bars. No legend. No highlighted points. Above the chart, a teal arrow with an open chevron head points right, indicating the capital allocation order of priority. The arrow and its label are the only non-bar graphics. The teal logo at bottom right is a stylised ring of four lobes in #00857C. No photographs.

**Design**

Background: Solid white #FFFFFF. Clean corporate style with a white background and a dark navy header band. Title is white Invention-Light sans-serif, regular weight, about 5.1 percent of slide height. Subtitle 3Q Spend is mint #6ECEB2 Invention-Light, about 3.3 percent. The arrow label is mint #6ECEB2 Invention-Bold, about 3.3 percent. Callout text is about 3.3 percent in Invention-Regular navy #0C2340 with bold emphasis words in teal #00857C Invention-Bold. Bar value labels are white Invention-Bold about 2.2 percent. Category labels are navy #0C2340 Invention-Regular about 2.0 percent. Footnotes are navy Invention-Regular about 1.7 percent. Page number is light grey #9EA7B3 about 1.3 percent. Bars are flat with no shadows, gradients or rounded corners. The callout box is flat #F7F7F7 with square corners and no border. Accent colours are teal #00857C, mint #6ECEB2, navy #0C2340, periwinkle and sky blue.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100: Full-slide background rectangle filled white (fill #FFFFFF, no border)
- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Header band rectangle filled navy (full width, flat, no border)
- shape at x 68.4, y 41.2, w 28.5, h 30.6 [#F7F7F7]: Callout box rectangle filled light grey (square corners, no border, no shadow)
- shape at x 8.5, y 41.7, w 6.5, h 31.3 [#00857C]: Bar: After-Tax R&D (flat, square corners)
- shape at x 20.3, y 64.9, w 6.5, h 8.1 [#6ECEB2]: Bar: CapEx (flat, square corners)
- shape at x 32.2, y 56.7, w 6.5, h 16.4 [#0C2340]: Bar: Dividends Paid (flat, square corners)
- shape at x 44.1, y 67.5, w 6.5, h 5.5 [#6B8FE6]: Bar: Business Development (ex-divestitures) (estimated box, flat, square corners)
- shape at x 55.9, y 67.9, w 6.5, h 5 [#66B8F5]: Bar: Share Repurchase (estimated box, flat, square corners)
- line at x 5.8, y 72.8, w 59.3, h 0.8 [#0C2340]: Chart baseline with five tick marks at category boundaries (stroke navy #0C2340 about 0.2 percent of height, ticks extend downward about 0.5 percent at x 5.8, 17.7, 29.5, 41.4, 53.2, 65.1)
- line at x 3.5, y 29.2, w 61.8, h 4.8 [#6ECEB2]: Arrow line with open chevron arrowhead pointing right indicating capital allocation order of priority (stroke mint #6ECEB2 about 0.3 percent of height, open chevron head at right end, no fill)
- title at x 3.1, y 4.9, w 72.5, h 5.1 [Invention-Light, regular weight, sans-serif; font size 5.09% of slide height; #FFFFFF; left aligned]: Remain committed to balanced capital allocation strategy
- subtitle at x 3.1, y 10.2, w 19.9, h 3.3 [Invention-Light, regular weight, sans-serif; font size 3.33% of slide height; #6ECEB2; left aligned]: 3Q Spend ($ in billions)1 (superscript 1 at x 22.1 y 10.1, font size 2.22, mint #6ECEB2)
- caption at x 19.5, y 32.7, w 29.5, h 3.3 [Invention-Bold, sans-serif; font size 3.33% of slide height; #6ECEB2; left aligned]: Capital allocation order of priority
- body at x 10.5, y 43.3, w 3, h 2.2 [Invention-Bold, sans-serif; font size 2.22% of slide height; #FFFFFF; center aligned]: $4.0 (value label inside top of After-Tax R&D bar)
- body at x 22.5, y 66.5, w 2.8, h 2.2 [Invention-Bold, sans-serif; font size 2.22% of slide height; #FFFFFF; center aligned]: $1.0 (value label inside CapEx bar)
- body at x 34.4, y 58.2, w 2.7, h 2.2 [Invention-Bold, sans-serif; font size 2.22% of slide height; #FFFFFF; center aligned]: $2.1 (value label inside Dividends Paid bar)
- body at x 46.1, y 69, w 2.9, h 2.2 [Invention-Bold, sans-serif; font size 2.22% of slide height; #FFFFFF; center aligned]: $0.7 (value label inside Business Development bar)
- body at x 58, y 69.5, w 2.9, h 2.2 [Invention-Bold, sans-serif; font size 2.22% of slide height; #FFFFFF; center aligned]: $0.7 (value label inside Share Repurchase bar)
- body at x 7.5, y 75.2, w 8.4, h 2 [Invention-Regular, sans-serif; font size 2.04% of slide height; #0C2340; center aligned]: After-Tax R&D2 (superscript 2 after R&D)
- body at x 22, y 75.2, w 3.3, h 2 [Invention-Regular, sans-serif; font size 2.04% of slide height; #0C2340; center aligned]: CapEx
- body at x 32.9, y 75.2, w 5.1, h 4.8 [Invention-Regular, sans-serif; font size 2.04% of slide height; #0C2340; center aligned]: Dividends / Paid
- body at x 43, y 75.2, w 8.7, h 7.6 [Invention-Regular, sans-serif; font size 2.04% of slide height; #0C2340; center aligned]: Business / Development 3 / (ex-divestitures) (superscript 3 after Development at x 51.0 y 77.4, font size 1.11)
- body at x 54.3, y 75.2, w 9.4, h 2 [Invention-Regular, sans-serif; font size 2.04% of slide height; #0C2340; center aligned]: Share Repurchase
- body at x 69.9, y 45.9, w 25.1, h 13.4 [Invention-Regular with Invention-Bold emphasis, sans-serif; font size 3.33% of slide height; #0C2340; left aligned]: Augmented our pipeline with / value-enhancing / business development / while investing / in our pipeline and business / as well as returning / cash to shareholders (emphasis words business development pipeline business cash to shareholders in bold teal #00857C; line spacing about 3.6 percent of height)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Teal stylised ring logo of four rounded lobes (image 125 by 150 pixels, flat, no shadow)
- footer at x 3.1, y 97.3, w 83.5, h 1.7 [Invention-Regular, sans-serif; font size 1.67% of slide height; #0C2340; left aligned]: 1. Reflects quarter spend subject to finalization of the Company’s statement of cash flows 2. Reflects R&D excluding Business Development 3. Includes BD payments reflected in operating cash flow
- page number at x 96.2, y 95.5, w 0.7, h 1.3 [Invention-Regular, sans-serif; font size 1.29% of slide height; #9EA7B3; right aligned]: 17

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- fill at x 68.4, y 41.2, w 28.5, h 30.6: #F7F7F7
- fill at x 8.5, y 41.7, w 6.5, h 31.3: #00857C
- fill at x 20.3, y 64.9, w 6.5, h 8.1: #6ECEB2
- fill at x 32.2, y 56.7, w 6.5, h 16.4: #0C2340
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 4.9, w 72.5, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Remain committed to balanced capital allocation strategy
- text at x 3.1, y 10.2, w 19.0, h 3.3 [Invention-Light; font size 3.33; #6ECEB2]: 3Q Spend ($ in billions)
- text at x 22.1, y 10.1, w 0.5, h 2.2 [Invention-Light; font size 2.22; #6ECEB2]: 1
- text at x 19.5, y 32.7, w 29.5, h 3.3 [Invention-Bold; font size 3.33; #6ECEB2]: Capital allocation order of priority
- text at x 69.9, y 45.9, w 25.1, h 6.9 [Invention-Regular; font size 3.33; #0C2340]: Augmented our pipeline with value-enhancing
- text at x 69.9, y 49.5, w 22.4, h 6.9 [Invention-Bold; font size 3.33; #00857C]: business development
- text at x 69.9, y 53.1, w 24.9, h 6.9 [Invention-Regular; font size 3.33; #0C2340]: while investing in our
- text at x 75.2, y 56.7, w 6.9, h 3.3 [Invention-Bold; font size 3.33; #00857C]: pipeline
- text at x 82.1, y 56.7, w 3.9, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: and
- text at x 86.1, y 56.7, w 7.6, h 3.3 [Invention-Bold; font size 3.33; #00857C]: business
- text at x 69.9, y 56.7, w 24.1, h 6.9 [Invention-Regular; font size 3.33; #0C2340]: as well as returning
- text at x 69.9, y 60.3, w 23.4, h 6.9 [Invention-Bold; font size 3.33; #00857C]: cash to shareholders
- text at x 10.5, y 43.3, w 3.0, h 2.2 [Invention-Bold; font size 2.22; #FFFFFF]: $4.0
- text at x 34.4, y 58.2, w 2.7, h 2.2 [Invention-Bold; font size 2.22; #FFFFFF]: $2.1
- text at x 22.5, y 66.5, w 2.8, h 2.2 [Invention-Bold; font size 2.22; #FFFFFF]: $1.0
- text at x 46.1, y 69.0, w 2.9, h 2.2 [Invention-Bold; font size 2.22; #FFFFFF]: $0.7
- text at x 58.0, y 69.5, w 2.9, h 2.2 [Invention-Bold; font size 2.22; #FFFFFF]: $0.7
- text at x 7.5, y 75.2, w 8.4, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: After-Tax R&D²
- text at x 22.0, y 75.2, w 3.3, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: CapEx
- text at x 54.3, y 75.2, w 9.4, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: Share Repurchase
- text at x 32.9, y 75.2, w 5.1, h 4.8 [Invention-Regular; font size 2.04; #0C2340]: DividendsPaid
- text at x 43.0, y 75.2, w 8.7, h 7.6 [Invention-Regular; font size 2.04; #0C2340]: BusinessDevelopment(ex-divestitures)
- text at x 3.1, y 97.3, w 83.5, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 1. Reflects quarter spend subject to finalization of the Company’s statement of cash flows 2. Reflects R&D excluding Business Development 3. Includes BD payments reflected in operating cash flow
- text at x 51.0, y 77.4, w 0.4, h 1.1 [Invention-Regular; font size 1.11; #000000]: 3
- text at x 96.2, y 95.5, w 0.7, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 17

### Slide 18

**Text**

Research Update
Dr. Dean Y. Li
Executive Vice President and President,
Research Laboratories
18

**Layout**

Two-column split layout: the left half is a white text column with the title and subtitle block vertically centred around the middle of the slide, left-aligned at about 3.1% margin. The right half is a full-height photograph boxed at the top right, ending at about 93% of slide height. A small logo and the slide number sit in the bottom-right footer strip on white.

**Visuals**

Photograph of a bald man with black rectangular glasses, smiling broadly showing teeth, wearing a grey checked suit, white collared shirt and a yellow tie with blue small-square pattern, head and shoulders framed as a head-and-shoulders portrait, slightly turned toward the camera. Set against a plain mid-grey studio backdrop, soft even studio lighting from the front. Dominant colours: mid-grey background, grey suit, white shirt, yellow-and-blue tie. The photo is rectangular, not cropped to a shape, not full-bleed (it stops above the footer strip). Small teal logo icon at bottom right: a four-lobed teal/green mark of rounded shapes, approximately #13857A.

**Design**

Background: Solid white #FFFFFF. White background. Title in Invention-Light style sans-serif, regular weight, navy #0C2340, large size around 8.2% of slide height for the title line. Subtitle lines in the same Invention-Light sans-serif at about 3% of slide height, navy #0C2340, line spacing about 3.5% of slide height. Slide number in Invention-Regular sans-serif about 1.3% of slide height, grey #9EA7B3. Photo is a plain rectangle with no border, shadow or rounding. A light grey #D9D9D9 fill sits behind the right half.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: White background fill covering the full slide (Full-slide base fill, no outline.)
- shape at x 50, y 0, w 50, h 93.1 [#D9D9D9]: Light grey panel behind the right half of the slide (Rectangle sitting behind the photograph, no outline, no shadow.)
- photo at x 50, y 0, w 50, h 93.1 [#808080]: Head-and-shoulders portrait of a smiling bald man with black rectangular glasses, grey checked suit, white shirt and yellow patterned tie against a grey studio backdrop (Rectangular photo, not cropped to a shape, not full-bleed on the bottom edge; overlaps the grey panel. Source image 459 by 480 pixels.)
- title at x 3.1, y 41, w 35, h 8.2 [Invention-Light, sans-serif, regular weight; font size 8.16% of slide height; #0C2340; left aligned]: Research Update
- subtitle at x 3.1, y 51.1, w 29.7, h 10.5 [Invention-Light, sans-serif, regular weight; font size 2.96% of slide height; #0C2340; left aligned]: Dr. Dean Y. Li / Executive Vice President and President, / Research Laboratories (Three lines, line spacing about 3.5% of slide height; first line box x 3.1 y 51.1 w 10.1 h 3.0, second line x 3.1 y 54.6 w 29.7 h 3.0, third line x 3.1 y 58.2 w 16.6 h 3.0.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#13857A]: Teal four-lobed corner logo mark (Small logo image at bottom right, 125 by 150 pixels, sitting on white footer strip below the photo.)
- page number at x 96.2, y 95.5, w 0.7, h 1.3 [Invention-Regular, sans-serif, regular weight; font size 1.29% of slide height; #9EA7B3; right aligned]: 18

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 50.0, y 0.0, w 50.0, h 93.1: #D9D9D9
- image at x 50.0, y 0.0, w 50.0, h 93.1: 459 by 480 pixels
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 41.0, w 35.0, h 8.2 [Invention-Light; font size 8.16; #0C2340]: Research Update
- text at x 3.1, y 51.1, w 10.1, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Dr. Dean Y. Li
- text at x 3.1, y 54.6, w 29.7, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Executive Vice President and President,
- text at x 3.1, y 58.2, w 16.6, h 3.0 [Invention-Light; font size 2.96; #0C2340]: Research Laboratories
- text at x 96.2, y 95.5, w 0.7, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 18

### Slide 19

**Text**

Meaningful progress across innovative oncology pipeline and portfolio / ESMO data highlights / Recent regulatory milestones / • TroFuse-005: sac-TMT the first and only TROP2 ADC to improve OS and PFS in certain patients with advanced endometrial cancer1 versus chemotherapy2 / − Reduced risk of death by 32%, extending median OS by 6.9 months (19.0 vs. 12.1) / − Reduced risk of disease progression or death by 41% / • OptiTROP-Lung063: Positive findings from Phase 3 study conducted in China evaluating sac-TMT plus KEYTRUDA versus KEYTRUDA plus chemotherapy as 1L treatment for patients with PD-L1-negative locally advanced or metastatic non-squamous NSCLC / • INTerpath-001: intismeran autogene4 plus KEYTRUDA improved RFS and DMFS over standard-of-care KEYTRUDA in patients with completely resected stage IIB-IV melanoma / • Subcutaneous pembrolizumab and berahyaluronidase alfa approved by regulatory authorities in Japan and China / • EC approved KEYTRUDA plus Padcev as perioperative treatment in adults with resectable muscle-invasive bladder cancer / • FDA approved WELIREG plus LENVIMA for treatment of patients with advanced ccRCC following treatment with a PD-1/PD-L1 inhibitor / 1. Advanced or recurrent endometrial cancer who have received prior platinum-based chemotherapy and anti-PD-1/L1 immunotherapy 2. Chemotherapy = treatment of physician’s choice (doxorubicin or paclitaxel) 3. Conducted by Kelun Biotech 4. In collaboration / 19

**Layout**

Two-column layout below a full-width navy title band: a wider left column (ESMO data highlights, x 3.1 to about 53%) and a narrower right column (Recent regulatory milestones, x 59.3 to 96.9%), separated by a faint dotted vertical divider at about x 56%. The title sits left-aligned in the band at y 6.7%, with a 3.1% left margin. Column headings sit at y 24.7% under teal rules at y 22.2%. The footnote runs along the bottom at y 94.4%, the logo sits bottom right at x 91.8%, and the page number sits at the far bottom right at x 96.2%.

**Visuals**

Non-text visuals: a teal four-lobed logo mark at bottom right (125 by 150 px image, x 91.8%, y 92.8%, w 3.1%, h 6.6%); a solid teal horizontal rule above the left column and a lighter mint horizontal rule above the right column; a faint grey dotted vertical divider between the columns; and small navy bullet markers and dash markers in the lists. No photographs, charts, tables or diagrams.

**Design**

Background: Solid white #FFFFFF, with a full-width navy #0C2340 band across the top 18.4% of the slide. Clean corporate look. Title is white Invention Light sans-serif, about 5.1% of slide height, on a navy band. Column headings are Invention Bold about 3.3% of height, teal #00857C on the left and mint #6ECEB2 on the right. Body text is Invention Regular about 3.0% of height in navy #0C2340, with key terms and figures in Invention Bold teal #00857C (left) or mint #6ECEB2 (right). Footnotes are Invention Regular about 1.7% in navy. Lines are flat with no shadows, gradients or rounded corners; the divider is a dotted light grey line.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Navy title band across the top of the slide (Flat rectangle, no shadow or border, runs full width behind the title.)
- title at x 3.1, y 6.7, w 87.7, h 5.1 [Invention Light, regular weight, sentence case; font size 5.09% of slide height; #FFFFFF; left aligned]: Meaningful progress across innovative oncology pipeline and portfolio
- line at x 3.1, y 22.2, w 49.8, h 0.4 [#00857C]: Teal rule above left column (Solid horizontal bar, about 0.4% of height thick.)
- line at x 59.3, y 22.2, w 37.6, h 0.4 [#6ECEB2]: Mint rule above right column (Solid horizontal bar, about 0.4% of height thick.)
- line at x 56, y 22.4, w 0.2, h 67.8 [#C8CDD3]: Dotted vertical divider between columns (Dotted light grey line with small evenly spaced dots, running from below the rules to about y 90%.)
- subtitle at x 3.1, y 24.7, w 18.5, h 3.3 [Invention Bold, sans-serif, sentence case; font size 3.33% of slide height; #00857C; left aligned]: ESMO data highlights
- subtitle at x 59.3, y 24.6, w 25.1, h 3.3 [Invention Bold, sans-serif, sentence case; font size 3.33% of slide height; #6ECEB2; left aligned]: Recent regulatory milestones
- bullet list at x 3.1, y 30.2, w 50, h 63 [Invention Regular, sans-serif, sentence case; key terms in Invention Bold; font size 2.96% of slide height; #0C2340; left aligned]: • TroFuse-005: sac-TMT the first and only TROP2 ADC to improve OS and PFS in certain patients with advanced endometrial cancer1 versus chemotherapy2 / − Reduced risk of death by 32%, extending median OS by 6.9 months (19.0 vs. 12.1) / − Reduced risk of disease progression or death by 41% / • OptiTROP-Lung063: Positive findings from Phase 3 study conducted in China evaluating sac-TMT plus KEYTRUDA versus KEYTRUDA plus chemotherapy as 1L treatment for patients with PD-L1-negative locally advanced or metastatic non-squamous NSCLC / • INTerpath-001: intismeran autogene4 plus KEYTRUDA improved RFS and DMFS over standard-of-care KEYTRUDA in patients with completely resected stage IIB-IV melanoma (Navy round-bullet markers at the first level and navy en-dash markers at the sub-level, indented. Teal #00857C bold for trial names, drug names, OS, PFS, 32%, 41%, RFS, DMFS, sac-TMT, KEYTRUDA, Phase 3 study, intismeran autogene and INTerpath-001. Superscripts 1, 2, 3, 4 at about 1.98% of height in navy or teal. Line spacing about 1.1, with space between bullet groups.)
- bullet list at x 59.3, y 30.2, w 37.6, h 26 [Invention Regular, sans-serif, sentence case; key terms in Invention Bold; font size 2.96% of slide height; #0C2340; left aligned]: • Subcutaneous pembrolizumab and berahyaluronidase alfa approved by regulatory authorities in Japan and China / • EC approved KEYTRUDA plus Padcev as perioperative treatment in adults with resectable muscle-invasive bladder cancer / • FDA approved WELIREG plus LENVIMA for treatment of patients with advanced ccRCC following treatment with a PD-1/PD-L1 inhibitor (Navy round bullet markers, hanging indent. Mint #6ECEB2 bold for Subcutaneous pembrolizumab and berahyaluronidase alfa, Japan, China, KEYTRUDA, Padcev, WELIREG, LENVIMA. Line spacing about 1.1, with space between bullets.)
- caption at x 3.1, y 94.4, w 85.6, h 3.4 [Invention Regular, sans-serif, sentence case; font size 1.67% of slide height; #0C2340; left aligned]: 1. Advanced or recurrent endometrial cancer who have received prior platinum-based chemotherapy and anti-PD-1/L1 immunotherapy 2. Chemotherapy = treatment of physician’s choice (doxorubicin or paclitaxel) 3. Conducted by Kelun Biotech 4. In collaboration (Two lines of footnote text, the second line starting with paclitaxel.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Teal four-lobed logo mark (company symbol) (Image of 125 by 150 px, bottom right, four rounded lobes arranged around a white centre, no text.)
- page number at x 96.2, y 95.5, w 0.7, h 1.3 [Invention Regular, sans-serif; font size 1.29% of slide height; #9EA7B3; right aligned]: 19

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 6.7, w 87.7, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Meaningful progress across innovative oncology pipeline and portfolio
- text at x 3.1, y 24.7, w 18.5, h 3.3 [Invention-Bold; font size 3.33; #00857C]: ESMO data highlights
- text at x 59.3, y 24.6, w 25.1, h 3.3 [Invention-Bold; font size 3.33; #6ECEB2]: Recent regulatory milestones
- text at x 3.1, y 30.2, w 0.6, h 3.0 [ArialMT; font size 2.96; #0C2340]: •
- text at x 5.4, y 30.2, w 10.1, h 3.0 [Invention-Bold; font size 2.96; #00857C]: TroFuse-005
- text at x 15.5, y 30.2, w 10.8, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: : sac-TMT the
- text at x 26.3, y 30.2, w 10.5, h 3.0 [Invention-Bold; font size 2.96; #00857C]: first and only
- text at x 59.3, y 31.0, w 0.6, h 3.0 [ArialMT; font size 2.96; #0C2340]: •
- text at x 61.7, y 31.0, w 27.1, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: Subcutaneous pembrolizumab and
- text at x 5.4, y 30.2, w 43.0, h 6.2 [Invention-Regular; font size 2.96; #0C2340]: TROP2 ADC to improve
- text at x 12.0, y 33.4, w 2.3, h 3.0 [Invention-Bold; font size 2.96; #00857C]: OS
- text at x 14.3, y 33.4, w 3.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: and
- text at x 17.8, y 33.4, w 3.1, h 3.0 [Invention-Bold; font size 2.96; #00857C]: PFS
- text at x 61.7, y 34.6, w 17.9, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: berahyaluronidase alfa
- text at x 79.6, y 34.6, w 9.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: approved by
- text at x 5.4, y 33.4, w 41.1, h 6.2 [Invention-Regular; font size 2.96; #0C2340]: in certain patients with advanced endometrial cancer
- text at x 20.3, y 36.6, w 16.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: versus chemotherapy
- text at x 61.7, y 38.1, w 18.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: regulatory authorities in
- text at x 80.3, y 38.1, w 4.7, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: Japan
- text at x 85.3, y 38.1, w 3.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: and
- text at x 88.5, y 38.1, w 4.4, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: China
- text at x 6.8, y 40.9, w 21.3, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: − Reduced risk of death by
- text at x 28.1, y 40.9, w 3.3, h 3.0 [Invention-Bold; font size 2.96; #00857C]: 32%
- text at x 9.2, y 40.9, w 41.8, h 6.2 [Invention-Regular; font size 2.96; #0C2340]: , extending median OS by 6.9 months (19.0 vs. 12.1)
- text at x 59.3, y 43.6, w 0.6, h 3.0 [ArialMT; font size 2.96; #0C2340]: •
- text at x 61.7, y 43.6, w 9.9, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: EC approved
- text at x 71.6, y 43.6, w 9.4, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: KEYTRUDA
- text at x 81.0, y 43.6, w 3.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: plus
- text at x 84.4, y 43.6, w 5.9, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: Padcev
- text at x 90.4, y 43.6, w 2.0, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: as
- text at x 61.7, y 46.8, w 29.2, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: perioperative treatment in adults with
- text at x 6.8, y 48.4, w 38.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: − Reduced risk of disease progression or death by
- text at x 45.3, y 48.4, w 3.2, h 3.0 [Invention-Bold; font size 2.96; #00857C]: 41%
- text at x 61.7, y 50.0, w 31.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: resectable muscle-invasive bladder cancer
- text at x 3.1, y 53.9, w 0.6, h 3.0 [ArialMT; font size 2.96; #0C2340]: •
- text at x 5.4, y 53.9, w 14.6, h 3.0 [Invention-Bold; font size 2.96; #00857C]: OptiTROP-Lung06
- text at x 20.7, y 53.9, w 17.9, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: : Positive findings from
- text at x 38.6, y 53.9, w 11.1, h 3.0 [Invention-Bold; font size 2.96; #00857C]: Phase 3 study
- text at x 19.9, y 36.5, w 0.4, h 2.0 [Invention-Regular; font size 1.98; #0C2340]: 1
- text at x 37.0, y 36.5, w 0.6, h 2.0 [Invention-Regular; font size 1.98; #0C2340]: 2
- text at x 59.3, y 55.4, w 0.6, h 3.0 [ArialMT; font size 2.96; #0C2340]: •
- text at x 61.7, y 55.4, w 11.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: FDA approved
- text at x 72.8, y 55.4, w 8.0, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: WELIREG
- text at x 80.8, y 55.4, w 3.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: plus
- text at x 84.3, y 55.4, w 7.9, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: LENVIMA
- text at x 92.2, y 55.4, w 2.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: for
- text at x 5.4, y 57.1, w 22.9, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: conducted in China evaluating
- text at x 28.3, y 57.1, w 6.7, h 3.0 [Invention-Bold; font size 2.96; #00857C]: sac-TMT
- text at x 35.0, y 57.1, w 3.8, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: plus
- text at x 38.8, y 57.1, w 9.4, h 3.0 [Invention-Bold; font size 2.96; #00857C]: KEYTRUDA
- text at x 61.7, y 58.6, w 32.9, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: treatment of patients with advanced ccRCC
- text at x 61.7, y 61.8, w 29.8, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: following treatment with a PD-1/PD-L1
- text at x 5.4, y 60.3, w 45.6, h 9.4 [Invention-Regular; font size 2.96; #0C2340]: versus KEYTRUDA plus chemotherapy as 1L treatment for patients with PD-L1-negative locally advanced or metastatic non-squamous NSCLC
- text at x 61.7, y 65.0, w 6.4, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: inhibitor
- text at x 3.1, y 72.4, w 0.6, h 3.0 [ArialMT; font size 2.96; #0C2340]: •
- text at x 5.4, y 72.4, w 11.5, h 3.0 [Invention-Bold; font size 2.96; #00857C]: INTerpath-001
- text at x 16.9, y 72.4, w 0.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: :
- text at x 17.4, y 72.4, w 16.5, h 3.0 [Invention-Bold; font size 2.96; #00857C]: intismeran autogene
- text at x 34.9, y 72.4, w 3.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: plus
- text at x 38.0, y 72.4, w 9.8, h 3.0 [Invention-Bold; font size 2.96; #00857C]: KEYTRUDA
- text at x 5.4, y 76.0, w 7.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: improved
- text at x 13.0, y 76.0, w 3.2, h 3.0 [Invention-Bold; font size 2.96; #00857C]: RFS
- text at x 16.1, y 76.0, w 3.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: and
- text at x 19.7, y 76.0, w 4.7, h 3.0 [Invention-Bold; font size 2.96; #00857C]: DMFS
- text at x 5.4, y 76.0, w 47.3, h 6.5 [Invention-Regular; font size 2.96; #0C2340]: over standard-of-care KEYTRUDA in patients with completely resected stage IIB-IV melanoma
- text at x 20.0, y 53.8, w 0.6, h 2.0 [Invention-Regular; font size 1.98; #00857C]: 3
- text at x 33.9, y 72.3, w 0.7, h 2.0 [Invention-Regular; font size 1.98; #00857C]: 4
- text at x 3.1, y 94.4, w 85.6, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 1. Advanced or recurrent endometrial cancer who have received prior platinum-based chemotherapy and anti-PD-1/L1 immunotherapy 2. Chemotherapy = treatment of physician’s choice (doxorubicin or
- text at x 3.1, y 96.2, w 25.8, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: paclitaxel) 3. Conducted by Kelun Biotech 4. In collaboration
- text at x 96.2, y 95.5, w 0.7, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 19

### Slide 20

**Text**

Expanding impact of WINREVAIR in pulmonary hypertension
WINREVAIR
Pulmonary hypertension development program
WHO Group 1
PAH
WHO Group 2
CpCPH-HFpEF
• FDA approved update to U.S. label incorporating positive results from Phase 3 HYPERION study in adults on background therapy newly diagnosed1 with PAH at intermediate or high risk of disease progression
• Plan to initiate Phase 3 CHORUS study in patients with combined post- and pre-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction shortly
Phase 2
CADENCE
Phase 3
CHORUS
1. Diagnosed within 12 months
20

**Layout**

Full-width navy title band across the top with the title left-aligned at about 3% margin. Below it, two columns: left column WINREVAIR with bullet list, right column development program with two WHO group header boxes and a stacked column of trial logos (Stellar, Zenith, Hyperion) beneath the WHO Group 1 box, and phase labels beneath the WHO Group 2 box; a dotted vertical divider sits between columns. Footnote bottom-left, small teal logo and page number bottom-right.

**Visuals**

Three starburst-style trial logos stacked in the right column under WHO Group 1: STELLAR (dark slate-blue wordmark with green radiating lines, top), ZENITH (dark slate-blue wordmark with green radiating lines, middle), HYPERION (dark slate-blue wordmark with light green radiating lines, bottom); each logo is a wordmark with a sunburst of thin green lines extending to the right of the word. A small teal four-lobed corporate logo mark sits bottom-right near the page number. No charts, photographs or other illustrations. Two navy rectangular header boxes with white text: WHO Group 1 / PAH and WHO Group 2 / CpCPH-HFpEF. A thin light grey dotted vertical line divides the columns.

**Design**

Background: Solid white #FFFFFF. White background with a full-width dark navy header band (#0C2340) across the top 18.4% of the slide. Title in white light-weight sans-serif (Invention Light style), about 5.1% of slide height. Column headings bold sans-serif: WINREVAIR in teal #00857C, right heading in light mint #6ECEB2, about 3.3% of slide height. Body text regular sans-serif in navy #0C2340 at about 3.3% of slide height; key phrases bold in teal #00857C. Thin rule above each column heading: teal #00857C on left, light mint #6ECEB2 on right, about 0.4% of height thick. WHO boxes are solid navy rectangles with square corners, no shadows, white bold text. Phase labels bold teal #00857C. Footnote 1.7% of height in navy. Page number light grey #9EA7B3 at about 1.3% of height. Bullets are navy round dots.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: White full-slide background fill (Covers the entire slide, no border)
- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Navy title band (Rectangle, square corners, no shadow, full width)
- title at x 3.1, y 6.7, w 77, h 5.1 [Invention Light, sans-serif, regular weight, no italics, no capitals; font size 5.09% of slide height; #FFFFFF; left aligned]: Expanding impact of WINREVAIR in pulmonary hypertension
- line at x 3.1, y 22, w 44.9, h 0.4 [#00857C]: Teal rule above WINREVAIR column heading (Solid horizontal bar, square ends)
- line at x 52, y 22, w 45, h 0.4 [#6ECEB2]: Light mint rule above right column heading (Solid horizontal bar, square ends)
- line at x 50, y 22.2, w 0.2, h 65.6 [#C8CDD3]: Dotted vertical divider between columns (Dotted line, light grey, stroke about 0.1% width)
- subtitle at x 3.1, y 24.6, w 10.7, h 3.3 [Invention Bold, sans-serif, bold weight, no italics, no capitals; font size 3.33% of slide height; #00857C; left aligned]: WINREVAIR
- subtitle at x 52, y 24.5, w 40.8, h 3.3 [Invention Bold, sans-serif, bold weight, no italics, no capitals; font size 3.33% of slide height; #6ECEB2; left aligned]: Pulmonary hypertension development program
- shape at x 54.6, y 30.5, w 17.2, h 12 [#0C2340]: WHO Group 1 header box (Solid navy rectangle, square corners, no shadow)
- text at x 58, y 33.5, w 10.5, h 3 [Invention Bold, sans-serif, bold weight, no italics, no capitals; font size 2.96% of slide height; #FFFFFF; center aligned]: WHO Group 1 / PAH (PAH line is Invention Regular at 2.22 percent, white, centered beneath WHO Group 1)
- shape at x 77, y 30.5, w 17.2, h 12 [#0C2340]: WHO Group 2 header box (Solid navy rectangle, square corners, no shadow)
- text at x 80.2, y 33.5, w 10.7, h 3 [Invention Bold, sans-serif, bold weight, no italics, no capitals; font size 2.96% of slide height; #FFFFFF; center aligned]: WHO Group 2 / CpCPH-HFpEF (CpCPH-HFpEF line is Invention Regular at 2.22 percent, white, centered beneath WHO Group 2)
- logo at x 58.9, y 46.5, w 8.7, h 11.3 [#0C2340]: STELLAR trial logo (Placed image 228 by 167 pixels, wordmark dark slate blue with green sunburst lines to the right, no box)
- text at x 81.2, y 49.3, w 8.8, h 7.3 [Invention Bold, sans-serif, bold weight, no italics, no capitals; font size 3.33% of slide height; #00857C; center aligned]: Phase 2 / CADENCE (Two lines, centered in WHO Group 2 column)
- logo at x 59.2, y 60.7, w 8.1, h 11.6 [#0C2340]: ZENITH trial logo (Placed image 197 by 159 pixels, wordmark dark slate blue with green sunburst lines to the right, no box)
- text at x 81.2, y 63.7, w 8.7, h 7.7 [Invention Bold, sans-serif, bold weight, no italics, no capitals; font size 3.71% of slide height; #00857C; center aligned]: Phase 3 / CHORUS (Two lines, centered in WHO Group 2 column)
- logo at x 58.2, y 76, w 9.9, h 10.7 [#0C2340]: HYPERION trial logo (Placed image 261 by 158 pixels, wordmark dark slate blue with light green sunburst lines to the right, no box)
- text at x 3.1, y 30.9, w 45, h 21 [Invention Regular, sans-serif, regular weight, bold teal runs for key phrases, no capitals; font size 3.33% of slide height; #0C2340; left aligned]: FDA approved update to U.S. label incorporating / positive results from Phase 3 HYPERION study in / adults on background therapy newly diagnosed1 / with PAH at intermediate or high risk of disease / progression (Bullet list with navy round bullet at x 3.1; key phrases FDA approved, Phase 3 HYPERION and newly diagnosed in bold teal #00857C; 1 is a superscript in teal; line spacing about 1.2)
- text at x 3.1, y 51.2, w 40, h 14.1 [Invention Regular, sans-serif, regular weight, bold teal runs for key phrases, no capitals; font size 3.33% of slide height; #0C2340; left aligned]: Plan to initiate Phase 3 CHORUS study in / patients with combined post- and pre-capillary / pulmonary hypertension associated with heart / failure with preserved ejection fraction shortly (Second bullet with navy round bullet at x 3.1; initiate Phase 3 CHORUS study in bold teal #00857C; line spacing about 1.2)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Small teal corporate logo mark (Placed image 125 by 150 pixels, four-lobed teal emblem, bottom right)
- footer at x 3.1, y 97.3, w 12.8, h 1.7 [Invention Regular, sans-serif, regular weight, no italics, no capitals; font size 1.67% of slide height; #0C2340; left aligned]: 1. Diagnosed within 12 months (Footnote)
- page number at x 96, y 95.5, w 0.9, h 1.3 [Invention Regular, sans-serif, regular weight, no italics, no capitals; font size 1.29% of slide height; #9EA7B3; right aligned]: 20

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- fill at x 54.6, y 30.5, w 17.2, h 12.0: #0C2340
- fill at x 77.0, y 30.5, w 17.2, h 12.0: #0C2340
- image at x 58.2, y 76.0, w 9.9, h 10.7: 261 by 158 pixels
- image at x 58.9, y 46.5, w 8.7, h 11.3: 228 by 167 pixels
- image at x 59.2, y 60.7, w 8.1, h 11.6: 197 by 159 pixels
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 6.7, w 77.0, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Expanding impact of WINREVAIR in pulmonary hypertension
- text at x 3.1, y 24.6, w 10.7, h 3.3 [Invention-Bold; font size 3.33; #00857C]: WINREVAIR
- text at x 52.0, y 24.5, w 40.8, h 3.3 [Invention-Bold; font size 3.33; #6ECEB2]: Pulmonary hypertension development program
- text at x 3.1, y 30.9, w 0.7, h 3.3 [ArialMT; font size 3.33; #0C2340]: •
- text at x 5.5, y 30.9, w 12.8, h 3.3 [Invention-Bold; font size 3.33; #00857C]: FDA approved
- text at x 5.5, y 30.9, w 41.8, h 6.9 [Invention-Regular; font size 3.33; #0C2340]: update to U.S. label incorporating positive results from
- text at x 23.4, y 34.5, w 17.3, h 3.3 [Invention-Bold; font size 3.33; #00857C]: Phase 3 HYPERION
- text at x 5.4, y 34.5, w 42.5, h 6.9 [Invention-Regular; font size 3.33; #0C2340]: study in adults on background therapy
- text at x 31.2, y 38.1, w 14.5, h 3.3 [Invention-Bold; font size 3.33; #00857C]: newly diagnosed
- text at x 58.0, y 33.5, w 10.5, h 3.0 [Invention-Bold; font size 2.96; #FFFFFF]: WHO Group 1
- text at x 80.2, y 33.5, w 10.7, h 3.0 [Invention-Bold; font size 2.96; #FFFFFF]: WHO Group 2
- text at x 5.5, y 38.1, w 41.1, h 10.5 [Invention-Regular; font size 3.33; #0C2340]: with PAH at intermediate or high risk of disease progression
- text at x 3.1, y 51.2, w 0.7, h 3.3 [ArialMT; font size 3.33; #0C2340]: •
- text at x 5.5, y 51.2, w 6.4, h 3.3 [Invention-Regular; font size 3.33; #0C2340]: Plan to
- text at x 11.8, y 51.2, w 27.5, h 3.3 [Invention-Bold; font size 3.33; #00857C]: initiate Phase 3 CHORUS study
- text at x 81.2, y 49.3, w 8.8, h 7.3 [Invention-Bold; font size 3.33; #00857C]: Phase 2 CADENCE
- text at x 5.4, y 51.2, w 40.0, h 14.1 [Invention-Regular; font size 3.33; #0C2340]: in patients with combined post- and pre-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction shortly
- text at x 45.7, y 38.0, w 0.5, h 2.2 [Invention-Regular; font size 2.22; #00857C]: 1
- text at x 61.9, y 37.4, w 2.6, h 2.2 [Invention-Regular; font size 2.22; #FFFFFF]: PAH
- text at x 81.2, y 37.4, w 8.7, h 2.2 [Invention-Regular; font size 2.22; #FFFFFF]: CpCPH-HFpEF
- text at x 81.8, y 63.7, w 7.5, h 3.7 [Invention-Bold; font size 3.71; #00857C]: Phase 3
- text at x 81.2, y 68.2, w 8.7, h 3.7 [Invention-Bold; font size 3.71; #00857C]: CHORUS
- text at x 3.1, y 97.3, w 12.8, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 1. Diagnosed within 12 months
- text at x 96.0, y 95.5, w 0.9, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 20

### Slide 21

**Text**

Progressing late-stage immunology and ophthalmology pipeline
Tulisokibart
Remigromig
• Presented promising Phase 2b results in adults with moderate to severe hidradenitis suppurativa, with safety profile comparable to placebo
− First positive Phase 2 data for anti-TL1A antibody in a dermatology indication
− Plan to advance to Phase 3 in HS
• Positive Phase 3 BRUNELLO presented at AAO
− Both doses (0.5mg and 0.8mg) of remigromig independently demonstrated non-inferiority to 0.5mg ranibizumab in mean change from baseline in BCVA at one year in adults with DME
• Potential first-in-class tetravalent tri-specific antibody designed to agonize Wnt pathway to maintain vascular integrity and reduce vascular leakage
• Anti-VEGF efficacy ceiling reached with up to 40% of patients with persistent DME after six months of treatment
21

**Layout**

Full-width navy header band across the top 18.4% of the slide holds a single left-aligned title vertically centred at about x 3.1%. Below it, two equal text columns sit side by side: left column from x 3.1% to about 49%, right column from x 52% to about 96.9%, separated by a dotted vertical divider at x about 49.9%. Each column has a coloured rule at y about 21.8% with its heading beneath it and bulleted body text below. Left margin is about 3.1%. The footer row holds a corner logo at bottom right (x 91.8%) and the slide number at x 98.7%, y 96.4%.

**Visuals**

Non-text elements: one small teal clover-shaped logo at bottom right, and a thin dotted light-grey vertical divider between the two columns. Also two horizontal rules, one teal above the left column and one mint above the right column. No photographs, charts, tables or diagrams.

**Design**

Background white. Title in white Invention Light (sans-serif, regular weight, about 5.1% of slide height) on navy #0C2340 header band. Column headings in Invention Bold (about 3.3% of slide height): Tulisokibart in teal #00857C, Remigromig in mint #6ECEB2. Body text in Invention Regular (about 3.0% of slide height) in navy #0C2340. Emphasis runs are Invention Bold in teal #00857C on the left and mint #6ECEB2 on the right. Bullets are solid round dots in navy (ArialMT) for level 1 and en dashes in navy for level 2. Rules are about 0.3% of slide height thick, square-ended. Divider is a dotted light grey line. No shadows, gradients or rounded corners.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide white background fill (Covers the entire slide, no border.)
- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Navy header band (Full-width rectangle, square corners, no shadow.)
- line at x 3.1, y 21.7, w 45.8, h 0.4 [#00857C]: Teal rule above left column (Horizontal solid line, about 0.3% of slide height thick.)
- line at x 52, y 21.7, w 44.9, h 0.4 [#6ECEB2]: Mint rule above right column (Horizontal solid line, about 0.3% of slide height thick.)
- line at x 49.8, y 22.3, w 0.2, h 65 [#C8CDD3]: Dotted vertical divider between columns (Dotted line, light grey, about 0.2% width.)
- title at x 3.1, y 6.7, w 80.8, h 5.1 [Invention Light, sans-serif, regular weight; font size 5.09% of slide height; #FFFFFF; left aligned]: Progressing late-stage immunology and ophthalmology pipeline
- subtitle at x 3.1, y 23.9, w 10.3, h 3.3 [Invention Bold, sans-serif, bold; font size 3.33% of slide height; #00857C; left aligned]: Tulisokibart
- subtitle at x 52, y 23.9, w 10.6, h 3.3 [Invention Bold, sans-serif, bold; font size 3.33% of slide height; #6ECEB2; left aligned]: Remigromig
- bullet list at x 3.1, y 30.2, w 46, h 19 [Invention Regular, sans-serif, regular weight; emphasis runs Invention Bold; font size 2.96% of slide height; #0C2340; left aligned]: • Presented promising Phase 2b results in adults with moderate to severe hidradenitis suppurativa, with safety profile comparable to placebo / − First positive Phase 2 data for anti-TL1A antibody / in a dermatology indication / − Plan to advance to Phase 3 in HS (Level 1 bullet is a navy solid dot; level 2 bullets are navy en dashes indented about 3.5%. Line spacing about 1.2. Bold teal runs: promising Phase 2b results, hidradenitis suppurativa, First positive Phase 2, Phase 3.)
- bullet list at x 52, y 30.2, w 46.5, h 35 [Invention Regular, sans-serif, regular weight; emphasis runs Invention Bold; font size 2.96% of slide height; #0C2340; left aligned]: • Positive Phase 3 BRUNELLO presented at AAO / − Both doses (0.5mg and 0.8mg) of remigromig independently demonstrated non-inferiority to 0.5mg ranibizumab in mean change from baseline in BCVA at one year in adults with DME / • Potential first-in-class tetravalent tri-specific antibody designed to agonize Wnt pathway to maintain vascular integrity and reduce vascular leakage / • Anti-VEGF efficacy ceiling reached with up to 40% of patients with persistent DME after six months of treatment (Level 1 bullet is a navy solid dot; level 2 bullet is a navy en dash. Bold mint runs: Positive, Both doses, non-inferiority, mean change from baseline in BCVA, agonize Wnt pathway, maintain vascular integrity, reduce vascular leakage, up to 40%, persistent DME. Line spacing about 1.2, paragraph gaps about 2% of slide height.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Corner logo: teal clover-shaped mark made of four rounded lobes (Bitmap image 125 by 150 pixels, placed bottom right, no frame.)
- page number at x 98.7, y 96.4, w 0.7, h 1.3 [Invention Regular, sans-serif, regular weight; font size 1.29% of slide height; #9EA7B3; right aligned]: 21

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 6.7, w 80.8, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Progressing late-stage immunology and ophthalmology pipeline
- text at x 3.1, y 23.9, w 10.3, h 3.3 [Invention-Bold; font size 3.33; #00857C]: Tulisokibart
- text at x 52.0, y 23.9, w 10.6, h 3.3 [Invention-Bold; font size 3.33; #6ECEB2]: Remigromig
- text at x 52.0, y 30.2, w 0.6, h 3.0 [ArialMT; font size 2.96; #0C2340]: •
- text at x 54.3, y 30.2, w 6.3, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: Positive
- text at x 60.6, y 30.2, w 29.4, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: Phase 3 BRUNELLO presented at AAO
- text at x 3.1, y 30.4, w 0.6, h 3.0 [ArialMT; font size 2.96; #0C2340]: •
- text at x 5.4, y 30.4, w 8.2, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: Presented
- text at x 13.6, y 30.4, w 21.3, h 3.0 [Invention-Bold; font size 2.96; #00857C]: promising Phase 2b results
- text at x 5.4, y 30.4, w 40.0, h 6.2 [Invention-Regular; font size 2.96; #0C2340]: in adults with moderate to severe
- text at x 20.5, y 33.6, w 19.0, h 3.0 [Invention-Bold; font size 2.96; #00857C]: hidradenitis suppurativa
- text at x 55.7, y 34.6, w 1.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: −
- text at x 58.1, y 34.6, w 9.0, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: Both doses
- text at x 5.4, y 33.6, w 38.7, h 6.2 [Invention-Regular; font size 2.96; #0C2340]: , with safety profile comparable to placebo
- text at x 58.1, y 34.6, w 35.1, h 6.2 [Invention-Regular; font size 2.96; #0C2340]: (0.5mg and 0.8mg) of remigromig independently demonstrated
- text at x 80.4, y 37.8, w 11.4, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: non-inferiority
- text at x 58.1, y 37.8, w 36.1, h 6.2 [Invention-Regular; font size 2.96; #0C2340]: to 0.5mg ranibizumab in
- text at x 6.8, y 41.1, w 1.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: −
- text at x 9.2, y 41.1, w 16.9, h 3.0 [Invention-Bold; font size 2.96; #00857C]: First positive Phase 2
- text at x 9.2, y 41.1, w 38.0, h 6.2 [Invention-Regular; font size 2.96; #0C2340]: data for anti-TL1A antibody in a dermatology indication
- text at x 58.1, y 41.0, w 38.2, h 6.2 [Invention-Bold; font size 2.96; #6ECEB2]: mean change from baseline in BCVA
- text at x 64.8, y 44.2, w 22.9, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: at one year in adults with DME
- text at x 6.8, y 48.6, w 16.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: − Plan to advance to
- text at x 23.4, y 48.6, w 6.0, h 3.0 [Invention-Bold; font size 2.96; #00857C]: Phase 3
- text at x 29.8, y 48.6, w 4.4, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: in HS
- text at x 52.0, y 49.6, w 0.6, h 3.0 [ArialMT; font size 2.96; #0C2340]: •
- text at x 54.3, y 49.6, w 41.6, h 6.2 [Invention-Regular; font size 2.96; #0C2340]: Potential first-in-class tetravalent tri-specific antibody designed to
- text at x 63.5, y 52.8, w 17.2, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: agonize Wnt pathway
- text at x 80.7, y 52.8, w 2.0, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: to
- text at x 54.3, y 52.8, w 42.3, h 6.2 [Invention-Bold; font size 2.96; #6ECEB2]: maintain vascular integrity
- text at x 61.5, y 56.0, w 3.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: and
- text at x 64.7, y 56.0, w 18.3, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: reduce vascular leakage
- text at x 52.0, y 61.4, w 0.6, h 3.0 [ArialMT; font size 2.96; #0C2340]: •
- text at x 54.3, y 61.4, w 30.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: Anti-VEGF efficacy ceiling reached with
- text at x 84.4, y 61.4, w 8.3, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: up to 40%
- text at x 54.3, y 61.4, w 40.3, h 6.2 [Invention-Regular; font size 2.96; #0C2340]: of patients with
- text at x 64.7, y 64.6, w 12.4, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: persistent DME
- text at x 54.3, y 64.6, w 37.4, h 6.2 [Invention-Regular; font size 2.96; #0C2340]: after six months of treatment
- text at x 98.7, y 96.4, w 0.7, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 21

### Slide 22

**Review notes**

- Review: Weaknesses are consequential: several pages are dense or small (slides 3, 14, 15, 22, 27, 28), slide 8's launch chart has an unexplained hatched box and no growth label, and pale mint bars with white labels on slides 10 to 13 are weaker in contrast.
- What would change the score: Cut or split the dense pipeline and milestone pages (slides 22 and 27) and give slide 16 and the text-light chart pages a visual anchor so whitespace reads as design rather than leftover room.

**Text**

Significant late-stage pipeline milestones expected over next twelve months
Immunology
Tulisokibart
PCD in August for Phase 3 ATLAS-UC trial
Phase 2 data in additional indications including RA, R-axSpA and PsA
Ophthalmology
Remigromig
PCD in March for Phase 2b/3 BAROLO trial in DME
Cardiometabolic & respiratory
WINREVAIR
Initiation of Phase 3 CHORUS study in CpcPH-HFpEF
Efinopegdutide
Presentation of results from Phase 2b trial in MASH at AASLD
Infectious Disease
Efitazanamivir alfa (MK-1406)
PCD in June for Phase 3 ANCHOR trial in prevention of influenza
Alimatravir
PCD in July for Phase 3 EXPrESSIVE-11 trial in HIV PrEP
Islatravir/lenacapavir1
Anticipated regulatory filings
IDVYNSO
PDUFA date April 22nd based on MK-8591A-053 (treatment naïve)
ENFLONSIA
Second season SMART PDUFA date March 22nd
Oncology
Sac-TMT
PDUFA date June 15th based on TroFuse-005
PCDs in January, May, and July for Phase 3 TroFuse program
Intismeran autogene1
Anticipated regulatory filings
1. In collaboration
22

**Layout**

Full-width navy header band across the top carrying a single-line-plus-wrap white title, with the content in two columns below: left column holds Immunology, Ophthalmology and Cardiometabolic & respiratory sections, right column holds Infectious Disease and Oncology sections, each section headed by a coloured vertical accent bar. Text is left-aligned with a left margin of about 3.1% and a right text edge near 96%. The footnote '1. In collaboration' sits bottom-left at about 97.3% height, the teal logo sits bottom-right and the page number '22' sits just left of the logo at about 95.5% height.

**Visuals**

One logo at bottom right: a teal (#00857C) four-lobed rounded mark resembling a stylised flower or knot with a central gap, about 3.1% wide and 6.6% high. Four vertical accent bars beside section headings, each a solid rectangle about 1% wide: lime #BFED33 beside Immunology (y 22.7 to 41.1%), mint #6ECEB2 beside Ophthalmology (y 46.5 to 61.4%), violet #5350E4 beside Cardiometabolic & respiratory (y 66.8 to 92.2%), light blue #69B8F7 beside Infectious Disease (y 22.7 to 66.7%) and teal #00857C beside Oncology (y 70.0 to 92.2%). No photographs, charts or diagrams.

**Design**

Background: Solid white #FFFFFF, with a navy #0C2340 band across the top 18.4% of the slide.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Full-width navy header band behind title (Solid rectangle, no border, no shadow, sharp corners, sits behind the title.)
- shape at x 3.1, y 22.7, w 1, h 18.4 [#BFED33]: Accent bar beside Immunology heading (Solid rectangle, no border, sharp corners.)
- shape at x 3.1, y 46.5, w 1, h 14.9 [#6ECEB2]: Accent bar beside Ophthalmology heading (Solid rectangle, no border, sharp corners.)
- shape at x 3.1, y 66.8, w 1, h 25.4 [#5350E4]: Accent bar beside Cardiometabolic & respiratory heading (Solid rectangle, no border, sharp corners.)
- shape at x 47.6, y 22.7, w 1, h 44.1 [#69B8F7]: Accent bar beside Infectious Disease heading (Solid rectangle, no border, sharp corners.)
- shape at x 47.6, y 70, w 1, h 22.2 [#00857C]: Accent bar beside Oncology heading (Solid rectangle, no border, sharp corners.)
- title at x 3.1, y 3.9, w 86.6, h 10.6 [Invention Light, regular weight, sans-serif; font size 5.09% of slide height; #FFFFFF; left aligned]: Significant late-stage pipeline milestones expected over next twelve / months (Two lines, sentence case, line spacing about 1.0, sits on the navy band.)
- body at x 5.1, y 23.3, w 10.9, h 3.3 [Invention Bold, sans-serif; font size 3.33% of slide height; #BFED33; left aligned]: Immunology (Section heading, lime.)
- body at x 5.1, y 28.2, w 8.2, h 2.6 [Invention Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Tulisokibart (Drug name, bold.)
- body at x 7, y 31.4, w 35.9, h 8.8 [Invention Regular, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: PCD in August for Phase 3 ATLAS-UC trial / Phase 2 data in additional indications including RA, R-axSpA and PsA (Two bullets with dot marker '•' in ArialMT at x 7.0%, text indented to x 9.3%, line spacing about 1.2, second bullet wraps onto two lines (RA, / R-axSpA and PsA).)
- body at x 5.1, y 47.2, w 13.5, h 3.3 [Invention Bold, sans-serif; font size 3.33% of slide height; #6ECEB2; left aligned]: Ophthalmology (Section heading, mint.)
- body at x 5.1, y 52.1, w 8.4, h 2.6 [Invention Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Remigromig (Drug name, bold.)
- body at x 7, y 55.3, w 35.6, h 2.6 [Invention Regular, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: PCD in March for Phase 2b/3 BAROLO trial in DME (Single bullet, dot marker '•' in ArialMT, text indented to x 9.3%.)
- body at x 5.1, y 67.4, w 26.8, h 3.3 [Invention Bold, sans-serif; font size 3.33% of slide height; #5350E4; left aligned]: Cardiometabolic & respiratory (Section heading, violet.)
- body at x 5.1, y 72.4, w 8.5, h 2.6 [Invention Bold, sans-serif, all capitals; font size 2.6% of slide height; #0C2340; left aligned]: WINREVAIR (Drug name, bold capitals.)
- body at x 7, y 75.5, w 32.8, h 5.7 [Invention Regular, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Initiation of Phase 3 CHORUS study in CpcPH-HFpEF (Single bullet with dot marker '•' in ArialMT, wraps to two lines (CpcPH- / HFpEF).)
- body at x 5.1, y 82.8, w 10.6, h 2.6 [Invention Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Efinopegdutide (Drug name, bold.)
- body at x 7, y 85.9, w 36.7, h 5.7 [Invention Regular, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Presentation of results from Phase 2b trial in MASH at AASLD (Single bullet with dot marker '•' in ArialMT, wraps to two lines (MASH / at AASLD).)
- body at x 49.5, y 23.3, w 15.9, h 3.3 [Invention Bold, sans-serif; font size 3.33% of slide height; #69B8F7; left aligned]: Infectious Disease (Section heading, light blue.)
- body at x 49.5, y 28.3, w 20.8, h 2.6 [Invention Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Efitazanamivir alfa (MK-1406) (Drug name, bold.)
- body at x 51.4, y 31.4, w 44.7, h 2.6 [Invention Regular, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: PCD in June for Phase 3 ANCHOR trial in prevention of influenza (Single bullet with dot marker '•' in ArialMT at x 51.4%, text at x 53.8%.)
- body at x 49.5, y 35.6, w 8.4, h 2.6 [Invention Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Alimatravir (Drug name, bold.)
- body at x 51.4, y 38.7, w 39.1, h 2.6 [Invention Regular, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: PCD in July for Phase 3 EXPrESSIVE-11 trial in HIV PrEP (Single bullet with dot marker '•' in ArialMT at x 51.4%, text at x 53.8%.)
- body at x 49.5, y 43, w 14.5, h 2.6 [Invention Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Islatravir/lenacapavir1 (Drug name, bold, with superscript footnote marker '1' at x 64.1%, y 42.9%, Invention Regular 1.73% of slide height.)
- body at x 51.4, y 46.1, w 21.7, h 2.6 [Invention Regular, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Anticipated regulatory filings (Single bullet with dot marker '•' in ArialMT.)
- body at x 49.5, y 50.3, w 6.6, h 2.6 [Invention Bold, sans-serif, all capitals; font size 2.6% of slide height; #0C2340; left aligned]: IDVYNSO (Drug name, bold capitals.)
- body at x 51.4, y 53.4, w 42, h 5.7 [Invention Regular, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: PDUFA date April 22nd based on MK-8591A-053 (treatment naïve) (Single bullet with dot marker '•' in ArialMT, wraps to two lines (treatment / naïve); 'nd' is superscript at x 67.4%, y 53.3%, 1.73% of slide height.)
- body at x 49.5, y 60.7, w 8.3, h 2.6 [Invention Bold, sans-serif, all capitals; font size 2.6% of slide height; #0C2340; left aligned]: ENFLONSIA (Drug name, bold capitals.)
- body at x 51.4, y 63.9, w 33.6, h 2.6 [Invention Regular, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Second season SMART PDUFA date March 22nd (Single bullet with dot marker '•' in ArialMT; 'nd' superscript at x 83.9%, y 63.8%, 1.73% of slide height.)
- body at x 49.5, y 70.5, w 8.2, h 3.3 [Invention Bold, sans-serif; font size 3.33% of slide height; #00857C; left aligned]: Oncology (Section heading, teal.)
- body at x 49.5, y 75.6, w 6.1, h 2.6 [Invention Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Sac-TMT (Drug name, bold.)
- body at x 51.4, y 78.6, w 28, h 2.6 [Calibri, regular, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: PDUFA date June 15th based on TroFuse-005 (Single bullet with dot marker '•' in ArialMT; 'th' superscript at x 65.7%, y 79.2%, Calibri 1.11% of slide height.)
- body at x 51.4, y 81.7, w 37, h 2.6 [Calibri, regular, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: PCDs in January, May, and July for Phase 3 TroFuse program (Single bullet with dot marker '•' in ArialMT.)
- body at x 49.5, y 86, w 14.2, h 2.6 [Invention Bold, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Intismeran autogene1 (Drug name, bold, with superscript footnote marker '1' at x 63.7%, y 85.9%, 1.73% of slide height.)
- body at x 51.4, y 89.1, w 21.7, h 2.6 [Invention Regular, sans-serif; font size 2.6% of slide height; #0C2340; left aligned]: Anticipated regulatory filings (Single bullet with dot marker '•' in ArialMT.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Teal four-lobed rounded logo mark, bottom right corner (Raster image 125 by 150 pixels, no border, no background box.)
- footer at x 3.1, y 97.3, w 7.4, h 1.7 [Invention Regular, sans-serif; font size 1.67% of slide height; #0C2340; left aligned]: 1. In collaboration (Footnote, bottom left.)
- page number at x 96.1, y 95.5, w 0.8, h 1.3 [Invention Regular, sans-serif; font size 1.29% of slide height; #9EA7B3; right aligned]: 22 (Grey page number, bottom right, left of the logo's horizontal band.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- fill at x 47.6, y 22.7, w 1.0, h 44.1: #69B8F7
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 3.9, w 86.6, h 10.6 [Invention-Light; font size 5.09; #FFFFFF]: Significant late-stage pipeline milestones expected over next twelve months
- text at x 5.1, y 23.3, w 10.9, h 3.3 [Invention-Bold; font size 3.33; #BFED33]: Immunology
- text at x 49.5, y 23.3, w 15.9, h 3.3 [Invention-Bold; font size 3.33; #69B8F7]: Infectious Disease
- text at x 5.1, y 28.2, w 8.2, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Tulisokibart
- text at x 49.5, y 28.3, w 20.8, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Efitazanamivir alfa (MK-1406)
- text at x 7.0, y 31.4, w 0.5, h 2.6 [ArialMT; font size 2.60; #0C2340]: •
- text at x 9.3, y 31.4, w 28.1, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: PCD in August for Phase 3 ATLAS-UC trial
- text at x 51.4, y 31.4, w 0.5, h 2.6 [ArialMT; font size 2.60; #0C2340]: •
- text at x 53.8, y 31.4, w 42.3, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: PCD in June for Phase 3 ANCHOR trial in prevention of influenza
- text at x 7.0, y 34.5, w 0.5, h 2.6 [ArialMT; font size 2.60; #0C2340]: •
- text at x 49.5, y 35.6, w 8.4, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Alimatravir
- text at x 5.1, y 47.2, w 13.5, h 3.3 [Invention-Bold; font size 3.33; #6ECEB2]: Ophthalmology
- text at x 9.3, y 34.5, w 33.6, h 5.7 [Invention-Regular; font size 2.60; #0C2340]: Phase 2 data in additional indications including RA, R-axSpA and PsA
- text at x 51.4, y 38.7, w 0.5, h 2.6 [ArialMT; font size 2.60; #0C2340]: •
- text at x 53.8, y 38.7, w 36.7, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: PCD in July for Phase 3 EXPrESSIVE-11 trial in HIV PrEP
- text at x 49.5, y 43.0, w 14.5, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Islatravir/lenacapavir
- text at x 51.4, y 46.1, w 0.5, h 2.6 [ArialMT; font size 2.60; #0C2340]: •
- text at x 53.8, y 46.1, w 19.2, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: Anticipated regulatory filings
- text at x 49.5, y 50.3, w 6.6, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: IDVYNSO
- text at x 5.1, y 67.4, w 26.8, h 3.3 [Invention-Bold; font size 3.33; #5350E4]: Cardiometabolic & respiratory
- text at x 5.1, y 52.1, w 8.4, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Remigromig
- text at x 51.4, y 53.4, w 0.5, h 2.6 [ArialMT; font size 2.60; #0C2340]: •
- text at x 53.8, y 53.4, w 13.6, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: PDUFA date April 22
- text at x 49.5, y 70.5, w 8.2, h 3.3 [Invention-Bold; font size 3.33; #00857C]: Oncology
- text at x 53.8, y 53.4, w 39.6, h 5.7 [Invention-Regular; font size 2.60; #0C2340]: based on MK-8591A-053 (treatment naïve)
- text at x 7.0, y 55.3, w 0.5, h 2.6 [ArialMT; font size 2.60; #0C2340]: •
- text at x 9.3, y 55.3, w 33.3, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: PCD in March for Phase 2b/3 BAROLO trial in DME
- text at x 49.5, y 60.7, w 8.3, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: ENFLONSIA
- text at x 51.4, y 63.9, w 0.5, h 2.6 [ArialMT; font size 2.60; #0C2340]: •
- text at x 53.8, y 63.9, w 30.1, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: Second season SMART PDUFA date March 22
- text at x 64.1, y 42.9, w 0.4, h 1.7 [Invention-Regular; font size 1.73; #0C2340]: 1
- text at x 5.1, y 72.4, w 8.5, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: WINREVAIR
- text at x 7.0, y 75.5, w 0.5, h 2.6 [ArialMT; font size 2.60; #0C2340]: •
- text at x 49.5, y 75.6, w 6.1, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Sac-TMT
- text at x 9.3, y 75.5, w 30.5, h 5.7 [Invention-Regular; font size 2.60; #0C2340]: Initiation of Phase 3 CHORUS study in CpcPH-HFpEF
- text at x 51.4, y 78.6, w 0.5, h 2.6 [ArialMT; font size 2.60; #0C2340]: •
- text at x 53.8, y 78.6, w 25.6, h 2.6 [Calibri; font size 2.60; #0C2340]: PDUFA date June 15 based on TroFuse-005
- text at x 67.4, y 53.3, w 1.1, h 1.7 [Invention-Regular; font size 1.73; #0C2340]: nd
- text at x 51.4, y 81.7, w 0.5, h 2.6 [ArialMT; font size 2.60; #0C2340]: •
- text at x 53.8, y 81.7, w 35.2, h 2.6 [Calibri; font size 2.60; #0C2340]: PCDs in January, May, and July for Phase 3 TroFuse program
- text at x 5.1, y 82.8, w 10.6, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Efinopegdutide
- text at x 7.0, y 85.9, w 0.5, h 2.6 [ArialMT; font size 2.60; #0C2340]: •
- text at x 49.5, y 86.0, w 14.2, h 2.6 [Invention-Bold; font size 2.60; #0C2340]: Intismeran autogene
- text at x 9.3, y 85.9, w 34.4, h 5.7 [Invention-Regular; font size 2.60; #0C2340]: Presentation of results from Phase 2b trial in MASH at AASLD
- text at x 51.4, y 89.1, w 0.5, h 2.6 [ArialMT; font size 2.60; #0C2340]: •
- text at x 53.8, y 89.1, w 19.2, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: Anticipated regulatory filings
- text at x 83.9, y 63.8, w 1.1, h 1.7 [Invention-Regular; font size 1.73; #0C2340]: nd
- text at x 63.7, y 85.9, w 0.4, h 1.7 [Invention-Regular; font size 1.73; #0C2340]: 1
- text at x 3.1, y 97.3, w 7.4, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 1. In collaboration
- text at x 65.7, y 79.2, w 0.7, h 1.1 [Calibri; font size 1.11; #0C2340]: th
- text at x 96.1, y 95.5, w 0.8, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 22

### Slide 23

**Text**

Q&A
Robert M. Davis
Chairman and Chief
Executive Officer
Caroline Litchfield
Executive Vice President
and Chief Financial Officer
Dr. Dean Y. Li
Executive Vice President
and President, Merck
Research Laboratories
Jannie Oosthuizen
Executive Vice President
and President, Oncology
and MSD International
Brian Foard
Executive Vice President
and President, Specialty,
Pharma & Infectious
Diseases
Peter Dannenbaum
Senior Vice President,
Investor Relations

**Layout**

Two-column split: the left half is a white column holding a teal logo at top left, the large title 'Q&A' below it, and a grid of six portraits in three columns by two rows with name and role captions beneath each. The right half (from x 50%) is a photograph running from the top edge to 88.9% of the slide height, leaving a white strip along the bottom. The title sits top-left at x 3.1%, all text is left-aligned to the x 3.1% margin, there is no footer and no slide number.

**Visuals**

Logo: a teal (#00857C) four-lobed quatrefoil mark made of stacked rounded lobes with thin white horizontal gaps, at top left (x 1.1%, y 2.1%, 6.4% by 13.7%). Portraits: six head-and-shoulders photographs, each in a square-ish box with no border, cropped at the chest. Robert M. Davis: bald man with glasses, smiling, navy suit, white shirt, lavender tie, plain mid-grey backdrop. Caroline Litchfield: woman with shoulder-length light brown hair, smiling, navy top, bright blurred window backdrop. Dr. Dean Y. Li: smiling man with glasses and short hair, grey suit, white shirt, olive and cream striped tie, grey backdrop. Jannie Oosthuizen: man with silver hair, navy blazer, open white collar, blurred grey-green backdrop. Brian Foard: smiling bald man, navy suit, open white shirt, blurred green window backdrop. Peter Dannenbaum: man with short dark hair, dark suit, white shirt, striped tie, warm brown backdrop. Right photograph: an audience in a bright indoor hall seen from behind; in the foreground a woman with curly reddish-brown hair, hoop earrings, a beaded bracelet and a navy polka-dot long-sleeve top raises her right arm, and other raised hands and blurred heads fill the background. Lighting is soft ambient with bokeh ceiling lights at the top; dominant colours are warm browns and tans, navy and off-white, with a blue-grey wall at upper right. The photo is cropped at the frame edges and boxed as a rectangle, not full-bleed. Grey placeholder fills #D9D9D9 sit behind the right photo and behind the Jannie Oosthuizen portrait.

**Design**

Background is plain white #FFFFFF. Title 'Q&A' is in Invention Light (a geometric humanist sans-serif, light weight) in navy #0C2340, about 7.9% of slide height (cap height about 5.5%). Names are Invention Bold in teal #00857C at about 2.0% of slide height (caps about 1.4%). Role lines are Invention Regular in navy #0C2340 at about 1.7% of slide height, with tight leading of roughly 2.0% between lines. Accents are teal #00857C. Shapes have square corners, no borders, no shadows, no gradients; photos are unframed rectangles.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: White slide background (Full-bleed fill, no outline.)
- shape at x 50, y 0, w 50, h 88.9 [#D9D9D9]: Grey placeholder rectangle behind right photograph (Fully covered by the photograph; no outline, square corners.)
- photo at x 50, y 0, w 50, h 88.9 [#8A5A3C]: Audience photograph: woman with curly reddish-brown hair in foreground seen from behind, raising her arm in a navy polka-dot top, other raised hands and blurred audience behind, bokeh ceiling lights at top (Square-cornered rectangle, cropped at slide edges, not full-bleed vertically; soft focus background; warm, shallow depth of field.)
- shape at x 3.1, y 58.2, w 11.2, h 20 [#D9D9D9]: Grey placeholder rectangle behind Jannie Oosthuizen portrait (Covered by the portrait; no outline.)
- photo at x 3.1, y 27.7, w 11.2, h 20 [#4A4A4A]: Portrait of Robert M. Davis: bald man with glasses, smiling, navy suit, lavender tie, grey backdrop (Square-cornered, unbordered, head and shoulders.)
- photo at x 18.6, y 27.8, w 11.2, h 20 [#E8E8E8]: Portrait of Caroline Litchfield: smiling woman with shoulder-length light brown hair, navy top, bright window backdrop (Square-cornered, unbordered, head and shoulders.)
- photo at x 34.1, y 27.7, w 11.3, h 19.9 [#5E5E5E]: Portrait of Dr. Dean Y. Li: smiling man with glasses, grey suit, striped tie, grey backdrop (Square-cornered, unbordered, head and shoulders.)
- photo at x 3.1, y 58.2, w 11.3, h 20 [#6B7480]: Portrait of Jannie Oosthuizen: man with silver hair, navy blazer, open white collar, blurred grey-green backdrop (Square-cornered, unbordered, head and shoulders.)
- photo at x 18.6, y 58.2, w 11.3, h 20 [#7A8A6A]: Portrait of Brian Foard: smiling bald man, navy suit, open white shirt, blurred green window backdrop (Square-cornered, unbordered, head and shoulders.)
- photo at x 34.1, y 58.2, w 11.3, h 20 [#5A4632]: Portrait of Peter Dannenbaum: man with short dark hair, dark suit, striped tie, warm brown backdrop (Square-cornered, unbordered, head and shoulders.)
- logo at x 1.1, y 2.1, w 6.4, h 13.7 [#00857C]: Teal four-lobed quatrefoil logo mark (Stacked rounded lobes with thin white horizontal gaps.)
- title at x 3.1, y 15.7, w 9.9, h 7.9 [Invention Light, regular sans-serif, no italics, no capitals, normal letter-spacing; font size 7.87% of slide height; #0C2340; left aligned]: Q&A
- body at x 3.1, y 48.6, w 8.5, h 2 [Invention Bold, sans-serif, bold, normal letter-spacing; font size 2.04% of slide height; #00857C; left aligned]: Robert M. Davis
- body at x 3.1, y 51, w 8.5, h 3.7 [Invention Regular, sans-serif, regular, normal letter-spacing; font size 1.67% of slide height; #0C2340; left aligned]: Chairman and Chief / Executive Officer (Line spacing about 2.0% of slide height.)
- body at x 18.6, y 48.6, w 9.8, h 2 [Invention Bold, sans-serif, bold, normal letter-spacing; font size 2.04% of slide height; #00857C; left aligned]: Caroline Litchfield
- body at x 18.6, y 51, w 11.1, h 3.7 [Invention Regular, sans-serif, regular, normal letter-spacing; font size 1.67% of slide height; #0C2340; left aligned]: Executive Vice President / and Chief Financial Officer (Line spacing about 2.0% of slide height.)
- body at x 34.1, y 48.6, w 7.3, h 2 [Invention Bold, sans-serif, bold, normal letter-spacing; font size 2.04% of slide height; #00857C; left aligned]: Dr. Dean Y. Li
- body at x 34.1, y 51, w 9.6, h 5.7 [Invention Regular, sans-serif, regular, normal letter-spacing; font size 1.67% of slide height; #0C2340; left aligned]: Executive Vice President / and President, Merck / Research Laboratories (Line spacing about 2.0% of slide height.)
- body at x 3.1, y 79.2, w 9.9, h 2 [Invention Bold, sans-serif, bold, normal letter-spacing; font size 2.04% of slide height; #00857C; left aligned]: Jannie Oosthuizen
- body at x 3.1, y 81.6, w 10.6, h 3.7 [Invention Regular, sans-serif, regular, normal letter-spacing; font size 1.67% of slide height; #0C2340; left aligned]: Executive Vice President / and President, Oncology / and MSD International (Line spacing about 2.0% of slide height.)
- body at x 18.6, y 79.2, w 6.2, h 2 [Invention Bold, sans-serif, bold, normal letter-spacing; font size 2.04% of slide height; #00857C; left aligned]: Brian Foard
- body at x 18.6, y 81.6, w 10.8, h 6 [Invention Regular, sans-serif, regular, normal letter-spacing; font size 1.67% of slide height; #0C2340; left aligned]: Executive Vice President / and President, Specialty, / Pharma & Infectious / Diseases (Line spacing about 2.0% of slide height.)
- body at x 34.1, y 79.2, w 10.4, h 2 [Invention Bold, sans-serif, bold, normal letter-spacing; font size 2.04% of slide height; #00857C; left aligned]: Peter Dannenbaum
- body at x 34.1, y 81.6, w 9.6, h 3.7 [Invention Regular, sans-serif, regular, normal letter-spacing; font size 1.67% of slide height; #0C2340; left aligned]: Senior Vice President, / Investor Relations (Line spacing about 2.0% of slide height.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 50.0, y 0.0, w 50.0, h 88.9: #D9D9D9
- fill at x 3.1, y 58.2, w 11.2, h 20.0: #D9D9D9
- image at x 50.0, y 0.0, w 50.0, h 88.9: 1000 by 1000 pixels
- image at x 18.6, y 58.2, w 11.3, h 20.0: 226 by 226 pixels
- image at x 34.1, y 58.2, w 11.2, h 20.0: 166 by 166 pixels
- image at x 18.6, y 27.8, w 11.2, h 20.0: 240 by 240 pixels
- image at x 3.1, y 58.2, w 11.3, h 20.0: 226 by 225 pixels
- image at x 34.1, y 27.7, w 11.3, h 19.9: 323 by 323 pixels
- image at x 3.1, y 27.7, w 11.2, h 20.0: 225 by 226 pixels
- image at x 1.1, y 2.1, w 6.4, h 13.7: 65 by 78 pixels
- text at x 3.1, y 15.7, w 9.9, h 7.9 [Invention-Light; font size 7.87; #0C2340]: Q&A
- text at x 3.1, y 48.6, w 8.5, h 2.0 [Invention-Bold; font size 2.04; #00857C]: Robert M. Davis
- text at x 18.6, y 48.6, w 9.8, h 2.0 [Invention-Bold; font size 2.04; #00857C]: Caroline Litchfield
- text at x 34.1, y 48.6, w 7.3, h 2.0 [Invention-Bold; font size 2.04; #00857C]: Dr. Dean Y. Li
- text at x 3.1, y 51.0, w 8.5, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Chairman and Chief
- text at x 18.6, y 51.0, w 10.7, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Executive Vice President
- text at x 34.1, y 51.0, w 10.7, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Executive Vice President
- text at x 3.1, y 53.0, w 7.3, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Executive Officer
- text at x 18.6, y 53.0, w 11.1, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: and Chief Financial Officer
- text at x 34.1, y 53.0, w 9.3, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: and President, Merck
- text at x 34.1, y 55.0, w 9.6, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Research Laboratories
- text at x 3.1, y 79.2, w 9.9, h 2.0 [Invention-Bold; font size 2.04; #00857C]: Jannie Oosthuizen
- text at x 18.6, y 79.2, w 6.2, h 2.0 [Invention-Bold; font size 2.04; #00857C]: Brian Foard
- text at x 34.1, y 79.2, w 10.4, h 2.0 [Invention-Bold; font size 2.04; #00857C]: Peter Dannenbaum
- text at x 3.1, y 81.6, w 10.7, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Executive Vice President
- text at x 18.6, y 81.6, w 10.7, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Executive Vice President
- text at x 34.1, y 81.6, w 9.6, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Senior Vice President,
- text at x 3.1, y 83.6, w 10.6, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: and President, Oncology
- text at x 18.6, y 83.6, w 10.8, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: and President, Specialty,
- text at x 34.1, y 83.6, w 7.7, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Investor Relations
- text at x 3.1, y 85.6, w 9.6, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: and MSD International
- text at x 18.6, y 85.6, w 9.0, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Pharma & Infectious
- text at x 18.6, y 87.6, w 3.7, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Diseases

### Slide 24

**Text**

Appendix / 24

**Layout**

Single title block set left-aligned at the vertical lower-middle of the slide (title baseline near 65% of height), with a small logo mark and slide number grouped at the bottom-right corner; the rest of the slide is empty. Left margin about 3% of slide width; no header or footer text.

**Visuals**

Small teal four-lobed logo mark at bottom-right, about 3% wide and 7% tall, colour teal #0E8A7E-like green. No photographs, charts or diagrams.

**Design**

Background: Solid navy #0C2340 covering the entire slide. Full-bleed dark navy background #0C2340 with no gradient or pattern. Title 'Appendix' in Invention-Light, white #FFFFFF, mixed case, approximately 10.6% of slide height, regular letter-spacing. Slide number in Invention-Regular, grey #9EA7B3, about 1.3% of slide height. Logo in teal. No shapes, lines, shadows or corner radii.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#0C2340]: Full-slide background rectangle, dark navy fill (Covers the whole slide, no border, opacity 100%.)
- title at x 3.1, y 56.2, w 25.1, h 10.6 [Invention-Light, sans-serif, weight light, mixed case, no italics, no letter-spacing change; font size 10.64% of slide height; #FFFFFF; left aligned]: Appendix
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#0E8A7E]: Teal four-lobed logo mark (Image placed as 125 by 150 pixels, no border, sits left of the slide number.)
- page number at x 96, y 95.5, w 0.9, h 1.3 [Invention-Regular, sans-serif, weight regular; font size 1.29% of slide height; #9EA7B3; right aligned]: 24

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #0C2340 (covers the slide)
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 56.2, w 25.1, h 10.6 [Invention-Light; font size 10.64; #FFFFFF]: Appendix
- text at x 96.0, y 95.5, w 0.9, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 24

### Slide 25

**Text**

Q3 2026 GAAP financial results summary
$ in billions, except EPS amounts
Q3 2026
Q3 2025
Change
Change Ex-FX
Sales
$18.1
$17.3
+5%
+4%
Operating Expenses
$7.4
$6.9
+8%
+8%
(SG&A and R&D)
1,2
Tax Rate
8.9%
14.2%
-5.3 pts
N/A
GAAP EPS
1,2
$2.04
$2.32
-12%
-13%
1. Q3 2026 GAAP results include a charge of $400 million, or $0.12 negative EPS impact, related to an exclusive global license agreement with SciBrunch Therapeutics. 2. Q3 2025 GAAP results include a
charge of $300 million, or $0.10 negative EPS impact, related to the LaNova Medicines technology transfer milestone payment
25

**Layout**

A full-width navy header band occupies the top 18.4% of the slide and holds the left-aligned title and subtitle at x 3.1%. Below it, a white field holds a 5-column grid (row-label column plus four value columns, Q3 2026, Q3 2025, Change, Change Ex-FX) with a header row and four body rows, starting at x 3.1% and y 25.7% and spanning to x 96.9%; cells are separated by thin white gutters. Footnotes sit bottom-left at y 95.6%, the logo sits bottom-right at x 91.8%, and the page number '25' sits at the far bottom-right (x 96.1%, y 95.5%).

**Visuals**

Table with 4 value columns and a row-label column. Header row: (blank corner cell), 'Q3 2026' (white bold text on teal #00857C fill, the only filled teal header), 'Q3 2025' (navy bold on #E2E2E2), 'Change' (navy bold on #E2E2E2), 'Change Ex-FX' (navy bold on #E2E2E2). Row 1 'Sales': $18.1 | $17.3 | +5% | +4%. Row 2 'Operating Expenses (SG&A and R&D)' with superscript 1,2: $7.4 | $6.9 | +8% | +8%. Row 3 'Tax Rate': 8.9% | 14.2% | -5.3 pts | N/A. Row 4 'GAAP EPS' with superscript 1,2: $2.04 | $2.32 | -12% | -13%. Body row-label cells and Q3 2025/Change/Change Ex-FX cells are #F7F7F7; the Q3 2026 value column cells are pale mint #E2F5F0. No chart, no photographs. Small logo at bottom right: a stylised four-lobed mark in teal #00857C with white centre cut-outs, 125 by 150 px.

**Design**

Background: Solid white #FFFFFF. Flat, clean corporate look with no gradients, shadows or rounded corners. Background white #FFFFFF. Header band navy #0C2340 full width. Title white #FFFFFF in Invention Light, roughly 5.1% of slide height, sentence case. Subtitle mint #6ECEB2 in Invention Light, about 3.3% of slide height. Table headers and row labels in Invention Bold, navy #0C2340, about 3.3% (headers) and 3.0% (row labels) of slide height. Table values in Invention Regular, navy #0C2340, about 3.0% of slide height. Accent teal #00857C on the Q3 2026 header; pale mint #E2F5F0 column tint. Footnotes in Invention Regular, navy #0C2340, about 1.7% of slide height. Page number in Invention Regular, grey #9EA7B3, about 1.3%. Cells are flat rectangles with square corners and no borders.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Navy header band, full width, top of slide (Flat rectangle, square corners, no shadow, sits behind title and subtitle.)
- title at x 3.1, y 4.9, w 52.3, h 5.1 [Invention, Light, sentence case; font size 5.09% of slide height; #FFFFFF; left aligned]: Q3 2026 GAAP financial results summary
- subtitle at x 3.1, y 10.2, w 27.4, h 3.3 [Invention, Light; font size 3.33% of slide height; #6ECEB2; left aligned]: $ in billions, except EPS amounts
- shape at x 24.7, y 25.7, w 18, h 9.6 [#00857C]: Table header cell, Q3 2026 column (Flat teal rectangle, square corners.)
- shape at x 42.6, y 25.7, w 16.8, h 9.6 [#E2E2E2]: Table header cell, Q3 2025 column (Flat light grey rectangle.)
- shape at x 59.4, y 25.7, w 19, h 9.6 [#E2E2E2]: Table header cell, Change column (Flat light grey rectangle.)
- shape at x 78.3, y 25.7, w 18.6, h 9.6 [#E2E2E2]: Table header cell, Change Ex-FX column (Flat light grey rectangle.)
- shape at x 3.1, y 35.3, w 21.6, h 9.6 [#F7F7F7]: Table body cell, Sales row label (Flat rectangle.)
- shape at x 24.7, y 35.3, w 18, h 9.6 [#E2F5F0]: Table body cell, Sales Q3 2026 (Flat pale mint rectangle.)
- shape at x 42.6, y 35.3, w 16.8, h 9.6 [#F7F7F7]: Table body cell, Sales Q3 2025 (Flat rectangle.)
- shape at x 59.4, y 35.3, w 19, h 9.6 [#F7F7F7]: Table body cell, Sales Change (Flat rectangle.)
- shape at x 78.3, y 35.3, w 18.6, h 9.6 [#F7F7F7]: Table body cell, Sales Change Ex-FX (Flat rectangle.)
- shape at x 3.1, y 44.9, w 21.6, h 9.6 [#F7F7F7]: Table body cell, Operating Expenses row label (Flat rectangle.)
- shape at x 24.7, y 44.9, w 18, h 9.6 [#E2F5F0]: Table body cell, Operating Expenses Q3 2026 (Flat pale mint rectangle.)
- shape at x 42.6, y 44.9, w 16.8, h 9.6 [#F7F7F7]: Table body cell, Operating Expenses Q3 2025 (Flat rectangle.)
- shape at x 59.4, y 44.9, w 19, h 9.6 [#F7F7F7]: Table body cell, Operating Expenses Change (Flat rectangle.)
- shape at x 78.3, y 44.9, w 18.6, h 9.6 [#F7F7F7]: Table body cell, Operating Expenses Change Ex-FX (Flat rectangle.)
- shape at x 3.1, y 54.5, w 21.6, h 9.6 [#F7F7F7]: Table body cell, Tax Rate row label (Flat rectangle.)
- shape at x 24.7, y 54.5, w 18, h 9.6 [#E2F5F0]: Table body cell, Tax Rate Q3 2026 (Flat pale mint rectangle.)
- shape at x 42.6, y 54.5, w 16.8, h 9.6 [#F7F7F7]: Table body cell, Tax Rate Q3 2025 (Flat rectangle.)
- shape at x 59.4, y 54.5, w 19, h 9.6 [#F7F7F7]: Table body cell, Tax Rate Change (Flat rectangle.)
- shape at x 78.3, y 54.5, w 18.6, h 9.6 [#F7F7F7]: Table body cell, Tax Rate Change Ex-FX (Flat rectangle.)
- shape at x 3.1, y 64.1, w 21.6, h 9.6 [#F7F7F7]: Table body cell, GAAP EPS row label (Flat rectangle.)
- shape at x 24.7, y 64.1, w 18, h 9.6 [#E2F5F0]: Table body cell, GAAP EPS Q3 2026 (Flat pale mint rectangle.)
- shape at x 42.6, y 64.1, w 16.8, h 9.6 [#F7F7F7]: Table body cell, GAAP EPS Q3 2025 (Flat rectangle.)
- shape at x 59.4, y 64.1, w 19, h 9.6 [#F7F7F7]: Table body cell, GAAP EPS Change (Flat rectangle.)
- shape at x 78.3, y 64.1, w 18.6, h 9.6 [#F7F7F7]: Table body cell, GAAP EPS Change Ex-FX (Flat rectangle.)
- body at x 30, y 29.2, w 7.3, h 3.3 [Invention, Bold; font size 3.33% of slide height; #FFFFFF; center aligned]: Q3 2026
- body at x 47.4, y 29.2, w 7.3, h 3.3 [Invention, Bold; font size 3.33% of slide height; #0C2340; center aligned]: Q3 2025
- body at x 65.6, y 29.2, w 6.6, h 3.3 [Invention, Bold; font size 3.33% of slide height; #0C2340; center aligned]: Change
- body at x 81.5, y 29.2, w 12.3, h 3.3 [Invention, Bold; font size 3.33% of slide height; #0C2340; center aligned]: Change Ex-FX
- body at x 4.6, y 38.9, w 4.1, h 3 [Invention, Bold; font size 2.96% of slide height; #0C2340; left aligned]: Sales
- body at x 31.7, y 38.9, w 3.9, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: $18.1
- body at x 49, y 38.9, w 4, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: $17.3
- body at x 67.1, y 38.9, w 3.4, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: +5%
- body at x 85.8, y 38.9, w 3.5, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: +4%
- body at x 4.6, y 46.7, w 15.9, h 3 [Invention, Bold; font size 2.96% of slide height; #0C2340; left aligned]: Operating Expenses
- body at x 4.6, y 50.3, w 13.4, h 3 [Invention, Bold; font size 2.96% of slide height; #0C2340; left aligned]: (SG&A and R&D)
- body at x 18, y 50.2, w 1.4, h 2 [Invention, Regular, superscript; font size 1.98% of slide height; #0C2340; left aligned]: 1,2
- body at x 31.9, y 48.5, w 3.5, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: $7.4
- body at x 49.2, y 48.5, w 3.6, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: $6.9
- body at x 67.1, y 48.5, w 3.5, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: +8%
- body at x 85.9, y 48.5, w 3.5, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: +8%
- body at x 4.6, y 58.1, w 6.8, h 3 [Invention, Bold; font size 2.96% of slide height; #0C2340; left aligned]: Tax Rate
- body at x 31.7, y 58.1, w 4, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: 8.9%
- body at x 48.7, y 58.1, w 4.5, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: 14.2%
- body at x 65.9, y 58.1, w 5.9, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: -5.3 pts
- body at x 86.1, y 58.1, w 3.1, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: N/A
- body at x 4.6, y 67.7, w 8.2, h 3 [Invention, Bold; font size 2.96% of slide height; #0C2340; left aligned]: GAAP EPS
- body at x 12.7, y 67.6, w 1.4, h 2 [Invention, Regular, superscript; font size 1.98% of slide height; #0C2340; left aligned]: 1,2
- body at x 31.4, y 67.7, w 4.6, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: $2.04
- body at x 48.8, y 67.7, w 4.4, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: $2.32
- body at x 67, y 67.7, w 3.7, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: -12%
- body at x 85.8, y 67.7, w 3.7, h 3 [Invention, Regular; font size 2.96% of slide height; #0C2340; center aligned]: -13%
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Corner logo: stylised four-lobed mark, teal #00857C with white centre cut-outs (Image 125 by 150 px, placed unboxed at bottom right.)
- caption at x 3.1, y 95.6, w 85.5, h 3.4 [Invention, Regular; font size 1.67% of slide height; #0C2340; left aligned]: 1. Q3 2026 GAAP results include a charge of $400 million, or $0.12 negative EPS impact, related to an exclusive global license agreement with SciBrunch Therapeutics. 2. Q3 2025 GAAP results include a / charge of $300 million, or $0.10 negative EPS impact, related to the LaNova Medicines technology transfer milestone payment (Two lines of footnote text, line spacing about 1.7% of slide height, second line starts at y 97.3%.)
- page number at x 96.1, y 95.5, w 0.8, h 1.3 [Invention, Regular; font size 1.29% of slide height; #9EA7B3; right aligned]: 25

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- fill at x 24.7, y 25.7, w 18.0, h 9.6: #00857C
- fill at x 42.6, y 25.7, w 16.8, h 9.6: #E2E2E2
- fill at x 59.4, y 25.7, w 19.0, h 9.6: #E2E2E2
- fill at x 78.3, y 25.7, w 18.6, h 9.6: #E2E2E2
- fill at x 3.1, y 35.3, w 21.6, h 9.6: #F7F7F7
- fill at x 24.7, y 35.3, w 18.0, h 9.6: #E2F5F0
- fill at x 42.6, y 35.3, w 16.8, h 9.6: #F7F7F7
- fill at x 59.4, y 35.3, w 19.0, h 9.6: #F7F7F7
- fill at x 78.3, y 35.3, w 18.6, h 9.6: #F7F7F7
- fill at x 3.1, y 44.9, w 21.6, h 9.6: #F7F7F7
- fill at x 24.7, y 44.9, w 18.0, h 9.6: #E2F5F0
- fill at x 42.6, y 44.9, w 16.8, h 9.6: #F7F7F7
- fill at x 59.4, y 44.9, w 19.0, h 9.6: #F7F7F7
- fill at x 78.3, y 44.9, w 18.6, h 9.6: #F7F7F7
- fill at x 3.1, y 54.5, w 21.6, h 9.6: #F7F7F7
- fill at x 24.7, y 54.5, w 18.0, h 9.6: #E2F5F0
- fill at x 42.6, y 54.5, w 16.8, h 9.6: #F7F7F7
- fill at x 59.4, y 54.5, w 19.0, h 9.6: #F7F7F7
- fill at x 78.3, y 54.5, w 18.6, h 9.6: #F7F7F7
- fill at x 3.1, y 64.1, w 21.6, h 9.6: #F7F7F7
- fill at x 24.7, y 64.1, w 18.0, h 9.6: #E2F5F0
- fill at x 42.6, y 64.1, w 16.8, h 9.6: #F7F7F7
- fill at x 59.4, y 64.1, w 19.0, h 9.6: #F7F7F7
- fill at x 78.3, y 64.1, w 18.6, h 9.6: #F7F7F7
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 4.9, w 52.3, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Q3 2026 GAAP financial results summary
- text at x 3.1, y 10.2, w 27.4, h 3.3 [Invention-Light; font size 3.33; #6ECEB2]: $ in billions, except EPS amounts
- text at x 30.0, y 29.2, w 7.3, h 3.3 [Invention-Bold; font size 3.33; #FFFFFF]: Q3 2026
- text at x 47.4, y 29.2, w 7.3, h 3.3 [Invention-Bold; font size 3.33; #0C2340]: Q3 2025
- text at x 65.6, y 29.2, w 6.6, h 3.3 [Invention-Bold; font size 3.33; #0C2340]: Change
- text at x 81.5, y 29.2, w 12.3, h 3.3 [Invention-Bold; font size 3.33; #0C2340]: Change Ex-FX
- text at x 4.6, y 38.9, w 4.1, h 3.0 [Invention-Bold; font size 2.96; #0C2340]: Sales
- text at x 31.7, y 38.9, w 3.9, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: $18.1
- text at x 49.0, y 38.9, w 4.0, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: $17.3
- text at x 67.1, y 38.9, w 3.4, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: +5%
- text at x 85.8, y 38.9, w 3.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: +4%
- text at x 4.6, y 46.7, w 15.9, h 3.0 [Invention-Bold; font size 2.96; #0C2340]: Operating Expenses
- text at x 31.9, y 48.5, w 3.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: $7.4
- text at x 49.2, y 48.5, w 3.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: $6.9
- text at x 67.1, y 48.5, w 3.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: +8%
- text at x 85.9, y 48.5, w 3.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: +8%
- text at x 4.6, y 50.3, w 13.4, h 3.0 [Invention-Bold; font size 2.96; #0C2340]: (SG&A and R&D)
- text at x 4.6, y 58.1, w 6.8, h 3.0 [Invention-Bold; font size 2.96; #0C2340]: Tax Rate
- text at x 31.7, y 58.1, w 4.0, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: 8.9%
- text at x 48.7, y 58.1, w 4.5, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: 14.2%
- text at x 65.9, y 58.1, w 5.9, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: -5.3 pts
- text at x 86.1, y 58.1, w 3.1, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: N/A
- text at x 4.6, y 67.7, w 8.2, h 3.0 [Invention-Bold; font size 2.96; #0C2340]: GAAP EPS
- text at x 31.4, y 67.7, w 4.6, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: $2.04
- text at x 48.8, y 67.7, w 4.4, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: $2.32
- text at x 67.0, y 67.7, w 3.7, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: -12%
- text at x 85.8, y 67.7, w 3.7, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: -13%
- text at x 18.0, y 50.2, w 1.4, h 2.0 [Invention-Regular; font size 1.98; #0C2340]: 1,2
- text at x 12.7, y 67.6, w 1.4, h 2.0 [Invention-Regular; font size 1.98; #0C2340]: 1,2
- text at x 3.1, y 95.6, w 85.5, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 1. Q3 2026 GAAP results include a charge of $400 million, or $0.12 negative EPS impact, related to an exclusive global license agreement with SciBrunch Therapeutics. 2. Q3 2025 GAAP results include a
- text at x 3.1, y 97.3, w 53.7, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: charge of $300 million, or $0.10 negative EPS impact, related to the LaNova Medicines technology transfer milestone payment
- text at x 96.1, y 95.5, w 0.8, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 25

### Slide 26

**Text**

Executing upon balanced capital allocation strategy / Over the past 12 months 1 / Capital allocation order of priority / $30 / $25 / $20 / $15 / $10 / $5 / $0 / Billions / $27.4 / $13.8 / $8.4 / $4.0 / $3.5 / After-Tax R&D 2 / CapEx / Dividends / Paid / Business 3 / Development / (ex-divestitures) / Share Repurchase / Well-positioned balance sheet with / capacity to fund additional value- / enhancing business development / opportunities / Capital investments / 2026 to 2030 / ~$19B / Over 5 years, including more than $14B in the U.S. / Committed to the dividend / +2% +2% +15% +11% +7% +6% +6% +5% +5% +5% / 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 / 1. Reflects trailing twelve months spend subject to finalization of the Company’s statement of cash flows 2. Reflects R&D excluding Business Development 3. Includes BD payments reflected in operating cash / flow / 26

**Layout**

Two-column layout on a white field under a full-width navy title band occupying the top 18.4% of the slide; the title sits left-aligned in the band at about 3.1% from the left edge and vertically centred. The left column (about 3.1% to 48% wide) holds a capital allocation bar chart over a navy rule and a capital investment figure below; the right column (about 52% to 97%) holds a centred statement above a dividend column chart. A faint dotted vertical divider runs at about 50% across the content area. The footnote runs along the bottom at about 94.4% of the height, the logo sits bottom-right and the page number sits at the far bottom-right corner.

**Visuals**

Chart 1 (left, top): vertical bar chart titled 'Over the past 12 months' with a teal arrow above the bars labelled 'Capital allocation order of priority'. Y-axis labelled 'Billions' runs $0 to $30 in $5 steps with tick labels at $0, $5, $10, $15, $20, $25, $30. Four series-free bars with printed values: After-Tax R&D $13.8 (dark teal #00857C), CapEx $4.0 (light green #6ECEB2), Dividends Paid $8.4 (navy #0C2340), Business Development (ex-divestitures) $27.4 (periwinkle #688CE8, the tallest bar and highlighted), Share Repurchase $3.5 (about #66B5EE). Bar value labels sit inside the top of each bar in white bold type. Category labels sit below the baseline with superscript footnote markers 2 after After-Tax R&D and 3 after Business. No legend. Chart 2 (right, bottom): vertical column chart titled 'Committed to the dividend' with ten light green (#6ECEB2) columns for 2017 to 2026, labels above each column reading +2%, +2%, +15%, +11%, +7%, +6%, +6%, +5%, +5%, +5% in light green bold. No y-axis or values beyond the printed labels; column heights are about proportional to the labelled growth rates in the sense that the tallest visible column is 2026 and the shortest is 2017 and 2018. Columns share a dark grey baseline with small tick marks between columns. Image: a teal four-lobed rounded logo mark at bottom right. Big-number callout: '~$19B' in very large navy bold type, with a thin light grey rule beneath it.

**Design**

Background: Solid white #FFFFFF, with a navy #0C2340 band across the top 18.4% of the slide. Clean corporate style. Title band navy #0C2340 with white light sans-serif title. Section headings are bold: 'Over the past 12 months' and 'Committed to the dividend' in teal #00857C and light green #6ECEB2; 'Capital investments' in navy #0C2340. Body text navy #0C2340. Accents: teal #00857C, light green #6ECEB2, periwinkle #688CE8. Typeface Invention family (Light for the title, Regular for body, Bold for headings and figures), a humanist sans-serif. Title is about 5.1% of slide height, section headings about 3.0%, body and axis labels about 1.7%, footnotes about 1.7%, the big figure about 10%. Rules are flat, with no shadows, rounded corners or gradients; the arrow is a thin teal line with an open chevron head.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Background fill covering the full slide (Solid white rectangle behind everything, no border.)
- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Title band rectangle (Flat navy rectangle across the top, no border, no shadow.)
- title at x 3.1, y 6.7, w 64.5, h 5.1 [Invention Light, regular sentence case, normal letter-spacing; font size 5.09% of slide height; #FFFFFF; left aligned]: Executing upon balanced capital allocation strategy
- shape at x 3.1, y 22.4, w 44.9, h 0.6 [#00857C]: Teal rule above left column (Flat horizontal bar, about 0.6% of slide height thick.)
- body at x 3.1, y 23.7, w 18.3, h 3 [Invention Bold, sentence case; font size 2.96% of slide height; #00857C; left aligned]: Over the past 12 months
- caption at x 21.4, y 23.6, w 0.4, h 2 [Invention Regular, superscript; font size 1.98% of slide height; #00857C; left aligned]: 1 (Superscript footnote marker after 'months'.)
- line at x 7, y 27.6, w 39, h 1.5 [#00857C]: Teal arrow above the bar chart pointing right (Thin horizontal line about 0.4% of slide height in stroke width, ending in an open chevron arrowhead at the right, at about 45.5% to 46% x.)
- body at x 15.4, y 28.6, w 19.6, h 2.2 [Invention Bold, sentence case; font size 2.22% of slide height; #00857C; center aligned]: Capital allocation order of priority
- shape at x 9.6, y 41.6, w 4.3, h 9.6 [#00857C]: Bar After-Tax R&D (Flat bar, no border, square corners, bottom at baseline 51.2%.)
- shape at x 17.5, y 48.5, w 4.4, h 2.7 [#6ECEB2]: Bar CapEx (Flat bar, no border, square corners, bottom at baseline 51.2%; colour about.)
- shape at x 25.4, y 45.4, w 4.4, h 5.8 [#0C2340]: Bar Dividends Paid (Flat bar, no border, square corners, bottom at baseline 51.2%.)
- shape at x 33.3, y 32.1, w 4.3, h 19.2 [#688CE8]: Bar Business Development (ex-divestitures), highlighted (Flat bar, no border, square corners, tallest bar, bottom at baseline 51.2%.)
- shape at x 41.2, y 48.8, w 4.4, h 2.4 [#66B5EE]: Bar Share Repurchase (Flat bar, no border, square corners, colour about, bottom at baseline 51.2%.)
- line at x 7.8, y 51.2, w 39.5, h 0.2 [#C8CDD4]: Chart baseline under the left bars (Thin horizontal axis line, no tick marks.)
- caption at x 5.1, y 29.5, w 2, h 22.2 [Invention Regular; font size 1.67% of slide height; #0C2340; right aligned]: $30 / $25 / $20 / $15 / $10 / $5 / $0 (Y-axis tick labels stacked top to bottom at centres approximately 30.5, 34.6, 37.8, 41.2, 44.5, 48.0, 51.7 percent of slide height; $30 at y 29.5, $25 at y 33.0, $20 at y 36.5, $15 at y 40.0, $10 at y 43.5, $5 at y 47.0, $0 at y 50.5, each box w about 1.7 and h 1.7.)
- caption at x 3.7, y 37.8, w 1, h 6 [Invention Regular; font size 1.84% of slide height; #0C2340; center aligned]: Billions (Y-axis title rotated 90 degrees anticlockwise, reading upward.)
- body at x 34, y 33.5, w 3, h 1.8 [Invention Bold; font size 1.84% of slide height; #FFFFFF; center aligned]: $27.4 (Value label inside top of the highlighted bar.)
- body at x 10.5, y 43.1, w 2.9, h 1.8 [Invention Bold; font size 1.84% of slide height; #FFFFFF; center aligned]: $13.8 (Value label inside top of the After-Tax R&D bar.)
- body at x 26.3, y 46.9, w 2.5, h 1.8 [Invention Bold; font size 1.84% of slide height; #FFFFFF; center aligned]: $8.4 (Value label inside top of the Dividends Paid bar.)
- body at x 18.4, y 49.1, w 2.5, h 1.8 [Invention Bold; font size 1.84% of slide height; #FFFFFF; center aligned]: $4.0 (Value label inside the CapEx bar.)
- body at x 42.4, y 49.3, w 2.4, h 1.8 [Invention Bold; font size 1.84% of slide height; #FFFFFF; center aligned]: $3.5 (Value label inside the Share Repurchase bar.)
- caption at x 8.5, y 53, w 6.5, h 1.7 [Invention Regular; font size 1.67% of slide height; #0C2340; center aligned]: After-Tax R&D 2 (Category label under bar, with superscript 2 at the end.)
- caption at x 18.4, y 53, w 2.7, h 1.7 [Invention Regular; font size 1.67% of slide height; #0C2340; center aligned]: CapEx
- caption at x 25.5, y 53, w 4.2, h 4 [Invention Regular; font size 1.67% of slide height; #0C2340; center aligned]: Dividends / Paid
- caption at x 31.9, y 53, w 7.1, h 4.6 [Invention Regular; font size 1.67% of slide height; #0C2340; center aligned]: Business 3 / Development / (ex-divestitures) (Category label under bar, three lines, superscript 3 after Business.)
- caption at x 39.4, y 53, w 7.7, h 1.7 [Invention Regular; font size 1.67% of slide height; #0C2340; center aligned]: Share Repurchase
- shape at x 3.1, y 59.6, w 44.8, h 0.5 [#0C2340]: Navy rule under left column (Flat horizontal bar, about 0.5% of slide height thick.)
- line at x 49.9, y 22.4, w 0.2, h 70 [#D0D5DD]: Vertical dotted divider between columns (Dotted vertical line, small round dots, about 0.2% wide.)
- shape at x 52, y 22.4, w 44.9, h 0.6 [#688CE8]: Blue rule above right column (Flat horizontal bar, about 0.6% of slide height thick.)
- body at x 32.5, y 31.5, w 35, h 16 [Invention Regular, with the phrase 'additional value-enhancing business development' in Invention Bold; font size 3.71% of slide height; #0C2340; center aligned]: Well-positioned balance sheet with / capacity to fund additional value- / enhancing business development / opportunities (Centred statement; the bold phrase 'additional value-enhancing business development' is coloured #688CE8; the rest is navy #0C2340.)
- shape at x 52, y 59.6, w 44.9, h 0.5 [#6ECEB2]: Light green rule above dividend chart (Flat horizontal bar, about 0.5% of slide height thick.)
- body at x 3.1, y 61.7, w 15.1, h 3 [Invention Bold, sentence case; font size 2.96% of slide height; #0C2340; left aligned]: Capital investments
- body at x 3.1, y 65.2, w 8.7, h 2.6 [Invention Regular, sentence case; font size 2.6% of slide height; #0C2340; left aligned]: 2026 to 2030
- body at x 17.1, y 69.5, w 16.8, h 10 [Invention Bold, sentence case; font size 10% of slide height; #0C2340; center aligned]: ~$19B
- shape at x 6, y 81, w 39, h 0.3 [#D0D5DD]: Light grey rule under the big figure (Flat horizontal line, no border.)
- body at x 6.6, y 82.4, w 37.8, h 3 [Invention Regular, sentence case; font size 2.96% of slide height; #0C2340; center aligned]: Over 5 years, including more than $14B in the U.S.
- body at x 52, y 61.7, w 20.3, h 3 [Invention Bold, sentence case; font size 2.96% of slide height; #6ECEB2; left aligned]: Committed to the dividend
- chart at x 55, y 65.3, w 39.3, h 24.4 [#6ECEB2]: Column chart of annual dividend growth percentages, 2017 to 2026, ten light green columns (Columns from left to right: 2017 +2% top about 76.1%, 2018 +2% top about 75.6%, 2019 +15% top about 72.5%, 2020 +11% top about 70.6%, 2021 +7% top about 70.7%, 2022 +6% top about 69.8%, 2023 +6% top about 68.6%, 2024 +5% top about 67.5%, 2025 +5% top about 66.3%, 2026 +5% top about 65.2%; column heights are estimates, none printed. Each column about 3.1% wide with about 1.0% gaps, flat, no border, square corners. Baseline at 89.6% in dark grey #3A3F47 with small tick marks between columns. No legend, no y-axis, no gridlines.)
- caption at x 55.3, y 62.8, w 36.6, h 11.3 [Invention Bold; font size 1.84% of slide height; #6ECEB2; center aligned]: +2% / +2% / +15% / +11% / +7% / +6% / +6% / +5% / +5% / +5% (Value labels above each column, each sitting just above its column: +2% at x 55.3 y 74.1; +2% at x 59.4 y 73.6; +15% at x 63.2 y 71.6; +11% at x 67.3 y 69.7; +7% at x 71.5 y 68.8; +6% at x 75.4 y 67.7; +6% at x 79.6 y 66.1; +5% at x 83.7 y 65.3; +5% at x 87.6 y 63.9; +5% at x 91.7 y 62.9; each about 2.2 wide, 1.8 high.)
- caption at x 55.6, y 91.4, w 38.6, h 1.7 [Invention Regular; font size 1.67% of slide height; #0C2340; center aligned]: 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 (Year labels under each column, centred: 2017 at x 55.6, 2018 at x 59.5, 2019 at x 63.6, 2020 at x 67.5, 2021 at x 71.7, 2022 at x 75.6, 2023 at x 79.6, 2024 at x 83.6, 2025 at x 87.7, 2026 at x 91.7; each about 2.1 wide, at y 91.4.)
- footer at x 3.1, y 94.4, w 88.2, h 3.5 [Invention Regular, sentence case; font size 1.67% of slide height; #0C2340; left aligned]: 1. Reflects trailing twelve months spend subject to finalization of the Company’s statement of cash flows 2. Reflects R&D excluding Business Development 3. Includes BD payments reflected in operating cash / flow (Two-line footnote, the second line containing only 'flow'.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Teal four-lobed rounded company logo mark (Image 125 by 150 pixels, placed bottom-right, not cropped, no boxing.)
- page number at x 96.1, y 95.5, w 0.8, h 1.3 [Invention Regular; font size 1.29% of slide height; #9EA7B3; right aligned]: 26

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 55.0, y 65.3, w 39.3, h 24.4: #6ECEB2
- fill at x 9.6, y 41.6, w 4.3, h 9.6: #00857C
- fill at x 33.3, y 32.1, w 4.3, h 19.2: #688CE8
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 6.7, w 64.5, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Executing upon balanced capital allocation strategy
- text at x 3.1, y 6.7, w 51.8, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Capital allocation: Trailing twelve months
- text at x 17.1, y 69.5, w 16.8, h 10.0 [Invention-Bold; font size 10.00; #0C2340]: ~$19B
- text at x 3.1, y 23.7, w 18.3, h 3.0 [Invention-Bold; font size 2.96; #00857C]: Over the past 12 months
- text at x 58.2, y 31.5, w 33.6, h 7.7 [Invention-Regular; font size 3.71; #0C2340]: Well-positioned balance sheet with capacity to fund
- text at x 58.7, y 35.5, w 32.6, h 7.7 [Invention-Bold; font size 3.71; #688CE8]: additional value-enhancing business development
- text at x 68.4, y 43.5, w 12.9, h 3.7 [Invention-Regular; font size 3.71; #0C2340]: opportunities
- text at x 21.4, y 23.6, w 0.4, h 2.0 [Invention-Regular; font size 1.98; #00857C]: 1
- text at x 15.4, y 28.6, w 19.6, h 2.2 [Invention-Bold; font size 2.22; #00857C]: Capital allocation order of priority
- text at x 5.1, y 29.5, w 1.7, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: $30
- text at x 34.0, y 33.5, w 3.0, h 1.8 [Invention-Bold; font size 1.84; #FFFFFF]: $27.4
- text at x 5.2, y 33.0, w 1.7, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: $25
- text at x 3.1, y 61.7, w 15.1, h 3.0 [Invention-Bold; font size 2.96; #0C2340]: Capital investments
- text at x 52.0, y 61.7, w 20.3, h 3.0 [Invention-Bold; font size 2.96; #6ECEB2]: Committed to the dividend
- text at x 3.7, y 37.8, w 1.0, h 6.0 [Invention-Regular; font size 1.84; #0C2340]: Billions
- text at x 5.1, y 36.5, w 1.7, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: $20
- text at x 10.5, y 43.1, w 2.9, h 1.8 [Invention-Bold; font size 1.84; #FFFFFF]: $13.8
- text at x 5.4, y 40.0, w 1.5, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: $15
- text at x 3.1, y 65.2, w 8.7, h 2.6 [Invention-Regular; font size 2.60; #0C2340]: 2026 to 2030
- text at x 26.3, y 46.9, w 2.5, h 1.8 [Invention-Bold; font size 1.84; #FFFFFF]: $8.4
- text at x 5.3, y 43.5, w 1.6, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: $10
- text at x 18.4, y 49.1, w 2.5, h 1.8 [Invention-Bold; font size 1.84; #FFFFFF]: $4.0
- text at x 42.4, y 49.3, w 2.4, h 1.8 [Invention-Bold; font size 1.84; #FFFFFF]: $3.5
- text at x 5.7, y 47.0, w 1.1, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: $5
- text at x 6.6, y 82.4, w 37.8, h 3.0 [Invention-Regular; font size 2.96; #0C2340]: Over 5 years, including more than $14B in the U.S.
- text at x 5.7, y 50.5, w 1.2, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: $0
- text at x 8.5, y 53.0, w 6.5, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: After-Tax R&D
- text at x 18.4, y 53.0, w 2.7, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: CapEx
- text at x 25.5, y 53.0, w 4.2, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Dividends
- text at x 33.6, y 53.0, w 3.8, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Business
- text at x 39.4, y 53.0, w 7.7, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Share Repurchase
- text at x 26.6, y 55.3, w 1.9, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Paid
- text at x 32.6, y 55.3, w 5.7, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: Development
- text at x 91.7, y 62.9, w 2.2, h 1.8 [Invention-Bold; font size 1.84; #6ECEB2]: +5%
- text at x 31.9, y 57.6, w 7.1, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: (ex-divestitures)
- text at x 87.6, y 63.9, w 2.2, h 1.8 [Invention-Bold; font size 1.84; #6ECEB2]: +5%
- text at x 83.7, y 65.3, w 2.2, h 1.8 [Invention-Bold; font size 1.84; #6ECEB2]: +5%
- text at x 79.6, y 66.1, w 2.2, h 1.8 [Invention-Bold; font size 1.84; #6ECEB2]: +6%
- text at x 75.4, y 67.7, w 2.2, h 1.8 [Invention-Bold; font size 1.84; #6ECEB2]: +6%
- text at x 71.5, y 68.8, w 2.1, h 1.8 [Invention-Bold; font size 1.84; #6ECEB2]: +7%
- text at x 67.3, y 69.7, w 2.4, h 1.8 [Invention-Bold; font size 1.84; #6ECEB2]: +11%
- text at x 63.2, y 71.6, w 2.6, h 1.8 [Invention-Bold; font size 1.84; #6ECEB2]: +15%
- text at x 55.3, y 74.1, w 2.1, h 1.8 [Invention-Bold; font size 1.84; #6ECEB2]: +2%
- text at x 59.4, y 73.6, w 2.1, h 1.8 [Invention-Bold; font size 1.84; #6ECEB2]: +2%
- text at x 15.3, y 53.0, w 0.3, h 1.1 [Invention-Regular; font size 1.11; #0C2340]: 2
- text at x 37.6, y 53.0, w 0.4, h 1.1 [Invention-Regular; font size 1.11; #000000]: 3
- text at x 55.6, y 91.4, w 2.0, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 2017
- text at x 59.5, y 91.4, w 2.1, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 2018
- text at x 63.6, y 91.4, w 2.1, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 2019
- text at x 67.5, y 91.4, w 2.2, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 2020
- text at x 71.7, y 91.4, w 2.0, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 2021
- text at x 75.6, y 91.4, w 2.2, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 2022
- text at x 79.6, y 91.4, w 2.2, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 2023
- text at x 83.6, y 91.4, w 2.2, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 2024
- text at x 87.7, y 91.4, w 2.2, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 2025
- text at x 91.7, y 91.4, w 2.2, h 1.7 [Invention-Regular; font size 1.67; #0C2340]: 2026
- text at x 3.1, y 94.4, w 88.2, h 3.5 [Invention-Regular; font size 1.67; #0C2340]: 1. Reflects trailing twelve months spend subject to finalization of the Company’s statement of cash flows 2. Reflects R&D excluding Business Development 3. Includes BD payments reflected in operating cash flow
- text at x 96.1, y 95.5, w 0.8, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 26

### Slide 27

**Review notes**

- Review: Weaknesses are consequential: several pages are dense or small (slides 3, 14, 15, 22, 27, 28), slide 8's launch chart has an unexplained hatched box and no growth label, and pale mint bars with white labels on slides 10 to 13 are weaker in contrast.
- What would change the score: Cut or split the dense pipeline and milestone pages (slides 22 and 27) and give slide 16 and the text-light chart pages a visual anchor so whitespace reads as design rather than leftover room.

**Text**

Broad and innovative pipeline to address significant unmet medical needs / Phase 2 / Phase 3 / Under regulatory review / Oncology / Cardiometabolic & Respiratory / Immunology / Infectious Diseases / Ophthalmology / Vaccines / Neuroscience / Oncology / MK-1022 (patritumab deruxtecan) / Bladder / Cervical / Esophageal / Gastric / Melanoma / NSCLC / MK-1045 / Hematological Malignancies / MK-1084 (calderasib) / Solid Tumors / MK-2010 / Solid Tumors / MK-2400 (ifinatamab deruxtecan) / Bladder / Endometrial / HCC / HNSCC / Melanoma / NSCLC / Ovarian / Solid Tumors / MK-2870 (sacituzumab tirumotecan) / Biliary / Esophageal / Neoplasm Malignant / KEYTRUDA (MK-3475) / Prostate / KEYTRUDA QLEX (MK-3475A) / Hematological Malignancies (U.S.) / MK-5684 (opevesostat) / Breast / Endometrial / Ovarian / MK-5909 (raludotatug deruxtecan) / Cervical / Endometrial / Gastric / NSCLC / SCLC / MK-6070 (gocatamig) / SCLC / WELIREG (MK-6482) / Breast / V940 (intismeran autogene) / Bladder / RCC / Neuroscience / MK-2214 / Alzheimer’s Disease / Cardiometabolic & Respiratory / MK-5884A (ensifentrine + glycopyrrolate) / COPD / MK-6024 (efinopegdutide) / MASH / MK-7262 / Atherosclerosis / WINREVAIR (MK-7962) / Pulmonary Hypertension due to Left Heart Disease / Immunology / MK-7240 (tulisokibart) / Axial Spondyloarthritis / Hidradenitis Suppurativa / Psoriatic Arthritis / Rheumatoid Arthritis / MK-8690 / Ulcerative Colitis / Infectious Diseases / MK-8591B (islatravir + ulonivirine) / HIV-1 Infection / Oncology / MK-1022 (patritumab deruxtecan) / Breast / MK-1026 (nemtabrutinib) / Hematological Malignancies / MK-1084 (calderasib) / CRC / NSCLC / MK-2140 (zilovertamab vedotin) / Hematological Malignancies / MK-2400 (ifinatamab deruxtecan) / Esophageal / Prostate / SCLC / MK-2870 (sacituzumab tirumotecan) / Bladder / Breast / Cervical / Endometrial (EU) / Gastric / NSCLC / Ovarian / KEYTRUDA (MK-3475) / SCLC / MK-3543 (bomedemstat) / Myeloproliferative Disorders / MK-5684 (opevesostat) / Prostate / MK-5909 (raludotatug deruxtecan) / Ovarian / LYNPARZA (MK-7339) / NSCLC / SCLC / V940 (intismeran autogene) / Melanoma / NSCLC / Ophthalmology / MK-3000 (remigromig) / Diabetic Macular Edema / MK-8748 / Neovascular Age-Related Macular Degeneration / Cardiometabolic & Respiratory / OHTUVAYRE (MK-5884) / COPD (EU) / Immunology / MK-7240 (tulisokibart) / Crohn’s Disease / Ulcerative Colitis / Infectious Diseases / MK-1406 (efitazanamivir alfa) / Influenza / LAGEVRIO (MK-4482) / COVID-19 (U.S.) / MK-8527 (alimatravir) / HIV-1 PrEP / MK-8591D (islatravir + lenacapavir) / HIV-1 Infection / Vaccines / V181 / Dengue Fever Virus / Oncology / MK-2870 (sacituzumab tirumotecan) / Previously Treated Endometrial (U.S.) / KEYTRUDA (MK-3475) / Cisplatin Eligible MIBC (JPN) / Cisplatin Ineligible MIBC (JPN) / Newly Diagnosed High-Risk Endometrial (EU) / WELIREG (MK-6482) / Clear Cell RCC Following Nephrectomy (EU, JPN) / Previously Treated Advanced RCC (EU, JPN) / Cardiometabolic & Respiratory / LIPFENDRA (MK-0616) / Hypercholesterolemia (EU, JPN) / Infectious Diseases / IDVYNSO (MK-8591A) / HIV-1 Infection (EU) / HIV-1 Infection (Treatment Naïve) (US) / Vaccines / ENFLONSIA MK-1654 / Respiratory Syncytial Virus (2nd Season) (US, EU, JPN) / 1. Being developed in a collaboration 2. On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials 3. Available in the U.S. under Emergency Use Authorization, which will terminate effective June 29, 2027 4. Program is in Phase 2/3 studies 5. Under review for combination use with KEYTRUDA 6. Under review in Japan for Lenvima, used in combination with WELIREG / As of November 4, 2026 / 27

**Layout**

Full-width navy title band across the top with the title left-aligned at about 3 percent margin. Below it three header bars span the content area in three columns: Phase 2 (two sub-columns, about 3 to 41 percent), Phase 3 (two sub-columns, about 41 to 79 percent) and Under regulatory review (one column, about 79 to 97 percent). Each column holds category headings in coloured Invention type with thin underlines, and pipeline entries listed beneath in two-line-spaced blocks. A date line sits right-aligned near the bottom right, a footnote block runs along the bottom left, and a logo and page number sit bottom right.

**Visuals**

None apart from a small teal logo mark at bottom right (approximately 92 to 95 percent x, 93 to 99 percent y), a stylised two-tone teal emblem. No charts, photographs or diagrams.

**Design**

Background: Solid white #FFFFFF. Flat white background with a full-width navy #0C2340 title band occupying the top 18.4 percent. Title in Invention Light, white #FFFFFF, sentence case, about 5.1 percent of slide height. Column header bars: Phase 2 teal #00857C, Phase 3 mint #6ECEB2, Under regulatory review periwinkle #688CE8, with white Invention Regular labels about 1.8 percent. Category headings: Oncology, Neuroscience and Infectious Diseases in teal #00857C or navy #0C2340; Cardiometabolic & Respiratory in indigo #5450E4; Immunology in light blue #69B8F7; Ophthalmology in periwinkle #688CE8; Vaccines in mint #6ECEB2; headings about 2.2 percent of slide height with thin underlines in matching colour (navy underline for Infectious Diseases). Body entries in Invention Regular about 1.5 percent: product codes in teal #00877C, indications in navy #0C2340. Superscript footnote markers about 1.0 percent. Footnote text in Invention Regular about 1.7 percent in navy #0C2340. Page number in grey #9EA7B3 about 1.3 percent. No shadows, gradients or rounded corners.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 100 [#FFFFFF]: Full-slide background rectangle (Flat fill, no outline, sits behind everything.)
- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Navy title band rectangle (Flat fill, no outline, full width.)
- shape at x 3.1, y 20.8, w 36.6, h 4.4 [#00857C]: Phase 2 header bar with label Phase 2 centred (Flat fill, no outline, square corners; label white Invention Regular about 1.84 percent centred.)
- shape at x 41.3, y 20.8, w 36.6, h 4.4 [#6ECEB2]: Phase 3 header bar with label Phase 3 centred (Flat fill, no outline, square corners; label white Invention Regular about 1.84 percent centred.)
- shape at x 79.4, y 20.8, w 17.5, h 4.4 [#688CE8]: Under regulatory review header bar with label Under regulatory review centred (Flat fill, no outline, square corners; label white Invention Regular about 1.84 percent centred.)
- title at x 3.1, y 6.7, w 92.3, h 5.1 [Invention Light, regular weight, sentence case; font size 5.09% of slide height; #FFFFFF; left aligned]: Broad and innovative pipeline to address significant unmet medical needs
- body at x 3.1, y 27, w 12.5, h 55.5 [Invention Regular; font size 1.49% of slide height; #0C2340; left aligned]: Oncology / MK-1022 (patritumab deruxtecan) / Bladder / Cervical / Esophageal / Gastric / Melanoma / NSCLC / MK-1045 / Hematological Malignancies / MK-1084 (calderasib) / Solid Tumors / MK-2010 / Solid Tumors / MK-2400 (ifinatamab deruxtecan) / Bladder / Endometrial / HCC / HNSCC / Melanoma / NSCLC / Ovarian / Solid Tumors / MK-2870 (sacituzumab tirumotecan) / Biliary / Esophageal / Neoplasm Malignant (Heading Oncology at 2.22 percent in teal #00857C with underline. Product codes in teal #00877C, indications in navy #0C2340. Superscript 1 after MK-1022 and MK-2400. Line spacing about 2.2 percent between entries.)
- body at x 15.5, y 30.3, w 11.7, h 56.8 [Invention Regular; font size 1.49% of slide height; #0C2340; left aligned]: KEYTRUDA (MK-3475) / Prostate / KEYTRUDA QLEX (MK-3475A) / Hematological Malignancies (U.S.) / MK-5684 (opevesostat) / Breast / Endometrial / Ovarian / MK-5909 (raludotatug deruxtecan) / Cervical / Endometrial / Gastric / NSCLC / SCLC / MK-6070 (gocatamig) / SCLC / WELIREG (MK-6482) / Breast / V940 (intismeran autogene) / Bladder / RCC / Neuroscience / MK-2214 / Alzheimer’s Disease (Neuroscience heading at x 15.2 y 79.9 in light blue #688CE8 at 2.22 percent with underline. Product codes teal #00877C, indications navy #0C2340.)
- body at x 27.9, y 32.9, w 11.2, h 18.5 [Invention Regular; font size 1.49% of slide height; #0C2340; left aligned]: MK-5884A (ensifentrine + glycopyrrolate) / COPD / MK-6024 (efinopegdutide) / MASH / MK-7262 / Atherosclerosis / WINREVAIR (MK-7962) / Pulmonary Hypertension due to Left Heart Disease (Heading Cardiometabolic & Respiratory in indigo #5450E4 at 2.22 percent with underline at x 27.9 y 27.0. Product codes teal #00877C, indications navy.)
- body at x 27.9, y 56.2, w 11.2, h 14 [Invention Regular; font size 1.49% of slide height; #0C2340; left aligned]: Immunology / MK-7240 (tulisokibart) / Axial Spondyloarthritis / Hidradenitis Suppurativa / Psoriatic Arthritis / Rheumatoid Arthritis / MK-8690 / Ulcerative Colitis (Immunology heading in light blue #69B8F7 at 2.22 percent with underline. MK-7240 and MK-8690 in teal #00877C.)
- body at x 27.9, y 75, w 10.9, h 6 [Invention Regular; font size 1.49% of slide height; #0C2340; left aligned]: Infectious Diseases / MK-8591B (islatravir + ulonivirine) / HIV-1 Infection (Heading Infectious Diseases in navy #0C2340 at 2.22 percent with navy underline. Product code teal #00877C.)
- body at x 41.3, y 27, w 12.5, h 47 [Invention Regular; font size 1.49% of slide height; #0C2340; left aligned]: Oncology / MK-1022 (patritumab deruxtecan) / Breast / MK-1026 (nemtabrutinib) / Hematological Malignancies / MK-1084 (calderasib) / CRC / NSCLC / MK-2140 (zilovertamab vedotin) / Hematological Malignancies / MK-2400 (ifinatamab deruxtecan) / Esophageal / Prostate / SCLC / MK-2870 (sacituzumab tirumotecan) / Bladder / Breast / Cervical / Endometrial (EU) / Gastric / NSCLC / Ovarian (Heading Oncology teal #00857C at 2.22 percent with underline. Product codes teal #00877C, indications navy #0C2340.)
- body at x 53.7, y 30.3, w 11, h 25 [Invention Regular; font size 1.49% of slide height; #0C2340; left aligned]: KEYTRUDA (MK-3475) / SCLC / MK-3543 (bomedemstat) / Myeloproliferative Disorders / MK-5684 (opevesostat) / Prostate / MK-5909 (raludotatug deruxtecan) / Ovarian / LYNPARZA (MK-7339) / NSCLC / SCLC / V940 (intismeran autogene) / Melanoma / NSCLC (Product codes teal #00877C, indications navy #0C2340.)
- body at x 53.7, y 66.4, w 12, h 9.5 [Invention Regular; font size 1.49% of slide height; #0C2340; left aligned]: Ophthalmology / MK-3000 (remigromig) / Diabetic Macular Edema / MK-8748 / Neovascular Age-Related Macular Degeneration (Heading Ophthalmology in periwinkle #688CE8 at 2.22 percent with underline. MK-3000 and MK-8748 teal #00877C; superscript 4 after each code.)
- body at x 65.9, y 27, w 12.5, h 43 [Invention Regular; font size 1.49% of slide height; #0C2340; left aligned]: Cardiometabolic & Respiratory / OHTUVAYRE (MK-5884) / COPD (EU) / Immunology / MK-7240 (tulisokibart) / Crohn’s Disease / Ulcerative Colitis / Infectious Diseases / MK-1406 (efitazanamivir alfa) / Influenza / LAGEVRIO (MK-4482) / COVID-19 (U.S.) / MK-8527 (alimatravir) / HIV-1 PrEP / MK-8591D (islatravir + lenacapavir) / HIV-1 Infection (Cardiometabolic & Respiratory heading indigo #5450E4, Immunology heading light blue #69B8F7, Infectious Diseases heading navy #0C2340 with navy underline, all about 2.22 percent. Product codes teal #00877C.)
- body at x 66.1, y 74.8, w 9, h 6 [Invention Regular; font size 1.49% of slide height; #0C2340; left aligned]: Vaccines / V181 / Dengue Fever Virus (Heading Vaccines in mint #6ECEB2 at 2.22 percent with mint underline. V181 teal #00877C.)
- body at x 79.4, y 27, w 17.5, h 21.5 [Invention Regular; font size 1.49% of slide height; #0C2340; left aligned]: Oncology / MK-2870 (sacituzumab tirumotecan) / Previously Treated Endometrial (U.S.) / KEYTRUDA (MK-3475) / Cisplatin Eligible MIBC (JPN) / Cisplatin Ineligible MIBC (JPN) / Newly Diagnosed High-Risk Endometrial (EU) / WELIREG (MK-6482) / Clear Cell RCC Following Nephrectomy (EU, JPN)5 / Previously Treated Advanced RCC (EU, JPN)1,6 (Heading Oncology teal #00857C at 2.22 percent with underline. Product codes teal #00877C, indications navy #0C2340.)
- body at x 79.4, y 51.5, w 17.5, h 7.5 [Invention Regular; font size 1.49% of slide height; #0C2340; left aligned]: Cardiometabolic & Respiratory / LIPFENDRA (MK-0616) / Hypercholesterolemia (EU, JPN) (Heading indigo #5450E4 at 2.22 percent with underline. LIPFENDRA teal #00877C.)
- body at x 79.4, y 63.4, w 17.5, h 8 [Invention Regular; font size 1.49% of slide height; #0C2340; left aligned]: Infectious Diseases / IDVYNSO (MK-8591A) / HIV-1 Infection (EU) / HIV-1 Infection (Treatment Naïve) (US) (Heading navy with navy underline at 2.22 percent. IDVYNSO teal #00877C.)
- body at x 79.4, y 74.7, w 17.5, h 7 [Invention Regular; font size 1.49% of slide height; #0C2340; left aligned]: Vaccines / ENFLONSIA MK-1654 / Respiratory Syncytial Virus (2nd Season) (US, EU, JPN) (Heading Vaccines mint #6ECEB2 at 2.22 percent with mint underline. ENFLONSIA MK-1654 teal #00877C.)
- body at x 3.1, y 95.6, w 87.1, h 3.4 [Invention Regular; font size 1.67% of slide height; #0C2340; left aligned]: 1. Being developed in a collaboration 2. On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials 3. Available in the U.S. under Emergency Use Authorization, which will terminate effective June 29, 2027 4. Program is in Phase 2/3 studies 5. Under review for combination use with KEYTRUDA 6. Under review in Japan for Lenvima, used in combination with WELIREG (Two lines of footnotes, running text separated by spaces, no bullets.)
- body at x 86.8, y 89.9, w 9.2, h 1.5 [Invention Regular; font size 1.49% of slide height; #0C2340; right aligned]: As of November 4, 2026 (Date line, right-aligned to about 96 percent x.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#00857C]: Teal logo mark, stylised two-tone emblem (Raster image 125 by 150 pixels, flat teal, no crop.)
- footer at x 96.1, y 95.7, w 0.8, h 1.3 [Invention Regular; font size 1.29% of slide height; #9EA7B3; right aligned]: 27 (Page number in grey.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- fill at x 79.4, y 20.8, w 17.5, h 4.4: #688CE8
- fill at x 41.3, y 20.8, w 36.6, h 4.4: #6ECEB2
- fill at x 3.1, y 20.8, w 36.6, h 4.4: #00857C
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 6.7, w 92.3, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Broad and innovative pipeline to address significant unmet medical needs
- text at x 3.1, y 27.0, w 5.3, h 2.2 [Invention-Regular; font size 2.22; #00857C]: Oncology
- text at x 19.6, y 22.2, w 3.7, h 1.8 [Invention-Regular; font size 1.84; #FFFFFF]: Phase 2
- text at x 41.3, y 27.0, w 5.6, h 2.2 [Invention-Regular; font size 2.22; #00857C]: Oncology
- text at x 57.7, y 22.2, w 3.7, h 1.8 [Invention-Regular; font size 1.84; #FFFFFF]: Phase 3
- text at x 59.9, y 22.2, w 3.7, h 1.8 [Invention-Regular; font size 1.84; #FFFFFF]: Phase 3
- text at x 79.4, y 27.0, w 5.3, h 2.2 [Invention-Regular; font size 2.22; #00857C]: Oncology
- text at x 82.5, y 22.2, w 11.4, h 1.8 [Invention-Regular; font size 1.84; #FFFFFF]: Under regulatory review
- text at x 27.9, y 27.0, w 10.8, h 4.6 [Invention-Regular; font size 2.22; #5450E4]: Cardiometabolic & Respiratory
- text at x 65.9, y 27.0, w 10.8, h 4.6 [Invention-Regular; font size 2.22; #5450E4]: Cardiometabolic & Respiratory
- text at x 66.1, y 37.8, w 7.4, h 2.2 [Invention-Regular; font size 2.22; #69B8F7]: Immunology
- text at x 15.5, y 30.3, w 8.8, h 1.5 [Invention-Regular; font size 1.49; #00877C]: KEYTRUDA (MK-3475)
- text at x 53.7, y 30.6, w 8.8, h 1.5 [Invention-Regular; font size 1.49; #00877C]: KEYTRUDA (MK-3475)
- text at x 79.4, y 30.3, w 14.0, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-2870 (sacituzumab tirumotecan)
- text at x 3.1, y 30.3, w 8.4, h 3.1 [Invention-Regular; font size 1.49; #00877C]: MK-1022 (patritumab deruxtecan)
- text at x 41.3, y 30.3, w 8.4, h 3.1 [Invention-Regular; font size 1.49; #00877C]: MK-1022 (patritumab deruxtecan)
- text at x 15.5, y 31.9, w 3.3, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Prostate
- text at x 53.7, y 32.2, w 2.2, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: SCLC
- text at x 66.1, y 48.3, w 11.5, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: Infectious Diseases
- text at x 79.4, y 31.9, w 14.3, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Previously Treated Endometrial (U.S.)
- text at x 65.9, y 32.9, w 9.6, h 1.5 [Invention-Regular; font size 1.49; #00877C]: OHTUVAYRE (MK-5884)
- text at x 3.1, y 33.5, w 3.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Bladder
- text at x 27.9, y 32.9, w 10.2, h 3.1 [Invention-Regular; font size 1.49; #00877C]: MK-5884A (ensifentrine + glycopyrrolate)
- text at x 41.3, y 33.5, w 2.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Breast
- text at x 65.9, y 34.5, w 4.2, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: COPD (EU)
- text at x 3.1, y 35.1, w 3.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Cervical
- text at x 15.5, y 35.1, w 11.7, h 1.5 [Invention-Regular; font size 1.49; #00877C]: KEYTRUDA QLEX (MK-3475A)
- text at x 79.4, y 35.1, w 8.8, h 1.5 [Invention-Regular; font size 1.49; #00877C]: KEYTRUDA (MK-3475)
- text at x 79.4, y 51.5, w 10.8, h 4.6 [Invention-Regular; font size 2.22; #5450E4]: Cardiometabolic & Respiratory
- text at x 53.7, y 35.4, w 9.7, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-3543 (bomedemstat)
- text at x 3.1, y 36.8, w 4.4, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Esophageal
- text at x 27.9, y 36.1, w 2.3, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: COPD
- text at x 41.3, y 36.7, w 9.7, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-1026 (nemtabrutinib)
- text at x 79.4, y 36.8, w 10.8, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Cisplatin Eligible MIBC (JPN)
- text at x 15.5, y 36.8, w 10.7, h 3.1 [Invention-Regular; font size 1.49; #0C2340]: Hematological Malignancies (U.S.)
- text at x 53.7, y 37.0, w 10.8, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Myeloproliferative Disorders
- text at x 27.9, y 56.2, w 7.4, h 2.2 [Invention-Regular; font size 2.22; #69B8F7]: Immunology
- text at x 3.1, y 38.4, w 2.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Gastric
- text at x 41.3, y 38.3, w 10.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Hematological Malignancies
- text at x 79.4, y 38.4, w 11.4, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Cisplatin Ineligible MIBC (JPN)
- text at x 27.9, y 39.3, w 10.2, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-6024 (efinopegdutide)
- text at x 3.1, y 40.0, w 4.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Melanoma
- text at x 53.7, y 40.4, w 9.1, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-5684 (opevesostat)
- text at x 79.4, y 40.0, w 17.1, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Newly Diagnosed High-Risk Endometrial (EU)
- text at x 27.9, y 40.9, w 2.4, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: MASH
- text at x 66.1, y 41.1, w 8.7, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-7240 (tulisokibart)
- text at x 3.1, y 41.6, w 2.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: NSCLC
- text at x 15.5, y 41.6, w 9.1, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-5684 (opevesostat)
- text at x 41.3, y 41.5, w 7.8, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-1084 (calderasib
- text at x 49.1, y 41.5, w 0.3, h 1.5 [Invention-Regular; font size 1.49; #00857C]: )
- text at x 53.7, y 42.0, w 3.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Prostate
- text at x 66.1, y 42.7, w 6.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Crohn’s Disease
- text at x 79.4, y 63.4, w 11.5, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: Infectious Diseases
- text at x 15.5, y 43.2, w 2.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Breast
- text at x 41.3, y 43.1, w 1.6, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: CRC
- text at x 79.4, y 43.2, w 8.2, h 1.5 [Invention-Regular; font size 1.49; #00877C]: WELIREG (MK-6482)
- text at x 27.9, y 44.1, w 3.5, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-7262
- text at x 66.1, y 44.3, w 6.3, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Ulcerative Colitis
- text at x 3.1, y 44.8, w 3.5, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-1045
- text at x 15.5, y 44.8, w 4.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Endometrial
- text at x 41.3, y 44.8, w 2.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: NSCLC
- text at x 53.7, y 66.4, w 9.2, h 2.2 [Invention-Regular; font size 2.22; #688CE8]: Ophthalmology
- text at x 27.9, y 45.7, w 5.9, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Atherosclerosis
- text at x 79.4, y 44.7, w 16.5, h 3.1 [Invention-Regular; font size 1.49; #0C2340]: Clear Cell RCC Following Nephrectomy (EU, JPN)
- text at x 3.1, y 46.4, w 10.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Hematological Malignancies
- text at x 15.5, y 46.4, w 2.9, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Ovarian
- text at x 53.7, y 45.2, w 8.8, h 3.1 [Invention-Regular; font size 1.49; #00877C]: MK-5909 (raludotatug deruxtecan)
- text at x 79.4, y 47.9, w 16.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Previously Treated Advanced RCC (EU, JPN)
- text at x 7.7, y 31.9, w 0.2, h 1.0 [Invention-Regular; font size 0.98; #00877C]: 1
- text at x 41.3, y 47.9, w 9.1, h 3.1 [Invention-Regular; font size 1.49; #00877C]: MK-2140 (zilovertamab vedotin)
- text at x 45.9, y 31.9, w 0.2, h 1.0 [Invention-Regular; font size 0.98; #00877C]: 1
- text at x 53.7, y 48.5, w 2.9, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Ovarian
- text at x 27.9, y 48.9, w 9.1, h 1.5 [Invention-Regular; font size 1.49; #00877C]: WINREVAIR (MK-7962)
- text at x 3.1, y 49.6, w 8.1, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-1084 (calderasib)
- text at x 66.1, y 74.8, w 5.2, h 2.2 [Invention-Regular; font size 2.22; #6ECEB2]: Vaccines
- text at x 79.4, y 74.7, w 5.2, h 2.2 [Invention-Regular; font size 2.22; #6ECEB2]: Vaccines
- text at x 15.5, y 49.6, w 8.8, h 3.1 [Invention-Regular; font size 1.49; #00877C]: MK-5909 (raludotatug deruxtecan)
- text at x 27.9, y 75.0, w 10.9, h 2.2 [Invention-Regular; font size 2.22; #0C2340]: Infectious Diseases
- text at x 3.1, y 51.2, w 5.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Solid Tumors
- text at x 27.9, y 50.5, w 11.2, h 3.1 [Invention-Regular; font size 1.49; #0C2340]: Pulmonary Hypertension due to Left Heart Disease
- text at x 41.3, y 51.2, w 10.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Hematological Malignancies
- text at x 66.1, y 51.5, w 11.2, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-1406 (efitazanamivir alfa)
- text at x 53.7, y 51.9, w 8.7, h 1.5 [Invention-Regular; font size 1.49; #00877C]: LYNPARZA (MK-7339)
- text at x 15.5, y 52.7, w 3.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Cervical
- text at x 66.1, y 53.1, w 3.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Influenza
- text at x 15.2, y 79.9, w 8.0, h 2.2 [Invention-Regular; font size 2.22; #688CE8]: Neuroscience
- text at x 53.7, y 53.5, w 2.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: NSCLC
- text at x 3.1, y 54.4, w 3.5, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-2010
- text at x 15.5, y 54.3, w 4.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Endometrial
- text at x 41.3, y 54.4, w 8.4, h 3.1 [Invention-Regular; font size 1.49; #00877C]: MK-2400 (ifinatamab deruxtecan)
- text at x 53.7, y 55.1, w 2.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: SCLC
- text at x 3.1, y 56.0, w 5.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Solid Tumors
- text at x 15.5, y 56.0, w 2.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Gastric
- text at x 66.1, y 56.3, w 8.6, h 1.5 [Invention-Regular; font size 1.49; #00877C]: LAGEVRIO (MK-4482)
- text at x 15.5, y 57.6, w 2.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: NSCLC
- text at x 41.3, y 57.5, w 4.4, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Esophageal
- text at x 79.4, y 57.0, w 9.1, h 1.5 [Invention-Regular; font size 1.49; #00877C]: LIPFENDRA (MK-0616)
- text at x 53.7, y 58.3, w 10.7, h 1.5 [Invention-Regular; font size 1.49; #00877C]: V940 (intismeran autogene)
- text at x 66.1, y 57.9, w 6.1, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: COVID-19 (U.S.)
- text at x 15.5, y 59.2, w 2.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: SCLC
- text at x 27.9, y 59.0, w 8.7, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-7240 (tulisokibart)
- text at x 41.3, y 59.1, w 3.3, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Prostate
- text at x 79.4, y 58.6, w 12.2, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Hypercholesterolemia (EU, JPN)
- text at x 3.1, y 58.6, w 8.4, h 3.1 [Invention-Regular; font size 1.49; #00877C]: MK-2400 (ifinatamab deruxtecan)
- text at x 53.7, y 59.9, w 4.1, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Melanoma
- text at x 27.9, y 60.6, w 8.6, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Axial Spondyloarthritis
- text at x 41.3, y 60.8, w 2.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: SCLC
- text at x 66.1, y 61.1, w 8.4, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-8527 (alimatravir)
- text at x 3.1, y 61.7, w 3.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Bladder
- text at x 15.5, y 62.2, w 8.4, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-6070 (gocatamig)
- text at x 53.7, y 61.5, w 2.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: NSCLC
- text at x 27.9, y 62.2, w 9.4, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Hidradenitis Suppurativa
- text at x 66.1, y 62.7, w 4.2, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: HIV-1 PrEP
- text at x 3.1, y 63.3, w 4.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Endometrial
- text at x 15.5, y 63.7, w 2.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: SCLC
- text at x 27.9, y 63.8, w 6.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Psoriatic Arthritis
- text at x 3.1, y 65.0, w 1.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: HCC
- text at x 41.3, y 64.1, w 9.0, h 3.1 [Invention-Regular; font size 1.49; #00877C]: MK-2870 (sacituzumab tirumotecan)
- text at x 27.9, y 65.4, w 8.1, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Rheumatoid Arthritis
- text at x 3.1, y 66.6, w 2.8, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: HNSCC
- text at x 15.5, y 66.9, w 8.2, h 1.5 [Invention-Regular; font size 1.49; #00877C]: WELIREG (MK-6482)
- text at x 66.1, y 65.9, w 8.7, h 3.1 [Invention-Regular; font size 1.49; #00877C]: MK-8591D (islatravir + lenacapavir)
- text at x 79.4, y 66.6, w 8.5, h 1.5 [Invention-Regular; font size 1.49; #00877C]: IDVYNSO (MK-8591A)
- text at x 41.3, y 67.5, w 3.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Bladder
- text at x 3.1, y 68.2, w 4.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Melanoma
- text at x 15.5, y 68.5, w 2.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Breast
- text at x 27.9, y 68.6, w 3.7, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-8690
- text at x 79.4, y 68.2, w 7.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: HIV-1 Infection (EU)
- text at x 41.3, y 69.3, w 2.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Breast
- text at x 66.1, y 69.1, w 5.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: HIV-1 Infection
- text at x 3.1, y 69.8, w 2.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: NSCLC
- text at x 27.9, y 70.2, w 6.3, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Ulcerative Colitis
- text at x 53.7, y 69.6, w 8.9, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-3000 (remigromig)
- text at x 79.4, y 69.8, w 14.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: HIV-1 Infection (Treatment Naïve) (US)
- text at x 41.3, y 71.1, w 3.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Cervical
- text at x 81.4, y 46.3, w 0.3, h 1.0 [Invention-Regular; font size 0.98; #0C2340]: 5
- text at x 3.1, y 71.4, w 2.9, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Ovarian
- text at x 15.5, y 71.7, w 10.7, h 1.5 [Invention-Regular; font size 1.49; #00877C]: V940 (intismeran autogene)
- text at x 53.7, y 71.2, w 9.1, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Diabetic Macular Edema
- text at x 58.3, y 46.7, w 0.2, h 1.0 [Invention-Regular; font size 0.98; #00877C]: 1
- text at x 3.1, y 73.0, w 5.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Solid Tumors
- text at x 41.3, y 72.8, w 6.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Endometrial (EU)
- text at x 96.2, y 47.9, w 0.7, h 1.0 [Invention-Regular; font size 0.98; #0C2340]: 1,6
- text at x 15.5, y 73.3, w 3.0, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Bladder
- text at x 41.3, y 74.6, w 2.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Gastric
- text at x 53.7, y 74.4, w 3.7, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-8748
- text at x 15.5, y 74.9, w 1.6, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: RCC
- text at x 3.1, y 76.2, w 9.0, h 3.1 [Invention-Regular; font size 1.49; #00877C]: MK-2870 (sacituzumab tirumotecan)
- text at x 41.3, y 76.4, w 2.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: NSCLC
- text at x 53.7, y 76.0, w 9.8, h 3.1 [Invention-Regular; font size 1.49; #0C2340]: Neovascular Age-Related Macular Degeneration
- text at x 20.1, y 51.1, w 0.2, h 1.0 [Invention-Regular; font size 0.98; #00877C]: 1
- text at x 41.3, y 78.2, w 2.9, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Ovarian
- text at x 66.1, y 78.3, w 1.7, h 1.5 [Invention-Regular; font size 1.49; #00877C]: V181
- text at x 79.4, y 78.1, w 8.3, h 1.5 [Invention-Regular; font size 1.49; #00877C]: ENFLONSIA MK-1654
- text at x 27.9, y 77.9, w 8.7, h 3.1 [Invention-Regular; font size 1.49; #00877C]: MK-8591B (islatravir + ulonivirine)
- text at x 62.4, y 51.9, w 0.2, h 1.0 [Invention-Regular; font size 0.98; #00877C]: 1
- text at x 3.1, y 79.4, w 2.4, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Biliary
- text at x 66.1, y 79.9, w 7.4, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Dengue Fever Virus
- text at x 79.4, y 79.7, w 11.1, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Respiratory Syncytial Virus (2
- text at x 79.4, y 79.7, w 17.0, h 3.1 [Invention-Regular; font size 1.49; #0C2340]: Season) (US, EU, JPN)
- text at x 3.1, y 81.0, w 4.4, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Esophageal
- text at x 27.9, y 81.1, w 5.7, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: HIV-1 Infection
- text at x 3.1, y 82.6, w 7.8, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Neoplasm Malignant
- text at x 15.2, y 82.9, w 3.4, h 1.5 [Invention-Regular; font size 1.49; #00877C]: MK-2214
- text at x 15.2, y 84.5, w 7.5, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: Alzheimer’s Disease
- text at x 45.9, y 55.9, w 0.2, h 1.0 [Invention-Regular; font size 0.98; #00877C]: 1
- text at x 74.7, y 56.3, w 0.7, h 1.0 [Invention-Regular; font size 0.98; #00877C]: 1,3
- text at x 3.1, y 95.6, w 87.1, h 3.4 [Invention-Regular; font size 1.67; #0C2340]: 1. Being developed in a collaboration 2. On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials 3. Available in the U.S. under Emergency Use Authorization, which will terminate effective June 29, 2027 4. Program is in Phase 2/3 studies 5. Under review for combination use with KEYTRUDA 6. Under review in Japan for Lenvima, used in combination with WELIREG
- text at x 64.4, y 58.3, w 0.2, h 1.0 [Invention-Regular; font size 0.98; #00877C]: 1
- text at x 86.8, y 89.9, w 9.2, h 1.5 [Invention-Regular; font size 1.49; #0C2340]: As of November 4, 2026
- text at x 7.7, y 60.1, w 0.2, h 1.0 [Invention-Regular; font size 0.98; #00877C]: 1
- text at x 23.9, y 62.1, w 0.2, h 1.0 [Invention-Regular; font size 0.98; #00877C]: 1
- text at x 70.7, y 67.5, w 0.7, h 1.0 [Invention-Regular; font size 0.98; #00877C]: 1,2
- text at x 62.6, y 69.6, w 0.3, h 1.0 [Invention-Regular; font size 0.98; #00877C]: 4
- text at x 26.2, y 71.7, w 0.2, h 1.0 [Invention-Regular; font size 0.98; #00877C]: 1
- text at x 96.1, y 95.7, w 0.8, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 27
- text at x 57.3, y 74.4, w 0.3, h 1.0 [Invention-Regular; font size 0.98; #00877C]: 4
- text at x 90.6, y 79.7, w 0.6, h 1.0 [Invention-Regular; font size 0.98; #0C2340]: nd

### Slide 28

**Review notes**

- Review: Weaknesses are consequential: several pages are dense or small (slides 3, 14, 15, 22, 27, 28), slide 8's launch chart has an unexplained hatched box and no growth label, and pale mint bars with white labels on slides 10 to 13 are weaker in contrast.

**Text**

Acronyms
AAO = American Academy of Ophthalmology
AASLD = American Association for the Study of Liver Diseases
ADC = Antibody-drug conjugate
B7-H3 = B7 homolog 3
BCVA = Best corrected visual acuity
BTKi = Bruton Tyrosine Kinase inhibitor
ccRCC = Clear cell renal cell carcinoma
CDH6 = Cadherin-6
COPD = Chronic obstructive pulmonary disease
CpcPH-HFpEF = Combined postcapillary and precapillary pulmonary hypertension associated with heart failure with preserved ejection fraction
CRC = Colorectal cancer
CYP11A1 = Cytochrome P450 Family 11 Subfamily A Member 1
DLL3 = Delta-like ligand 3
DME = Diabetic macular edema
DMFS = Distant metastasis-free survival
EADV = European Academy of Dermatology and Venereology
ESMO = European Society for Medical Oncology
FZD4 = Frizzled-4
HCC = Hepatocellular carcinoma
HIV-1 = Human Immunodeficiency Virus Type 1
HNSCC = Head and neck squamous cell carcinoma
HS = Hidradenitis Suppurativa
INT = Individualized neoantigen therapy
KRAS = Kirsten rat sarcoma viral oncogene homolog
LRP5 = Low-Density Lipoprotein Receptor-Related Protein 5
LSD1 = Lysine-specific demethylase 1
mAb = Monoclonal antibody
MASH = Metabolic Dysfunction-Associated Steatohepatitis
MIBC = Muscle invasive bladder cancer
NRTI = Nucleoside reverse transcriptase inhibitor
NNRTI = Non-nucleoside reverse transcriptase inhibitor
NSCLC = Non-small cell lung cancer
OS = Overall survival
PAH = Pulmonary arterial hypertension
PCD = Primary completion date
PD-1/PD-L1 = Programmed cell death protein-1/Programmed cell death ligand-1
PDUFA = Prescription Drug User Fee Act
PFS = Progression-free survival
PrEP = Pre-exposure prophylaxis
PsA = Psoriatic arthritis
RCC = Renal cell carcinoma
RA = Rheumatoid arthritis
R-axSpA = Radiographic axial spondyloarthritis
RFS = Recurrence-free survival
ROR1 = Receptor tyrosine kinase-like orphan receptor 1
SCLC = Small cell lung cancer
Tie2 = Tyrosine kinase with immunoglobulin-like and EGF-like domains 2
TL1A = Tumor Necrosis Factor-like Ligand 1A
TROP2 = Trophoblast cell surface antigen-2
UC = Ulcerative colitis
VEGF = Vascular endothelial growth factor
Wnt = Wingless-related integration site Pathway
28

**Layout**

Full-width dark navy header band across the top fifth of the slide holds the title 'Acronyms' left-aligned at about 3.1% from the left edge, vertically centred in the band. Below the band, the acronym list runs in three left-aligned text columns starting at x 3.1%, 35.8% and 68.6%, with the first line of each column at y 22.4%; a small teal logo and the page number 28 sit bottom right on the same baseline area.

**Visuals**

none apart from a small teal logo (a four-lobed rounded mark, roughly square, in teal green about #0F8B7E) at bottom right, x 91.8%, y 92.8%, 3.1% by 6.6%, and the page number. No charts, photographs or illustrations.

**Design**

Background white #FFFFFF with a full-width header band in navy #0C2340 covering the top 18.4% of the slide height. Title 'Acronyms' in white #FFFFFF Invention Light, a sans-serif, about 5.09% of slide height, sentence case. Body text in Invention Regular, a humanist sans-serif, about 2.04% of slide height, navy #0C2340; acronym labels set in Invention Bold, same colour, with the expansion following in regular weight after ' = '. Line spacing about 3.4% of slide height between entries, with wrapped lines tightly leaded. No bullets, rules, shapes, shadows, gradients or corner radii beyond the header band.

**Elements and positions** (back to front; x, y, width, height as % of the slide; type, colour and alignment in brackets)

- shape at x 0, y 0, w 100, h 18.4 [#0C2340]: Header band, full width, top of slide (Solid rectangle, no border, no shadow, square corners, sits behind title.)
- title at x 3.1, y 6.7, w 12.9, h 5.1 [Invention Light, sans-serif, regular weight, sentence case, no letter-spacing; font size 5.09% of slide height; #FFFFFF; left aligned]: Acronyms (Sits on the navy header band, vertically centred in it.)
- body at x 3.1, y 22.4, w 28.5, h 68.6 [Invention Regular with acronym labels in Invention Bold, sans-serif, normal case; font size 2.04% of slide height; #0C2340; left aligned]: AAO = American Academy of Ophthalmology / AASLD = American Association for the Study of Liver Diseases / ADC = Antibody-drug conjugate / B7-H3 = B7 homolog 3 / BCVA = Best corrected visual acuity / BTKi = Bruton Tyrosine Kinase inhibitor / ccRCC = Clear cell renal cell carcinoma / CDH6 = Cadherin-6 / COPD = Chronic obstructive pulmonary disease / CpcPH-HFpEF = Combined postcapillary and precapillary pulmonary hypertension associated with heart failure with preserved ejection fraction / CRC = Colorectal cancer / CYP11A1 = Cytochrome P450 Family 11 Subfamily A Member 1 / DLL3 = Delta-like ligand 3 / DME = Diabetic macular edema / DMFS = Distant metastasis-free survival / EADV = European Academy of Dermatology and Venereology / ESMO = European Society for Medical Oncology (Left column of 17 entries, one entry per paragraph, about 3.4% line pitch between entries; wrapped lines (AASLD, CpcPH-HFpEF, CYP11A1, EADV) indented to the left margin, no bullets.)
- body at x 35.8, y 22.4, w 32.5, h 64 [Invention Regular with acronym labels in Invention Bold, sans-serif, normal case; font size 2.04% of slide height; #0C2340; left aligned]: FZD4 = Frizzled-4 / HCC = Hepatocellular carcinoma / HIV-1 = Human Immunodeficiency Virus Type 1 / HNSCC = Head and neck squamous cell carcinoma / HS = Hidradenitis Suppurativa / INT = Individualized neoantigen therapy / KRAS = Kirsten rat sarcoma viral oncogene homolog / LRP5 = Low-Density Lipoprotein Receptor-Related Protein 5 / LSD1 = Lysine-specific demethylase 1 / mAb = Monoclonal antibody / MASH = Metabolic Dysfunction-Associated Steatohepatitis / MIBC = Muscle invasive bladder cancer / NRTI = Nucleoside reverse transcriptase inhibitor / NNRTI = Non-nucleoside reverse transcriptase inhibitor / NSCLC = Non-small cell lung cancer / OS = Overall survival / PAH = Pulmonary arterial hypertension (Middle column of 17 entries, one entry per paragraph, about 3.4% line pitch between entries; wrapped lines (LRP5, MASH, NNRTI) indented to the left margin, no bullets.)
- body at x 68.6, y 22.4, w 27.4, h 65 [Invention Regular with acronym labels in Invention Bold, sans-serif, normal case; font size 2.04% of slide height; #0C2340; left aligned]: PCD = Primary completion date / PD-1/PD-L1 = Programmed cell death protein-1/Programmed cell death ligand-1 / PDUFA = Prescription Drug User Fee Act / PFS = Progression-free survival / PrEP = Pre-exposure prophylaxis / PsA = Psoriatic arthritis / RCC = Renal cell carcinoma / RA = Rheumatoid arthritis / R-axSpA = Radiographic axial spondyloarthritis / RFS = Recurrence-free survival / ROR1 = Receptor tyrosine kinase-like orphan receptor 1 / SCLC = Small cell lung cancer / Tie2 = Tyrosine kinase with immunoglobulin-like and EGF-like domains 2 / TL1A = Tumor Necrosis Factor-like Ligand 1A / TROP2 = Trophoblast cell surface antigen-2 / UC = Ulcerative colitis / VEGF = Vascular endothelial growth factor / Wnt = Wingless-related integration site Pathway (Right column of 18 entries, one entry per paragraph, about 3.4% line pitch between entries; wrapped lines (PD-1/PD-L1, Tie2) indented to the left margin, no bullets.)
- logo at x 91.8, y 92.8, w 3.1, h 6.6 [#0F8B7E]: Teal four-lobed logo mark, bottom right (Raster image 125 by 150 pixels, teal green solid shape with white negative space between lobes, no border, not cropped.)
- page number at x 96, y 95.5, w 0.8, h 1.3 [Invention Regular, sans-serif, normal weight; font size 1.29% of slide height; #9EA7B3; right aligned]: 28 (Grey page number at bottom right, right of the logo.)

**Measured from the file** (exact, read from the PDF rather than estimated; x, y, w, h as % of the slide; font size as % of the slide height)

- fill at x 0.0, y 0.0, w 100.0, h 100.0: #FFFFFF (covers the slide)
- fill at x 0.0, y 0.0, w 100.0, h 18.4: #0C2340
- image at x 91.8, y 92.8, w 3.1, h 6.6: 125 by 150 pixels
- text at x 3.1, y 6.7, w 12.9, h 5.1 [Invention-Light; font size 5.09; #FFFFFF]: Acronyms
- text at x 3.1, y 22.5, w 2.7, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: AAO
- text at x 5.8, y 22.5, w 20.6, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = American Academy of Ophthalmology
- text at x 35.8, y 22.4, w 4.2, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: FZD4 =
- text at x 40.0, y 22.4, w 5.2, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: Frizzled-4
- text at x 68.6, y 22.4, w 2.4, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: PCD
- text at x 70.9, y 22.4, w 14.0, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Primary completion date
- text at x 3.1, y 25.9, w 4.1, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: AASLD
- text at x 7.1, y 25.9, w 0.7, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: =
- text at x 35.8, y 25.9, w 2.3, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: HCC
- text at x 38.2, y 25.9, w 14.3, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Hepatocellular carcinoma
- text at x 68.6, y 25.8, w 6.5, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: PD-1/PD-L1
- text at x 3.1, y 25.9, w 27.7, h 4.4 [Invention-Regular; font size 2.04; #0C2340]: American Association for the Study of Liver Diseases
- text at x 68.6, y 25.8, w 24.1, h 4.4 [Invention-Regular; font size 2.04; #0C2340]: = Programmed cell death protein-1/Programmed cell death ligand-1
- text at x 35.8, y 29.3, w 3.2, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: HIV-1
- text at x 39.0, y 29.3, w 21.0, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Human Immunodeficiency Virus Type 1
- text at x 3.1, y 31.7, w 2.4, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: ADC
- text at x 5.5, y 31.7, w 14.3, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Antibody-drug conjugate
- text at x 68.6, y 31.6, w 3.9, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: PDUFA
- text at x 72.5, y 31.6, w 17.4, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Prescription Drug User Fee Act
- text at x 35.8, y 32.7, w 3.9, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: HNSCC
- text at x 39.8, y 32.7, w 21.9, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Head and neck squamous cell carcinoma
- text at x 3.1, y 35.1, w 3.4, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: B7-H3
- text at x 6.5, y 35.1, w 8.2, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = B7 homolog 3
- text at x 68.6, y 35.0, w 2.2, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: PFS
- text at x 70.7, y 35.0, w 14.3, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Progression-free survival
- text at x 35.8, y 36.2, w 1.8, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: HS
- text at x 37.7, y 36.2, w 13.9, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Hidradenitis Suppurativa
- text at x 3.1, y 38.5, w 3.4, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: BCVA
- text at x 6.4, y 38.5, w 15.2, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Best corrected visual acuity
- text at x 68.6, y 38.5, w 2.7, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: PrEP
- text at x 71.3, y 38.5, w 14.5, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Pre-exposure prophylaxis
- text at x 35.8, y 39.6, w 2.2, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: INT
- text at x 38.0, y 39.6, w 18.5, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Individualized neoantigen therapy
- text at x 3.1, y 42.0, w 2.6, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: BTKi
- text at x 5.7, y 42.0, w 18.0, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Bruton Tyrosine Kinase inhibitor
- text at x 68.6, y 41.9, w 2.4, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: PsA
- text at x 70.9, y 41.9, w 10.0, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Psoriatic arthritis
- text at x 35.8, y 43.1, w 3.4, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: KRAS
- text at x 39.2, y 43.1, w 23.7, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Kirsten rat sarcoma viral oncogene homolog
- text at x 3.1, y 45.4, w 3.6, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: ccRCC
- text at x 6.7, y 45.4, w 16.0, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Clear cell renal cell carcinoma
- text at x 68.6, y 45.3, w 2.5, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: RCC
- text at x 71.1, y 45.3, w 11.5, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Renal cell carcinoma
- text at x 35.8, y 46.5, w 2.9, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: LRP5
- text at x 35.8, y 46.5, w 26.8, h 4.4 [Invention-Regular; font size 2.04; #0C2340]: = Low-Density Lipoprotein Receptor-Related Protein 5
- text at x 3.1, y 48.8, w 3.4, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: CDH6
- text at x 6.5, y 48.8, w 6.8, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Cadherin-6
- text at x 68.6, y 48.8, w 1.8, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: RA
- text at x 70.4, y 48.8, w 11.9, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Rheumatoid arthritis
- text at x 3.1, y 52.3, w 3.2, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: COPD
- text at x 6.3, y 52.3, w 21.3, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Chronic obstructive pulmonary disease
- text at x 35.8, y 52.2, w 2.9, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: LSD1
- text at x 38.8, y 52.2, w 16.2, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Lysine-specific demethylase 1
- text at x 68.6, y 52.2, w 4.9, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: R-axSpA
- text at x 73.5, y 52.2, w 19.5, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Radiographic axial spondyloarthritis
- text at x 3.1, y 55.7, w 7.9, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: CpcPH-HFpEF
- text at x 35.8, y 55.7, w 2.8, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: mAb
- text at x 38.6, y 55.7, w 11.7, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: =Monoclonal antibody
- text at x 68.6, y 55.6, w 2.4, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: RFS
- text at x 71.0, y 55.6, w 13.8, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Recurrence-free survival
- text at x 3.1, y 55.7, w 27.4, h 6.7 [Invention-Regular; font size 2.04; #0C2340]: = Combined postcapillary and precapillary pulmonary hypertension associated with heart failure with preserved ejection fraction
- text at x 35.8, y 59.1, w 3.4, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: MASH
- text at x 68.6, y 59.1, w 2.9, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: ROR1
- text at x 71.5, y 59.1, w 25.7, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Receptor tyrosine kinase-like orphan receptor 1
- text at x 35.8, y 59.1, w 22.6, h 4.4 [Invention-Regular; font size 2.04; #0C2340]: = Metabolic Dysfunction-Associated Steatohepatitis
- text at x 68.6, y 62.5, w 3.1, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: SCLC
- text at x 71.6, y 62.5, w 12.0, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Small cell lung cancer
- text at x 3.1, y 63.8, w 2.3, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: CRC
- text at x 5.4, y 63.8, w 10.2, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Colorectal cancer
- text at x 35.8, y 64.9, w 3.1, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: MIBC
- text at x 39.0, y 64.9, w 16.8, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Muscle invasive bladder cancer
- text at x 68.6, y 65.9, w 2.3, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: Tie2
- text at x 3.1, y 67.2, w 4.7, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: CYP11A1
- text at x 68.6, y 65.9, w 27.4, h 4.4 [Invention-Regular; font size 2.04; #0C2340]: = Tyrosine kinase with immunoglobulin-like and EGF-like domains 2
- text at x 3.1, y 67.2, w 26.7, h 4.4 [Invention-Regular; font size 2.04; #0C2340]: = Cytochrome P450 Family 11 Subfamily A Member 1
- text at x 35.8, y 68.3, w 3.0, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: NRTI
- text at x 38.8, y 68.3, w 22.6, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Nucleoside reverse transcriptase inhibitor
- text at x 35.8, y 71.7, w 3.6, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: NNRTI
- text at x 68.6, y 71.7, w 2.9, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: TL1A
- text at x 71.4, y 71.7, w 20.3, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Tumor Necrosis Factor-like Ligand 1A
- text at x 3.1, y 73.0, w 3.1, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: DLL3
- text at x 6.1, y 73.0, w 10.2, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Delta-like ligand 3
- text at x 35.8, y 71.7, w 24.5, h 4.4 [Invention-Regular; font size 2.04; #0C2340]: = Non-nucleoside reverse transcriptase inhibitor
- text at x 68.6, y 75.1, w 4.0, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: TROP2
- text at x 72.6, y 75.1, w 18.7, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Trophoblastcell surface antigen-2
- text at x 3.1, y 76.4, w 2.8, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: DME
- text at x 5.9, y 76.4, w 13.4, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Diabetic macular edema
- text at x 35.8, y 77.5, w 4.0, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: NSCLC
- text at x 39.8, y 77.5, w 14.4, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Non-small cell lung cancer
- text at x 68.6, y 78.5, w 1.6, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: UC
- text at x 70.1, y 78.5, w 9.8, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Ulcerative colitis
- text at x 3.1, y 79.8, w 3.3, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: DMFS
- text at x 6.4, y 79.8, w 17.8, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Distant metastasis-free survival
- text at x 35.8, y 80.9, w 1.6, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: OS
- text at x 37.4, y 80.9, w 9.1, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Overall survival
- text at x 68.6, y 82.0, w 3.2, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: VEGF
- text at x 71.8, y 82.0, w 18.9, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Vascular endothelial growth factor
- text at x 3.1, y 83.3, w 3.1, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: EADV
- text at x 3.1, y 83.3, w 25.2, h 4.4 [Invention-Regular; font size 2.04; #0C2340]: = European Academy of Dermatology and Venereology
- text at x 35.8, y 84.3, w 2.4, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: PAH
- text at x 38.3, y 84.3, w 18.0, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Pulmonary arterial hypertension
- text at x 68.6, y 85.4, w 2.6, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: Wnt
- text at x 71.2, y 85.4, w 22.9, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = Wingless-related integration site Pathway
- text at x 3.1, y 89.0, w 3.3, h 2.0 [Invention-Bold; font size 2.04; #0C2340]: ESMO
- text at x 6.4, y 89.0, w 21.4, h 2.0 [Invention-Regular; font size 2.04; #0C2340]: = European Society for Medical Oncology
- text at x 96.0, y 95.5, w 0.8, h 1.3 [Invention-Regular; font size 1.29; #9EA7B3]: 28
